

## PCT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

PLOUGMANN, VINGTOFT & PARTNERS A/S  
Sankt Annæ Plads 11  
P.O. Box 3007  
DK-1021 Copenhagen K  
DANEMARK

Date of mailing (day/month/year) 05 July 2000 (05.07.00)	
Applicant's or agent's file reference 22129 PC 1	<b>IMPORTANT NOTIFICATION</b>
International application No. PCT/DK99/00562	International filing date (day/month/year) 15 October 1999 (15.10.99)

1. The following indications appeared on record concerning:		
<input checked="" type="checkbox"/> the applicant	<input checked="" type="checkbox"/> the inventor	<input type="checkbox"/> the agent <input type="checkbox"/> the common representative
Name and Address ARKHAMMAR, Per, O., G. Helmfeltsgatan 13 S-254 40 Helsingborg Sweden	State of Nationality SE	State of Residence SE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:		
<input type="checkbox"/> the person	<input type="checkbox"/> the name	<input checked="" type="checkbox"/> the address <input type="checkbox"/> the nationality <input type="checkbox"/> the residence
Name and Address ARKHAMMAR, Per, O., G. Husensjövägen 97 S-25252 Helsingborg Sweden	State of Nationality SE	State of Residence SE
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to:		
<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned	
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned	
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:	

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer  Catherine Massetti Telephone No.: (41-22) 338.83.38
--	--

# INTERNET COOPERATION TREATY

## PCT

### NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C. 20231  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

<b>Date of mailing (day/month/year)</b> 06 June 2000 (06.06.00)	
<b>International application No.</b> PCT/DK99/00562	<b>Applicant's or agent's file reference</b> 22129 PC 1
<b>International filing date (day/month/year)</b> 15 October 1999 (15.10.99)	<b>Priority date (day/month/year)</b> 15 October 1998 (15.10.98)
<b>Applicant</b> ARKHAMMAR, Per, O., G. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

25 April 2000 (25.04.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No.: (41-22) 740.14.35	<b>Authorized officer</b>  <p style="text-align: center;">Manu Berrod</p> Telephone No.: (41-22) 338.83.38
--	--

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>22129 PC 1</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/DK 99/ 00562</b>	International filing date (day/month/year) <b>15/10/1999</b>	(Earliest) Priority Date (day/month/year) <b>15/10/1998</b>
Applicant <b>BIOIMAGE A/S et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 10 sheets.  
☒ It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

- a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ Certain claims were found unsearchable (See Box I).

3. ☒ Unity of invention is lacking (see Box II).

## 4. With regard to the title,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

**METHOD FOR EXTRACTING QUANTITATIVE INFORMATION RELATING TO AN INFLUENCE ON A CELLULAR RESPONSE**

## 5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

## 6. The figure of the drawings to be published with the abstract is Figure No.

☒ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

16

☐ None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK 99/00562

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-28, 39  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(v) PCT - Presentation of information: The subject-matter of claim 39 is a "set of data". This is a mere representation of presentation for which the ISA is not required to establish a search report.
2. ☒ Claims Nos.: 1-28  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 1.2

Claims Nos.: 1-28

Claim 1-28 are not supported by technical terms, as is required by Article 6 and Rule 6.3(a) PCT, which legitimately define the scope of the subject-matter for which protection is sought as no technical contribution to the state of the art commensurate to the scope of the present claims is derivable from the description in terms of a technical problem and a solution thereto as is required by Article 5 and Rule 5.1(iii) PCT. Insofar as claims 1-28 could be understood they would rely on the act of recording of signals from the underlying biological systems and the subsequent processing of the recorded signals. No technical features technically describing such act as a possible contribution to the state of the art is derivable other than the trivial use of state of the art photographic recording devices. No algorithms nor any unexpected combinations of hardware and software defines the subject-matter for which protection is sought. These flaws with respect to the requirements of Article 5 and 6 of the PCT are of such nature that a meaningful complete search could not be executed.

The only technical definition of subject-matter for which a meaningful search could be executed was found in claims limited to the involvement of the technically characterised luminophores as in claims 29-38 and in the parts of the description supporting these claims.

Moreover, the initial phase of the search for this limited subject-matter revealed a very large number of documents relevant to the issue of novelty of claim 1. So many documents were retrieved falling under the wide scope of claim 1-28 that it is impossible to determine which parts of these claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons also, a meaningful search over the whole breadth of the claim(s) is impossible.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 1.

2. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 3.

3. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 17

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 4. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 7.

## 5. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 9.

## 6. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 11.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 7. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 13.

## 8. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 15

## 9. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 17

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 99/00562

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 G01N33/50 G01N21/64

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N C12Q C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 98 45704 A (TULLIN SOEREN ;KASPER ALMHOLT (DK); NOVONORDISK AS (DK); SCUDDER K) 15 October 1998 (1998-10-15) cited in the application See SEQ ID's SEQ ID's identical to SEQ ID 1,3,5,7,9,11,13 and 15 are present.	1-39
X	WO 96 23898 A (NOVONORDISK AS ;THASTRUP OLE (DK); TULLIN SOEREN (DK); POULSEN LAR) 8 August 1996 (1996-08-08) page 8 -page 17	29-38
X	WO 97 11094 A (NOVONORDISK AS ;THASTRUP OLE (DK); TULLIN SOEREN (DK); POULSEN LAR) 27 March 1997 (1997-03-27) the whole document	29-38
-/-		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

2 February 2000

Date of mailing of the international search report

23. 03. 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3018

Authorized officer

Hoekstra, S

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 99/00562

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91 01305 A (UNIV WALES MEDICINE) 7 February 1991 (1991-02-07) page 5, line 15 - line 20	29-38
X	WO 95 07463 A (UNIV COLUMBIA ;WOODS HOLE OCEANOGRAPHIC INST (US); CHALFIE MARTIN) 16 March 1995 (1995-03-16) claim 26	29-38
X	WO 96 03649 A (UNIV NORTH CAROLINA) 8 February 1996 (1996-02-08) page 49; example 6.10	29-38
X	WO 97 20931 A (US HEALTH ;HTUN HAN (US); HAGER GORDON L (US)) 12 June 1997 (1997-06-12) claims 41-58	29-38
X	WO 97 30074 A (CYTOGEN CORP ;UNIV NORTH CAROLINA (US)) 21 August 1997 (1997-08-21) page 57	29-38
X	WO 98 02571 A (TSIEN ROGER Y ;CUBITT ANDREW B (US); UNIV CALIFORNIA (US)) 22 January 1998 (1998-01-22) claims	29-38
X	WO 98 30715 A (ISACOFF EHUD Y ;SIEGAL MICAH S (US); UNIV CALIFORNIA (US); CALIFOR) 16 July 1998 (1998-07-16) the whole document	29-38
X	SAKAI ET AL: "Translocation of protein kinase C-gamma and epsilon - Direct visualization in living cells using fusion protein with green fluorescent protein" THE JOURNAL OF CELL BIOLOGY,US,ROCKEFELLER UNIVERSITY PRESS, XP002078902 ISSN: 0021-9525 the whole document	29-38
X	SCHMIDT ET AL: "Dynamic analysis of alpha-PKC-GFP chimera translocation events in smooth muscle with ultra-high speed 3D fluorescence microscopy" FASEB JOURNAL,US,FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, vol. 3, no. 11, page A505 XP002077257 ISSN: 0892-6638 abstract	29-38

-/-

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SIDOROVA ET AL: "Cell cycle-regulated phosphorylation of Swi6 controls its nuclear localization"</p> <p>MOLECULAR BIOLOGY OF THE CELL,US,BETHESDA, MD,</p> <p>vol. 6, no. 12, page 1641-1658</p> <p>XP002089512</p> <p>ISSN: 1059-1524</p> <p>the whole document</p>	29-38
X	<p>HAN HTUN ET AL: "VISUALIZATION OF GLUCOCORTICOID RECEPTOR TRANSLOCATION AND INTRANUCLEAR ORGANIZATION IN LIVING CELLS WITH A GREEN FLUORESCENT PROTEIN CHIMERA"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,</p> <p>vol. 93, no. 10, page 4845-4850</p> <p>XP002029560</p> <p>ISSN: 0027-8424</p> <p>the whole document</p>	29-38
X	<p>CAREY K L ET AL: "EVIDENCE USING A GREEN FLUORESCENT PROTEIN-GLUCOCORTICOID RECEPTOR CHIMERA THAT THE RAN/TC4 GTPASE MEDIATES AN ESSENTIAL FUNCTION INDEPENDENT OF NUCLEAR PROTEIN IMPORT"</p> <p>THE JOURNAL OF CELL BIOLOGY,US,ROCKEFELLER UNIVERSITY PRESS,</p> <p>vol. 133, no. 5, page 985-996 XP000670316</p> <p>ISSN: 0021-9525</p> <p>the whole document</p>	29-38
X	<p>OGAWA H ET AL: "LOCALIZATION, TRAFFICKING, AND TEMPERATURE-DEPENDENCE OF THE AEQUOREA GREEN FLUORESCENT PROTEIN IN CULTURES VERTEBRATE CELLS"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,</p> <p>vol. 92, no. 25, page 11899-11903</p> <p>XP002029556</p> <p>ISSN: 0027-8424</p> <p>the whole document</p>	29-38
X	<p>WESTPHAL ET AL: "Microfilament dynamics during cell movement and chemotaxis monitored using a GFP - actin fusion protein"</p> <p>CURRENT BIOLOGY,GB,CURRENT SCIENCE,,</p> <p>vol. 7, no. 3, page 176-183 XP002090291</p> <p>ISSN: 0960-9822</p> <p>page 181, left-hand column, line 1</p> <p style="text-align: center;">—/—</p>	29-38

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TODA ET AL: "The fission yeast sts5+ gene is required for maintenance of growth polarity and functionally interacts with protein kinase C and an osmosensing MAP kinase pathway"</p> <p>JOURNAL OF CELL SCIENCE,GB,ESSEX, vol. 109, no. 9, page 2331-2342 XP002090292 abstract</p>	29-38
X	<p>WEBB ET AL: "Use of green fluorescent protein for visualization of cell-specific gene expression and subcellular protein localization during sporulation in Bacillus subtilis"</p> <p>JOURNAL OF BACTERIOLOGY,US,WASHINGTON, DC, vol. 177, no. 20, page 5906-5911 XP002089513 ISSN: 0021-9193 the whole document</p>	29-38
X	<p>WO 94 23039 A (CANCER RES INST ROYAL ;MARSHALL CHRISTOPHER JOHN (GB); ASHWORTH AL) 13 October 1994 (1994-10-13) the whole document</p>	29-38
X	<p>GERISCH ET AL: "Chemoattractant-controlled accumulation of coronin at the leading edge of Dictyostelium cells monitored using a green fluorescent protein-coronin fusion protein"</p> <p>CURRENT BIOLOGY,GB,CURRENT SCIENCE,, vol. 5, no. 11, page 1280-1285 XP002089510 ISSN: 0960-9822 page 1281, right-hand column</p>	29-38

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 99/00562

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9845704	A	15-10-1998	AU	6820998 A	30-10-1998
WO 9623898	A	08-08-1996	AU	4483096 A	21-08-1996
			CA	2217700 A	08-08-1996
			EP	0815257 A	07-01-1998
			US	5958713 A	28-09-1999
WO 9711094	A	27-03-1997	AT	184613 T	15-10-1999
			AU	4482996 A	09-04-1997
			CA	2232727 A	27-03-1997
			DE	69604298 D	21-10-1999
			EP	0851874 A	08-07-1998
			JP	11512441 T	26-10-1999
WO 9101305	A	07-02-1991	AU	6054590 A	22-02-1991
			CA	2064766 A	23-01-1991
			EP	0484369 A	13-05-1992
			JP	5501862 T	08-04-1993
			US	5683888 A	04-11-1997
WO 9507463	A	16-03-1995	US	5491084 A	13-02-1996
			AU	694745 B	30-07-1998
			AU	7795794 A	27-03-1995
			CA	2169298 A	16-03-1995
			EP	0759170 A	26-02-1997
			JP	9505981 T	17-06-1997
WO 9603649	A	08-02-1996	AU	3146095 A	22-02-1996
			CA	2195629 A	08-02-1996
			EP	0772773 A	14-05-1997
			JP	10503369 T	31-03-1998
WO 9720931	A	12-06-1997	AU	1283497 A	27-06-1997
			CA	2239951 A	12-06-1997
WO 9730074	A	21-08-1997	AU	2272397 A	02-09-1997
			CA	2246378 A	21-08-1997
			EP	0897392 A	24-02-1999
WO 9802571	A	22-01-1998	US	5912137 A	15-06-1999
			US	5925558 A	20-07-1999
			AU	3801997 A	09-02-1998
			EP	0915989 A	19-05-1999
WO 9830715	A	16-07-1998	AU	5090498 A	03-08-1998
WO 9423039	A	13-10-1994	AU	677834 B	08-05-1997
			AU	6382394 A	24-10-1994
			CA	2157774 A	13-10-1994
			EP	0703984 A	03-04-1996
			JP	9501302 T	10-02-1997
			US	5958721 A	28-09-1999
			AU	696939 B	24-09-1998
			AU	1586195 A	29-08-1995
			CA	2182967 A	17-08-1995
			EP	0742827 A	20-11-1996
			WO	9521923 A	17-08-1995
			JP	9508795 T	09-09-1997

09/807345

JC02 Rec'd PCT/PTO 1 2 APR 2001

PATENT  
0459-0571P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: ARKHAMMAR, Per O.G. et al.  
Int'l. Appl. No.: PCT/DK99/00562  
Appl. No.: New Group:  
Filed: April 12, 2001 Examiner:  
For: AN IMPROVED METHOD FOR EXTRACTING  
QUANTITATIVE INFORMATION RELATING TO AN  
INFLUENCE IN A CELLULAR RESPONSE

LETTER

**BOX PATENT APPLICATION**  
Assistant Commissioner for Patents  
Washington, D.C. 20231


April 12, 2001

Sir:

The PTO is requested to use the amended sheets/claims attached hereto (which correspond to Article 34 amendments or to claims attached to the International Preliminary Examination Report) during prosecution of the above-identified national phase PCT application.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
Leonard R. Svensson, #30,330

LRS/cqc  
0459-0571P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

## CLAIMS

1. A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising  
5 recording variation in spatially distributed light emitted from a luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a component which is capable of being redistributed in a manner which is related to the degree of the influence, as a change in light intensity measured by an instrument  
10 designed for the measurement of changes in fluorescence intensity.
2. A method according to claim 1, wherein the quantitative information which is indicative of the degree of the cellular response to the influence or the result of the influence on the subcellular component is extracted from the recorded variation according to a  
15 predetermined calibration based on responses or results, recorded in the same manner, to known degrees of a relevant specific influence.
3. A method according to claims 1 or 2, wherein the influence comprises contact between the mechanically intact or permeabilised living cells and a chemical substance and/or incubation of the mechanically intact or permeabilised living cells with a chemical  
20 substance.
4. A method according to any of claims 1-3, wherein the cells comprise a group of cells contained within a spatial limitation.
5. A method according to any of claims 1-4, wherein the cells comprise multiple groups of cells contained within multiple spatial limitations.
- 25 6. A method according to any of claims 1-5, wherein the cells comprise multiple groups of cells that are qualitatively the same but are subjected to different influences.
7. A method according to any of claims 1-5, wherein the cells comprise multiple groups of cells that are qualitatively different but are subjected to the same influence.
8. A method according to any of claims 1-7, wherein multiple spatial limitations are  
30 measured simultaneously by means of a one- or two-dimensional array detector, whereby the multiple spatial limitations are imaged onto the array detector such that

discrete subsets of the detecting units (pixels) in the array detector measure the signal from one and only one of the multiple spatial limitations, the signal from any one spatial limitation being the combined signal from those pixels that receive the image from one of the spatial limitations.

- 5 9. A method according to claim 8, wherein the detector is a linear diode array.
10. A method according to claim 8, wherein the detector is a video camera.
11. A method according to claim 8, wherein the detector is a charge transfer device.
12. A method according to claim 8, wherein the charge transfer device is a charge-coupled device.
- 10 13. A method according to any of claims 1-12, wherein all of the multiple spatial limitations are simultaneously illuminated during the measurement operation.
14. A method according to any of claims 1-12, wherein the individual spatial limitations are singly illuminated only during the time period in which they are being measured.
15. A method according to any of claims 1-14, wherein the illumination is provided by a  
15 laser which is scanned in a raster fashion over some or all of the spatial limitations being measured, the scanning taking place at a rate substantially faster than the measurement process such that the illumination appears to the measurement process to be continuous in time and spatially uniform over the region being measured.
16. A method according to any of claims 1-15, wherein the spatial limitations are spatial  
20 limitations arranged in one or more arrays on a common carrier.
17. A method according to claim 16, wherein the spatial limitations are wells in a plate of microtiter type.
18. A method according to any of claims 1-17, wherein the spatial limitations are domains defined on a substrate on which the cells are present.
- 25 19. A method according to claim 18, wherein the domains are domains established by the presence of the cells on the substrate in a pattern defining the domains.
20. A method according to claim 18, wherein the domains are domains established by the spatial pattern of the influence as it is applied to or contacted with the cells.

21. A method according to any of claims 1-20, wherein the recording is performed at a series of points in time, in which the application of the influence occurs at some time after the first time point in the series of recordings, the recording being performed, e.g., with a predetermined time spacing of from 0.1 seconds to 1 hour, preferably from 1 to 60  
5 seconds, more preferably from 1 to 30 seconds, in particular from 1 to 10 seconds, over a time span of from 1 second to 12 hours, such as from 10 seconds to 12 hours, e.g., from 10 seconds to one hour, such as from 60 seconds to 30 minutes or 20 minutes.
22. A method according to claim 21, wherein the recording is made at two points in time, one point being before, and the other point being after the application of the influence.
- 10 23. A method according to any of claims 1-22, wherein the cells are fixed at a point in time after the application of the influence at which the response has been predetermined to be significant, and the recording is made at an arbitrary later time.
24. A method according to any of claims 1-23, wherein the redistribution results in quenching of fluorescence, the quenching being measured as a decrease in the intensity  
15 of the fluorescence.
25. A method according to any of claims 1-24, wherein the redistribution results in energy transfer, the energy transfer being measured as a change in the intensity of the luminescence.
26. A method according to any of claims 1-24, wherein the illumination necessary to  
20 excite fluorescence is non-homogeneous such that the redistribution results in a greater or lesser number of fluorescent molecules being excited, the result being measured as a change in fluorescent intensity.
27. A method according to any of claims 1-24, wherein the intensity of the light being recorded is a function of the fluorescence lifetime, polarisation, wavelength shift, or other  
25 property which is modulated as a result of the underlying cellular response.
28. A method according to any of claims 1-27, wherein the light to be measured passes through a filter which selects the desired component of the light to be measured and rejects other components.

29. A method according to any of claims 1-28, wherein the fluorescence comes from a fluorophore encoded by and expressed from a nucleotide sequence harboured in the cells.

30. A method according to any of claims 1-28, wherein the fluorescence comes from a fluorophore introduced into the cells by any or various techniques for the bulk loading of material into cells such as transfection, incubation, scrape loading, electroporation.

31. A method according to any of the preceding claims, wherein the fluorescence comes from a luminescent polypeptide, such as GFP.

32. A method according to any of claims 1-31, wherein the cells are selected from the group consisting of fungal cells, such as yeast cells; invertebrate cells including insect cells; and vertebrate cells, such as mammalian cells.

33. A method according to claim 32, wherein the mechanically intact or permeabilised living cells are mammalian cells which, during the time period over which the influence is observed, are incubated at a temperature of 30°C or above, preferably at a temperature of from 32°C to 39°C, more preferably at a temperature of from 35°C to 38°C, and most preferably at a temperature of about 37°C.

34. A method according to any of the preceding claims, wherein the nucleic acid construct is a DNA construct with a sequence selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15 and 17 or is a variant thereof capable of encoding the same fusion polypeptide or a fusion polypeptide which is biologically equivalent thereto.

35. A method according to any of claims 1-34, used as a screening program.

36. A method according claim 35, wherein the method is a screening program for the identification of a biologically active substance that directly or indirectly affects an intracellular signalling pathway and is potentially useful as a medicament, wherein the result of the individual measurement of each substance being screened which indicates its potential biological activity is based on measurement of the redistribution of spatially resolved luminescence in living cells and which undergoes a change in distribution upon activation of an intracellular signalling pathway.

37. A method according to claim 35, wherein the method is a screening program for the identification of a biologically toxic substance as defined herein that exerts its toxic effect

by interfering with an intracellular signalling pathway, wherein the result of the individual measurement of each substance being screened which indicates its potential biologically toxic activity is based on measurement of the redistribution of said fluorescent probe in living cells and which undergoes a change in distribution upon activation of an  
5 intracellular signalling pathway.

38. A method according to any of claims 1-37 wherein a fluorescent probe is used in back-tracking of signal transduction pathways as defined herein.

39. A set of data relating to an influence on a cellular response in mechanically intact or permeabilised living cells, obtained by recording variation in spatially distributed light  
10 emitted from a luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a component which is capable of being redistributed in a manner which is related to the degree of the influence, as a change in light intensity measured by an instrument designed for the measurement of changes in  
15 fluorescence intensity.

# PATENT COOPERATION TREATY

PLUGMANN  
VINGTOFT  
& PARTNERS

**PCT09 / 807345** <sup>28 NOV. 2000</sup>

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference <b>22129 PC 1</b>		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) <b>FOR FURTHER ACTION</b>	
International application No. <b>PCT/DK99/00562</b>	International filing date (day/month/year) <b>15/10/1999</b>	Priority date (day/month/year) <b>15/10/1998</b>	
International Patent Classification (IPC) or national classification and IPC <b>C12Q1/68</b>			
Applicant <b>BIOIMAGE A/S et al.</b>			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 6 sheets, including this cover sheet.  
  
☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 3 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  <b>25/04/2000</b>	Date of completion of this report  <b>27.11.2000</b>
Name and mailing address of the international preliminary examining authority:  <b>European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016</b>	Authorized officer  <b>Hoekstra, S</b>  Telephone No. +31 70 340 2847 

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/DK99/00562

## I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*:

**Description, pages:**

1-57 as originally filed

**Claims, No.:**

1-20 as received on 01/11/2000 with letter of 01/11/2000

**Drawings, sheets:**

1/18-18/18 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☒ the claims, Nos.: 21-39

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/DK99/00562

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:  
**see separate sheet**

### III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 20.

because:

☒ the said international application, or the said claims Nos. 20 relate to the following subject matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

### V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

#### 1. Statement

Novelty (N)

Yes: Claims 1-19

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/DK99/00562

---

	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-19
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-19
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**R Item I**

The originally filed documents encompass as part of the description a 69 page sequence listing.

**Re Item III**

**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

Claim 20 relates to a set of data relating to experimental observations. Article 34(4)(a) PCT and Rule 67.1(v) PCT stipulates that the IPEA is not required to carry out the preliminary examination for subject-matter which is a mere presentation of information. It is noted that the data set per se does not give rise to any technical effect.

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

The statement on page 8 line 1, limits the invention to methods involving cells that contain an expressible nucleic acid that encodes a fusion polypeptide as "defined herein". This is a *de facto* limitation of all inventions in the set of claims filed 01.11.2000 to fluorogenic fusion proteins. All methods are further limited by the special technical features of the "...recording variation (...), as a change in light intensity wherein etc.". (derived from previous claim 15). These combined limitations provide the technical link making up a single general inventive concept required by Rule 13.1 PCT. The International search, having in mind these two limitations, covers the entire scope of the present claims 1-19 as intended by Article 15(3) PCT and Rule 33.3(b) PCT.

The presently claimed invention applies, in a method for extracting quantitative information relating to an influence on redistribution of at least one component in the cell, known technology from Schroeder, K. and Neagle, B.J. [(1996), Biomolecular screening, vol. 1, pp. 75-80.] in the form of a scanning laser imager (FLIPR<sup>tm</sup>) to record and quantify variation in spatially distributed light as a measure of a (chemical) influence applied to the cell.

The documents in the international search report did not disclose a method actually applying this technology for the quantification of the redistribution in a manner fit for

HTS.

The claims are therefore considered to relate to subject-matter that meets the requirements of Article 33(2) PCT.

Example 11 shows that redistribution of a GFP fusion protein (human PKC beta 1 - EGFP) can be detected and quantified in the FLIPR<sup>(tm)</sup> instrument when imaging with a resolution far below what is needed to resolve single cells or subcellular compartments.

The results obtained at this resolution are surprising. This is considered to be a positive indicator for the presence of an inventive step. It thus appears that the subject-matter of claims 1-19 meets the requirement of Article 33(3) PCT.

**Re Item VIII**

**Certain observations on the international application**

The technical effect of example 11 is considered surprising in view of the used resolution. The claims, however, do not limit the method to the use of a resolution far below what is needed to resolve single cells or subcellular compartments. The omission of this feature causes the claims to be seriously flawed with respect to Article 6 and Rule 6.3(a) PCT. As a result the present claims may also be considered to encompass the obvious application of the known FLIPR<sup>(tm)</sup> instrument in order to obtain expected of data on redistribution, like those obtainable with a confocal laser scanning fluorescent microscope (See e.g. Sakai, N. et al.; The Journal of Cell Biology, vol. 139 (1997).p 1465).

Also the limitation to methods involving cells that contain an expressible nucleic acid that encodes a fusion polypeptide as "defined herein", i.e. a GFP fusion protein, is absent from the claims as an essential technical feature.

PCT

## REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

09/807345

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference  
(if desired) (12 characters maximum) 22129 PC 1

## Box No. I TITLE OF INVENTION

An improved method for extracting quantitative information relating to an influence on a cellular response

## Box No. II APPLICANT

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

BioImage A/S  
Mørkhøj Bygade 28  
DK-2860 Søborg  
DK

☐ This person is also inventor.

Telephone No.

Facsimile No.

Teleprinter No.

State (that is, country) of nationality:  
DK

State (that is, country) of residence:  
DK

This person is applicant for the purposes of: ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

## Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

ARKHAMMAR, Per O. G.  
Helmfeltsgatan 13  
S-25440 Helsingborg  
SE

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:  
SE

State (that is, country) of residence:  
SE

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

## Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:

☒ agent ☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

Plougmann, Vingtoft & Partners A/S  
Sankt Annæ Plads 11  
P.O. Box 3007  
DK-1021 Copenhagen K  
DK

Telephone No.

+ 45 33 63 93 00

Facsimile No.

+ 45 33 63 96 00

Teleprinter No.

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

<b>Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)</b>	
<i>If none of the following sub-boxes is used, this sheet should not be included in the request.</i>	
<p><i>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i></p> <p>TERRY, Bernard Robert  Frederiksberg Allé 15,1.  1820 Frederiksberg C  DK</p>	<p>This person is:</p> <p><input type="checkbox"/> applicant only</p> <p><input checked="" type="checkbox"/> applicant and inventor</p> <p><input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)</p>
State (that is, country) of nationality: GB	State (that is, country) of residence: DK
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
<p><i>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i></p> <p>SCUDDER, Kurt Marshall  Lavendelhaven 70  DK-2830 Virum  DK</p>	<p>This person is:</p> <p><input type="checkbox"/> applicant only</p> <p><input checked="" type="checkbox"/> applicant and inventor</p> <p><input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)</p>
State (that is, country) of nationality: US	State (that is, country) of residence: DK
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
<p><i>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i></p> <p>BJØRN, Sara Petersen  Klampenborgvej 102  DK-2800 Lyngby  DK</p>	<p>This person is:</p> <p><input type="checkbox"/> applicant only</p> <p><input checked="" type="checkbox"/> applicant and inventor</p> <p><input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)</p>
State (that is, country) of nationality: DK	State (that is, country) of residence: DK
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
<p><i>Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)</i></p> <p>THASTRUP, Ole  Birkevej 37  DK-3460 Birkerød  DK</p>	<p>This person is:</p> <p><input type="checkbox"/> applicant only</p> <p><input checked="" type="checkbox"/> applicant and inventor</p> <p><input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)</p>
State (that is, country) of nationality: DK	State (that is, country) of residence: DK
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input checked="" type="checkbox"/> the States indicated in the Supplemental Box	
<input checked="" type="checkbox"/> Further applicants and/or (further) inventors are indicated on another continuation sheet.	

**Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)**

*If none of the following sub-boxes is used, this sheet should not be included in the request.*

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

HAGEL, Grith  
Harevænget 109  
DK-2791 Dragør  
DK

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:  
DK

State (that is, country) of residence:  
DK

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

## Box No.V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

## Regional Patent

- ☒ AP ARIPO Patent: GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SL Sierra Leone, SZ Swaziland, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ EA Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ EP European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ OA OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line) .....

## National Patent (if other kind of protection or treatment desired, specify on dotted line):

- |  |  |
|--|--|
| <input checked="" type="checkbox"/> AE United Arab Emirates                        | <input checked="" type="checkbox"/> LR Liberia   |
| <input checked="" type="checkbox"/> AL Albania .....                               | <input checked="" type="checkbox"/> LS Lesotho .....   |
| <input checked="" type="checkbox"/> AM Armenia .....                               | <input checked="" type="checkbox"/> LT Lithuania .....   |
| <input checked="" type="checkbox"/> AT Austria and utility model .....             | <input checked="" type="checkbox"/> LU Luxembourg .....  |
| <input checked="" type="checkbox"/> AU Australia .....                             | <input checked="" type="checkbox"/> LV Latvia .....  |
| <input checked="" type="checkbox"/> AZ Azerbaijan                                  | <input checked="" type="checkbox"/> MD Republic of Moldova .....   |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina .....                | <input checked="" type="checkbox"/> MG Madagascar .....  |
| <input checked="" type="checkbox"/> BB Barbados                                    | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia .....                       |
| <input checked="" type="checkbox"/> BG Bulgaria .....                              | <input checked="" type="checkbox"/> MN Mongolia  |
| <input checked="" type="checkbox"/> BR Brazil .....                                | <input checked="" type="checkbox"/> MW Malawi .....  |
| <input checked="" type="checkbox"/> BY Belarus .....                               | <input checked="" type="checkbox"/> MX Mexico .....  |
| <input checked="" type="checkbox"/> CA Canada                                      | <input checked="" type="checkbox"/> NO Norway  |
| <input checked="" type="checkbox"/> CH and LI Switzerland and Liechtenstein        | <input checked="" type="checkbox"/> NZ New Zealand .....   |
| <input checked="" type="checkbox"/> CN China .....                                 | <input checked="" type="checkbox"/> PL Poland .....  |
| <input checked="" type="checkbox"/> CU Cuba .....                                  | <input checked="" type="checkbox"/> PT Portugal .....  |
| <input checked="" type="checkbox"/> CZ Czech Republic and utility model .....      | <input checked="" type="checkbox"/> RO Romania   |
| <input checked="" type="checkbox"/> DE Germany and utility model .....             | <input checked="" type="checkbox"/> RU Russian Federation .....  |
| <input checked="" type="checkbox"/> DK Denmark and utility model .....             | <input checked="" type="checkbox"/> SD Sudan   |
| <input checked="" type="checkbox"/> EE Estonia and utility model .....             | <input checked="" type="checkbox"/> SE Sweden  |
| <input checked="" type="checkbox"/> ES Spain .....                                 | <input checked="" type="checkbox"/> SG Singapore   |
| <input checked="" type="checkbox"/> FI Finland and utility model .....             | <input checked="" type="checkbox"/> SI Slovenia .....  |
| <input checked="" type="checkbox"/> GB United Kingdom                              | <input checked="" type="checkbox"/> SK Slovakia and utility model .....                                      |
| <input checked="" type="checkbox"/> GD Grenada                                     | <input checked="" type="checkbox"/> SL Sierra Leone .....  |
| <input checked="" type="checkbox"/> GE Georgia .....                               | <input checked="" type="checkbox"/> TJ Tajikistan .....  |
| <input checked="" type="checkbox"/> GH Ghana .....                                 | <input checked="" type="checkbox"/> TM Turkmenistan .....  |
| <input checked="" type="checkbox"/> GM Gambia                                      | <input checked="" type="checkbox"/> TR Turkey .....  |
| <input checked="" type="checkbox"/> HR Croatia .....                               | <input checked="" type="checkbox"/> TT Trinidad and Tobago .....   |
| <input checked="" type="checkbox"/> HU Hungary .....                               | <input checked="" type="checkbox"/> UA Ukraine .....   |
| <input checked="" type="checkbox"/> ID Indonesia                                   | <input checked="" type="checkbox"/> UG Uganda .....  |
| <input checked="" type="checkbox"/> IL Israel .....                                | <input checked="" type="checkbox"/> US United States of America .....  |
| <input checked="" type="checkbox"/> IN India .....                                 | <input checked="" type="checkbox"/> UZ Uzbekistan .....  |
| <input checked="" type="checkbox"/> IS Iceland                                     | <input checked="" type="checkbox"/> VN Viet Nam .....  |
| <input checked="" type="checkbox"/> JP Japan .....                                 | <input checked="" type="checkbox"/> YU Yugoslavia .....  |
| <input checked="" type="checkbox"/> KE Kenya .....                                 | <input checked="" type="checkbox"/> ZA South Africa .....  |
| <input checked="" type="checkbox"/> KG Kyrgyzstan .....                            | <input checked="" type="checkbox"/> ZW Zimbabwe .....  |
| <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea ..... | Check-boxes reserved for designating States which have become party to the PCT after issuance of this sheet: |
| <input checked="" type="checkbox"/> KR Republic of Korea .....                     | <input checked="" type="checkbox"/> DM Dominica x MA Morocco .....   |
| <input checked="" type="checkbox"/> KZ Kazakhstan .....                            | <input checked="" type="checkbox"/> CR Costa Rica x TZ Tanzania .....  |
| <input checked="" type="checkbox"/> LC Saint Lucia                                 |  |
| <input checked="" type="checkbox"/> LK Sri Lanka                                   |  |

**Precautionary Designation Statement:** In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)


<b>Box No. VI PRIORITY CLAIM</b>		<input type="checkbox"/> Further priority claims are indicated in the Supplemental Box.		
Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country	regional application:* regional Office	international application: receiving Office
item (1) 15 October 1998	PA 1998 01320	DK		
item (2)				
item (3)				

☒ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s): (1)

\* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.

<b>Box No. VII INTERNATIONAL SEARCHING AUTHORITY</b>			
<b>Choice of International Searching Authority (ISA)</b> <small>(if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):</small>		<b>Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):</b>	
ISA/EP		Date (day/month/year)	Number Country (or regional Office)

<b>Box No. VIII CHECK LIST; LANGUAGE OF FILING</b>	
This international application contains the following number of sheets: request : 5 description (excluding sequence listing part) : 57 claims : 5 abstract : 1 drawings : 18 sequence listing part of description : 69 <b>Total number of sheets : 155</b>	This international application is accompanied by the item(s) marked below: 1. <input checked="" type="checkbox"/> fee calculation sheet 2. <input type="checkbox"/> separate signed power of attorney 3. <input type="checkbox"/> copy of general power of attorney; reference number, if any: 4. <input type="checkbox"/> statement explaining lack of signature 5. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s): 6. <input type="checkbox"/> translation of international application into (language): 7. <input type="checkbox"/> separate indications concerning deposited microorganism or other biological material 8. <input checked="" type="checkbox"/> nucleotide and/or amino acid sequence listing in computer readable form 9. <input checked="" type="checkbox"/> other (specify) letter concerning sequence listing
<b>Figure of the drawings which should accompany the abstract:</b> 16	<b>Language of filing of the international application:</b> English

<b>Box No. IX SIGNATURE OF APPLICANT OR AGENT</b>
Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).  Copenhagen, 15 October 1999 Plougmann, Vingtoft & Partners A/S  Peter 

For receiving Office use only	
1. Date of actual receipt of the purported international application:  3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:  4. Date of timely receipt of the required corrections under PCT Article 11(2):  5. International Searching Authority (if two or more are competent): ISA /	2. Drawings:  <input type="checkbox"/> received:  <input type="checkbox"/> not received:  6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid.

For International Bureau use only
Date of receipt of the record copy by the International Bureau:



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification <sup>7</sup> : <b>C12Q 1/68</b>		A2	(11) International Publication Number: <b>WO 00/23615</b>
			(43) International Publication Date: 27 April 2000 (27.04.00)
(21) International Application Number: PCT/DK99/00562 (22) International Filing Date: 15 October 1999 (15.10.99) (30) Priority Data: PA 1998 01320 15 October 1998 (15.10.98) DK (71) Applicant (for all designated States except US): BIOIMAGE A/S [DK/DK]; Mørkhøj Bygade 28, DK-2860 Søborg (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): ARKHAMMAR, Per, O., G. [SE/SE]; Helmfeltsgatan 13, S-254 40 Helsingborg (SE). TERRY, Bernard, Robert [GB/DK]; Frederiksberg Allé 15,1., DK-1820 Frederiksberg C (DK). SCUDDER, Kurt, Marshall [US/DK]; Lavendelhaven 70, DK-2830 Virum (DK). BJØRN, Sara, Petersen [DK/DK]; Klampenborgvej 102, DK-2800 Lyngby (DK). THASTRUP, Ole [DK/DK]; Birkevej 37, DK-3460 Birkerød (DK). HAGEL, Grith [DK/DK]; Harevænget 109, DK-2791 Dragør (DK). (74) Agent: PLOUGMANN, VINGTOFT & PARTNERS A/S; Sankt Annæ Plads 11, P.O. Box 3007, DK-1021 Copenhagen K (DK).			(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> Without international search report and to be republished upon receipt of that report.

(54) Title: AN IMPROVED METHOD FOR EXTRACTING QUANTITATIVE INFORMATION RELATING TO AN INFLUENCE ON A CELLULAR RESPONSE

## (57) Abstract

An improved method and tools for quantifying the effect of an influence on cellular response is described. In particular, an improved method is described for detecting intracellular translocation or redistribution of biologically active polypeptides. The invention also describes several ways of contacting the cells with a substance influencing a cellular response and extracting quantitative information relating to the response in a highly parallel fashion. The method may be used as a very efficient procedure for testing or discovering the influence of a substance on a physiological process using commercially available parallel, high volume assay techniques, for example in connection with screening for new drugs, testing of substances for toxicity, and identifying drug targets for known or novel drugs.

hPKCbeta1-GFP ATP dose-response  
in FLIPR (n=6)



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

AN IMPROVED METHOD FOR EXTRACTING QUANTITATIVE INFORMATION  
RELATING TO AN INFLUENCE ON A CELLULAR RESPONSE.

## SUMMARY OF THE INVENTION

- 5 The present invention relates to an improved method and tools for extracting quantitative information relating to an influence on a cellular response, in particular an influence caused by contacting or incubating the cell with a substance influencing a cellular response, wherein the cellular response is manifested in redistribution of at least one component in the cell. In particular, the invention relates to an improved method for
- 10 extracting the quantitative information relating to an influence on an intracellular pathway involving redistribution of at least one component associated with the pathway. The method of the invention may be used as a very efficient procedure for testing or discovering the influence of a substance on a physiological process, for example in connection with screening for new drugs, testing of substances for toxicity, identifying
- 15 drug targets for known or novel drugs. In particular, the present invention relates to an improved method for parallelisation of the testing procedure so that a large number of substances can be tested simultaneously using commercially available instrumentation. The invention also describes several ways of contacting the cells with a substance influencing a cellular response and modifications made to the actual cells before, during
- 20 or after contacting the cells with these substances as to improve the applicability and use of the method for extracting quantitative information relating to influence on an intracellular pathway in a highly parallel fashion. Other valuable uses of the method and technology of the invention will be apparent to the skilled person on the basis of the following disclosure. In a particular embodiment of the invention, the present invention
- 25 relates to a method of detecting intracellular translocation or redistribution of biologically active polypeptides, preferably an enzyme, affecting intracellular processes, and a DNA construct and a cell for use in the method.

## BACKGROUND OF THE INVENTION

- 30 Intracellular pathways are tightly regulated by a cascade of components that undergo modulation in a temporally and spatially characteristic manner. Several disease states can be attributed to altered activity of individual signalling components (i.e. protein

kinases, protein phosphatases, transcription factors). These components therefore render themselves as attractive targets for therapeutic intervention.

Protein kinases and phosphatases are well-described components of several  
5 intracellular signalling pathways. The catalytic activity of protein kinases and phosphatases are assumed to play a role in virtually all regulatable cellular processes. Although the involvement of protein kinases in cellular signalling and regulation have been subjected to extensive studies, detailed knowledge on e.g. the exact timing and spatial characteristics of signalling events is often difficult to obtain due to lack of a  
10 convenient technology.

The measurement of the activity of intracellular enzymes, such as kinases and phosphatases, can be performed by well-established procedures, both manually and in various automated forms, at throughput rates which make these measurements useful in  
15 the search for new drug candidates. In addition to measures of activity, measures of the distribution of these and other enzymes in the cell has proven useful, and established techniques exist for this type of measurement as well. Protein kinases often show a specific intracellular distribution before, during and after activation. Monitoring the translocation processes and/or redistribution of individual protein kinases or subunits  
20 thereof is thus likely to be indicative of their functional activity. A connection between translocation and catalytic activation has been shown for protein kinases like the diacyl glycerol (DAG)-dependent protein kinase C (PKC), the cAMP-dependent protein kinase (PKA) [(DeBernardi *et al.* 1996)] and the mitogen-activated-protein kinase Erk-1 [(Sano *et al.* 1995)]. Such methods of detection of intracellular localisation/activity of protein  
25 kinases and phosphatases include immunoprecipitation, Western blotting and immunocytochemical detection.

One aspect of the function of intracellular enzymes which has not been characterised so thoroughly is the redistribution of those enzymes. The importance of subcellular  
30 redistribution of enzymes as a mechanism of enzyme specificity, and of the general importance of the measurement of subcellular redistribution as a tool for identifying novel drug targets and searching for drug candidates which influence those targets, is disclosed in: A METHOD FOR EXTRACTING QUANTITATIVE INFORMATION RELATING TO AN INFLUENCE ON A CELLULAR RESPONSE ,the contents of which

were part of the priority application, and which, as WO9845704 has been published during the priority year, are hereby incorporated herein by reference.

While the redistribution of subcellular components is known to be important, the measurement of this phenomenon in real time has not been widely exploited. This is primarily due to the lack of a suitable technique. There is essentially only one direct technique: the microscopic imaging of cells in which the subcellular component of interest has been labelled in such a way that it can be visualised and recorded by the microscopic imaging system, using for example a video or scientific CCD camera and appropriate software for collecting and storing the images. Novel ways of monitoring specific modulation of intracellular pathways in intact, living cells is assumed to provide new opportunities in drug discovery, functional genomics, toxicology, patient monitoring etc.

Recently it was discovered that Green Fluorescent Protein (GFP) expressed in many different cell types, including mammalian cells, became highly fluorescent [(Chalfie *et al.* 1994)]. WO95/07463 describes a cell capable of expressing GFP and a method for detecting a protein of interest in a cell based on introducing into a cell a DNA molecule having DNA sequence encoding the protein of interest linked to DNA sequence encoding a GFP such that the protein produced by the DNA molecule will have the protein of interest fused to the GFP, then culturing the cells in conditions permitting expression of the fused protein and detecting the location of the fluorescence in the cell, thereby localizing the protein of interest in the cell. However, examples of such fused proteins are not provided, and the use of fusion proteins with GFP for detection or quantitation of translocation or redistribution of biologically active polypeptides affecting intracellular processes upon activation, such as proteins involved in signalling pathways, e.g. protein kinases or phosphatases, has not been suggested. WO 95/07463 further describes cells useful for the detection of molecules, such as hormones or heavy metals, in a biological sample, by operatively linking a regulatory element of the gene which is affected by the molecule of interest to a GFP, the presence of the molecules will affect the regulatory element which in turn will affect the expression of the GFP. In this way the gene encoding GFP is used as a reporter gene in a cell which is constructed for monitoring the presence of a specific molecular identity.

Green Fluorescent Protein has been used in an assay for the detection of translocation of the glucocorticoid receptor (GR) [(Carey, KL *et al.* 1996)]. A GR-S65TGFP fusion has been used to study the mechanisms involved in translocation of the glucocorticoid receptor (GR) in response to the agonist dexamethasone from the cytosol, where it is present in the absence of a ligand, through the nuclear pore to the nucleus where it remains after ligand binding. The use of a GR-GFP fusion enables real-time imaging and quantitation of nuclear/cytoplasmic ratios of the fluorescence signal. A similar genetic construct has been used to follow and quantify dexamethasone induced translocation of GR to the nucleus in HeLa cells [(Guiliano, K.A *et al.* 1997)] in a system called Array Scan™ (WO 97/45730) designed for automated drug screening. Recently, several other investigators have demonstrated that tagging a specific protein (or part of a protein) involved in an intracellular signalling pathway with GFP provides a new means to measure and quantify the influence of substances on this pathway. The concept has been shown to work both for cytoplasmic to nuclear translocation of the androgen receptor [(Georget V *et al.* 1997)] and transcription factors such as NF-ATc [(Beals CR *et al.* 1997)] in analogy with what has already been described for GR above. Another relevant example is a  $\beta$ -arrestin – GFP construct that was shown to report on activation of G-protein coupled receptors by translocating from the cytosol to the plasma membrane [(Barak LS *et al.* 1997)]. Finally, it has also been demonstrated that attaching GFP to a smaller part of a protein like the pleckstrin homology domain of phospholipase C  $\delta$  1 [(Stauffer TP *et al.* 1998)] and a cysteine-rich domain of PKC  $\gamma$  [(Oancea E *et al.* 1998)] can be used to report on an influence from a substance by quantifying their redistribution within the cells during activation of the specific signalling pathway to which they belong.

Many currently used screening programmes designed to find compounds that affect protein kinase activity are based on measurements of kinase phosphorylation of artificial or natural substrates, receptor binding and/or reporter gene expression. The interest in fluorescence measurements as the basis for future high-throughput drug screening has however increased dramatically over the last few years [(Silverman L *et al.* 1998)]. Of particular interest to the present invention is a scanning laser imager for rapid screening of fluorescence changes in living cells [(Schroeder K & Neagle B 1996)] currently offered commercially by Molecular Devices, Inc. as the FLIPR™.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention provides an important new dimension in the investigation of cellular systems involving redistribution in that the invention provides quantification of the redistribution responses or events caused by an influence, typically contact with a chemical substance or mixture of chemical substances, but also changes in the physical environment, in a massively parallel fashion. The quantification makes it possible to set up meaningful relationships, expressed numerically, or as curves or graphs, between the influences (or the degree of influences) on cellular systems and the redistribution response. This is highly advantageous because, as has been found, the quantification can be achieved in both a fast and reproducible manner, and - what is perhaps even more important - the systems which become quantifiable utilising the method of the invention are systems from which enormous amounts of new information and insight can be derived.

The present screening assays have the distinct advantage over other screening assays, e.g., receptor binding assays, enzymatic assays, and reporter gene assays, in providing a system in which biologically active substances with completely novel modes of action, e.g. inhibition or promotion of redistribution/translocation of a biologically active polypeptide as a way of regulating its action rather than inhibition/activation of enzymatic activity, can be identified in a way that insures very high selectivity to the particular isoform of the biologically active polypeptide and further development of compound selectivity versus other isoforms of the same biologically active polypeptide or other components of the same signalling pathway.

In one of its broadest aspects, the invention relates to an improved method, with higher throughput compared to previous methods, for extracting quantitative information relating to an influence on a cellular response, the method comprising recording variation, caused by the influence on mechanically intact living cells, in spatially distributed light emitted from a luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a component which is capable of being redistributed in a manner which is related to the degree of the influence, the association resulting in a modulation of the luminescence characteristics of the luminophore, detecting and recording the variation in spatially distributed light from the luminophore as

a change in fluorescence intensity using an instrument designed to measure changes in fluorescence intensity, and processing the recorded variation in the spatially distributed light to provide quantitative information correlating the spatial distribution or change in the spatial distribution to the degree of the influence. In one aspect of the present invention the mechanically intact living cell is permeabilised at some time after the influence has begun but during or before the actual experimental recording. In another aspect, the present invention relates to an improved method for extracting quantitative information relating to an influence on a cellular response, the method comprising recording variation, caused by the influence on permeabilised living cells, in spatially distributed light emitted from a luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a component which is capable of being redistributed in a manner which is related to the degree of the influence, the association resulting in a modulation of the luminescence characteristics of the luminophore, detecting and recording the spatially distributed light from the luminophore as a change in fluorescence intensity using an instrument designed to measure changes in fluorescence intensity, and processing the recorded variation in the spatially distributed light to provide quantitative information correlating the spatial distribution or change in the spatial distribution to the degree of the influence. In a preferred embodiment of the invention the luminophore, which is present in the cells, is capable of being redistributed by modulation of an intracellular pathway, in a manner which is related to the redistribution of at least one component of the intracellular pathway. In another preferred embodiment of the invention, the luminophore is a fluorophore.

Typically the cell and/or cells are mechanically intact and alive throughout the experiment. In another embodiment of the invention, the cells are fixed at a point in time after the application of the influence at which the response has been predetermined to be significant, and the recording is made at an arbitrary later time. In another embodiment the cell and/or cells are mechanically intact and alive throughout the experiment but are mechanically or chemically disrupted or permeabilised as the initial step of experimental analysis. In another aspect of the invention the cells have their plasma membrane permanently and stably permeabilised before the initiation of the experiment in such a way that the plasma membrane stays permeable during the experiment. This allows the components of intracellular pathways to be contacted by

substances that are not normally permeating the cell plasma membrane such as peptides, proteins and hydrophilic organic compounds..

The mechanically intact or permeabilised living cells could be selected from the group  
5 consisting of fungal cells, such as yeast cells; invertebrate cells including insect cells; and vertebrate cells, such as mammalian cells. These cells are incubated at a temperature of 30°C or above, preferably at a temperature of from 32°C to 39°C, more preferably at a temperature of from 35°C to 38°C, and most preferably at a temperature of about 37°C during the time period over which the influence is observed. In one aspect  
10 of the invention the mechanically intact or permeabilised living cell is part of a matrix of identical or non-identical cells. In one embodiment of the invention the cells comprise a group or groups of cells contained within a spatial limitation or spatial limitations. In one embodiment, the cells comprise multiple groups of cells that are qualitatively the same but subjected to different influences. In another embodiment, the cells comprise multiple  
15 groups of cells that are qualitatively different but subjected to the same influence.

In one embodiment of the invention the spatial limitations are domains defined on a substrate on which the cells are present. The spatial limitations may be arranged in one or more arrays on a common carrier. The spatial limitations may be wells in a plate of  
20 microtiter type, such that 96, 384, 864 and 1536 wells are situated on the common carrier. In another embodiment the spatial limitations are wells in a plate of a format different from the microtiter type. In one embodiment of the invention the domains are established by the presence of the cells on the substrate in a pattern that defines the domains. In another aspect of the invention, the domains are instead established by the  
25 spatial pattern or array of the influence or influences as it/they are applied to or contacted by the cells. This aspect is thoroughly disclosed in "Method and apparatus for high density format screening for bioactive molecules" the contents of which were part of the priority application, and which, as WO99/35496 has been published during the priority year, are hereby incorporated herein by reference. Briefly, in this aspect of the  
30 invention the mechanically intact or permeabilised living cells are part of a continuous or discontinuous sheet of cells cultured on an optically clear flat surface typically optimised for cell culture. The optically clear and flat surface may be a porous membrane that may allow cellular processes to grow through the membrane pores and may allow directed capillary flow of fluid through the pores.

A cell used in the present invention should contain a nucleic acid construct encoding a fusion polypeptide as defined herein and be capable of expressing the sequence encoded by the construct. The cell is a eukaryotic cell selected from the group consisting of fungal cells, such as yeast cells; invertebrate cells including insect cells; vertebrate  
5 cells such as mammalian cells. The preferred cells are mammalian cells.

In another aspect of the invention the cells could be from an organism carrying in at least one of its component cells a nucleic acid sequence encoding a fusion polypeptide as defined herein and be capable of expressing said nucleic acid sequence. The organism  
10 is selected from the group consisting of unicellular and multicellular organisms, such as a mammal.

The luminophore is the component that allows the redistribution to be visualised and/or recorded by emitting light in a spatial distribution related to the degree of influence. The  
15 term redistribution is intended to cover all aspects of a change in spatial location, such as a translocation of the luminophore or other components. In one embodiment of the invention, the luminophore is capable of being redistributed in a manner that is physiologically relevant to the degree of the influence. In another embodiment, the luminophore is capable of associating with a component that is capable of being  
20 redistributed in a manner that is physiologically relevant to the degree of the influence. In another embodiment, a correlation between the redistribution of the luminophore and the degree of the influence could be determined experimentally. In a preferred aspect of the invention, the luminophore is capable of being redistributed in substantially the same manner as the at least one component of an intracellular pathway. In another  
25 embodiment of the invention, the luminophore is capable of being quenched upon spatial association with a component that is redistributed by modulation of the pathway, the quenching being measured as a change in the intensity of the luminescence. In another embodiment of the invention, the luminophore is stationary but may have a certain spatial distribution, and interacts with at least one component that is capable of being  
30 redistributed in a manner which is physiologically relevant to the degree of the influence, in such a way that one or more luminescence characteristics of the luminophore is/are modulated as the component moves closer to, or farther from, the luminophore.

The luminophore could be a fluorophore. In a preferred embodiment of the invention, the  
35 luminophore is a polypeptide encoded by and expressed from a nucleotide sequence

harboured in the cells. The luminophore could be a hybrid polypeptide comprising a fusion of at least a portion of each of two polypeptides one of which comprises a luminescent polypeptide and the other one of which comprises a biologically active polypeptide, as defined herein.

5

The luminescent polypeptide could be a GFP as defined herein or could be selected from the group consisting of green fluorescent proteins having the F64L mutation as defined herein such as F64L-GFP, F64L-Y66H-GFP, F64L-S65T-GFP, and EGFP. The GFP could be N- or C-terminally tagged, optionally via a peptide linker, to the biologically  
10 active polypeptide or a part or a subunit thereof. The fluorescent probe could be a component of an intracellular signalling pathway. The probe is coded for by a nucleic acid construct.

In one aspect of the invention the pathway of investigation is an intracellular signalling  
15 pathway.

In a preferred embodiment of the invention, the influence could be contact between the group or groups of mechanically intact or permeabilised living cells and a chemical substance, and/or incubation of the group or groups of mechanically intact or  
20 permeabilised living cells with a chemical substance in solution. In one aspect of the invention that is thoroughly described in "Method and apparatus for high density format screening for bioactive molecules" the contents of which were part of the priority application, and which, as WO99/35496 has been published during the priority year, are hereby incorporated herein by reference, the chemical substances are attached to an  
25 underlying matrix. In this aspect, the chemical substances may also be produced and secreted from, or attached to the plasma membrane surfaces of, a sheet of genetically engineered cells. In this aspect of the invention the chemical substances may also have been separated two-dimensionally in a non-denaturing gel using electrophoresis and the gel is directly put in close proximity or direct contact with the mechanically intact or  
30 permeabilised living cells so that the chemical substances can contact the cells through diffusion or convection.

The influence will modulate the intracellular processes. In one aspect the modulation could be an activation of the intracellular processes. In another aspect the modulation  
35 could be a deactivation of the intracellular processes. In yet another aspect, the

influence could inhibit or promote the redistribution without directly affecting the metabolic activity of the component of the intracellular processes.

- In one embodiment the invention is used to establish a dose-response relationship for one or many chemical substances. In one embodiment the invention is used as a basis for a screening program, where the effect of unknown influences such as a compound library, can be compared to influence of known reference compounds under standardised conditions.
- 10 In addition to the intensity, there are several parameters of fluorescence or luminescence that can be modulated by the effect of the influence on the underlying cellular phenomena, and can therefore be used in the invention. Some examples are resonance energy transfer, fluorescence lifetime, polarisation, and wavelength shift. Each of these methods requires a particular kind of filter in the emission light path to select the
- 15 component of the light desired and reject other components. The recording of property of light could be in the form of an ordered array of values such as a CCD array or a vacuum tube device such as a vidicon. In addition, the translational mobility, or freedom of movement, of the luminophore attached to the protein of interest can be an important property affected by the influence on the underlying cellular phenomena, and can
- 20 therefore be used in the invention.

- In one embodiment of the invention, the spatially distributed light emitted by a luminophore is detected by a change in the resonance energy transfer between the luminophore and another luminescent entity capable of delivering energy to the
- 25 luminophore, each of which has been selected or engineered to become part of, bound to or associated with particular components of the intracellular pathway. In this embodiment, either the luminophore or the luminescent entity capable of delivering energy to the luminophore undergoes redistribution in response to an influence. The resonance energy transfer would be measured as a change in the intensity of emission
- 30 from the luminophore, preferably sensed by a single channel photodetector that responds only to the average intensity of the luminophore in a non-spatially resolved fashion.

- In one embodiment of the invention, the spatially distributed light emitted by a
- 35 luminophore includes the case of uniform spatial distribution of the light.

In one aspect of the invention, the luminophore is a fluorophore which redistributes through a non-homogenous excitation light field, resulting in a change in the intensity of the light emitted from the luminophore as a result of the change in the amount of  
5 excitation light intensity at different points in the field.

In one embodiment of the invention, the recording of the spatially distributed light could be made at a single point in time after the application of the influence. In another embodiment, the recording could be made at two points in time, one point being before,  
10 and the other point being after the application of the influence. The result or variation is determined from the change in fluorescence compared to the fluorescence measured prior to the influence or modulation. In another embodiment of the invention, the recording could be performed at a series of points in time, in which the application of the influence occurs at some time after the first time point in the series of recordings, the  
15 recording being performed, e.g., with a predetermined time spacing of from 0.1 seconds to 1 hour, preferably from 1 to 60 seconds, more preferably from 1 to 30 seconds, in particular from 1 to 10 seconds, over a time span of from 1 second to 12 hours, such as from 10 seconds to 12 hours, e.g., from 10 seconds to one hour, such as from 60 seconds to 30 minutes or 20 minutes. The result or variation is determined from the  
20 change in fluorescence over time. The result or variation could also be determined as a change in the spatial distribution of the fluorescence over time.

In one embodiment the recording comprises a time series of total luminescence of the cells of one or several of the spatial limitations. In one embodiment the signal from all of  
25 the spatial limitations, one at a time, is measured by a recording being made in the individual spatial limitations by means of an apparatus to sequentially position each one of the limitations in the field of view of the detector and repeating the positioning and measurement process until all of the spatial limitations have been measured. The detector may be a photomultiplier tube. In a preferred embodiment of the present  
30 invention more than one spatial limitation is measured simultaneously. This may be done by means of a one- or two-dimensional array detector, whereby the multiple spatial limitations are imaged onto the array detector such that discrete subsets of the detecting units (pixels) in the array detector measure the signal from one and only one of the multiple spatial limitations, the signal from any one spatial limitation being the combined  
35 signal from those pixels that receive the image from one of the spatial limitations. This

array detector may be a linear diode array, a video camera (according to any present or future standards and definitions of image acquisition and transmission) or a charge transfer device such as a charge-coupled device (CCD). In one embodiment the recording of signal requires illumination of the multiple spatial limitations to excite the

5 luminophores so that they emit light. In one embodiment all of the spatial limitations are simultaneously illuminated during the measurement. In another embodiment the spatial limitations are singly illuminated only during the time in which they are being measured. In a preferred embodiment the illumination is provided by a laser that is scanned in a raster fashion over some or all of the spatial limitations being measured. The scanning

10 may take place at a rate that is substantially faster than the measurement process such that the illumination appears to the measurement process to be continuous in time and spatially uniform over the region being measured.

The recording of spatially distributed luminescence emitted from the luminophore is

15 performed by an apparatus for measuring the distribution of fluorescence in the cells, and thereby any change in the distribution of fluorescence in the cells, which includes at a minimum the following component parts: (a) a light source, (b) a method for selecting the wavelength(s) of light from the source which will excite the luminescence of the luminophore, (c) a device which can rapidly block or pass the excitation light into the rest

20 of the system, (d) a series of optical elements for conveying the excitation light to the specimen, collecting the emitted fluorescence in a spatially resolved fashion, and forming an image from this fluorescence emission (or another type of intensity map relevant to the method of detection and measurement), (e) a bench or stand which holds the container of the cells being measured in a predetermined geometry with respect to the

25 series of optical elements, (f) a detector to record the spatially resolved fluorescence in the form of an image, (g) a computer or electronic system and associated software to acquire and store the recorded images, and to compute the degree of redistribution from the recorded images.

30 In a preferred embodiment of the invention the apparatus system is automated. In one embodiment the components in d and e mentioned above comprise a fluorescence microscope. In one embodiment the component in f mentioned above is a CCD camera. In one embodiment the component in f mentioned above is an array of photomultiplier tubes/devices.

In one embodiment the image is formed and recorded by an optical scanning system.

In one embodiment the optical scanning system is used to illuminate the bottom of a plate of microtiter type so that a time-resolved recording of changes in luminescence or  
5 fluorescence can be made from all spatial limitations simultaneously.

In a preferred embodiment the actual luminescence or fluorescence measurements are made in a FLIPR™ instrument, commercially available from Molecular Devices, Inc.

10 In one embodiment of the invention the actual fluorescence measurements are made in a standard type of fluorometer for plates of microtiter type (fluorescence plate reader).

In one embodiment a liquid addition system is used to add a known or unknown compound to any or all of the cells in the cell holder at a time determined in advance.

15 Preferably, the liquid addition system is under the control of the computer or electronic system. Such an automated system can be used for a screening program due to its ability to generate results from a larger number of test compounds than a human operator could generate using the apparatus in a manual fashion.

20 The methods whereby the detector layer of cells are physically contacted by the compounds can also be of another conceptual type where the compounds are delivered to the cells through a porous membrane by convection/diffusion or by directly contacting compounds attached to an inorganic or organic support (such as glass, plastic or the plasma membrane of intact living cells) with the cells. These methods are thoroughly  
25 described in "Method and apparatus for high density format screening for bioactive molecules" the contents of which were part of the priority application, and which, as WO99/35496 has been published during the priority year, are hereby incorporated herein by reference, but are also outlined in the following paragraphs.

30 In one aspect of the present invention where the detector layer of cells is a continuous or discontinuous sheet of cells without any separation into test units or wells. The compounds are printed onto a nonabsorbent sheet of porous material as a solution in solvent and allowed to dry. This printed sheet of compounds then defines the test pattern for the experiment as it is brought down in close proximity to or in direct contact with the  
35 underlying detector layer of cells. The compounds, now dissolved by the fluid layer on

the cells, is brought in contact with the cells through the pores of the membrane by convection. The porous membrane onto which the compounds are printed is optically clear and preferably composed as stated in "Method and apparatus for high density format screening for bioactive molecules" the contents of which were part of the priority application, and which, as WO99/35496 has been published during the priority year, are hereby incorporated herein by reference. In another embodiment of this aspect of the present invention the detector layer of cells is a continuous or discontinuous sheet of cells, without any separation into test units or wells, growing on a porous and optically clear membrane preferably of the types mentioned above. The porous membrane may allow the cells to send cellular processes through the pores of the membrane. The compounds are printed onto an optically clear substratum such as glass, plastic or quartz as solutions in solvent and allowed to dry. At the time of the experiment the cell sheet on the membrane, surrounded by a thin film of fluid, is layered on top of the printed compound pattern. The compounds then dissolve and contact the cells via diffusion and convection. The compounds may be made using combinatorial chemistry techniques, and may be peptides. The compounds may be covalently attached to the optically clear substratum or porous membrane. The compounds may also be proteins, polypeptides or peptides secreted by or attached to the plasma membrane of genetically modified cells growing as a continuous or discontinuous sheet on a flat optically clear surface or an optically clear porous membrane.

The recording of the variation or result with respect to light emitted from the luminophore is performed by recording the spatially distributed light as one or more digital images, and the processing of the recorded variation to reduce it to one or more numbers representative of the degree of redistribution comprises a digital image processing procedure or combination of digital image processing procedures. The quantitative information which is indicative of the degree of the cellular response to the influence or the result of the influence on the intracellular pathway is extracted from the recording or recordings according to a predetermined calibration based on responses or results, recorded in the same manner, to known degrees of a relevant specific influence. This calibration procedure is developed according to principles described below (Developing an Image-based Assay Technique). Specific descriptions of the procedures for particular assays are given in the examples.

While the stepwise procedure necessary to reduce the image or images to the value representative of the response caused by the influence is particular to each assay, the individual steps are generally well-known methods of image processing. Some examples of the individual steps are point operations such as subtraction, ratioing, and

5 thresholding, digital filtering methods such as smoothing, sharpening, and edge detection, spatial frequency methods such as Fourier filtering, image cross-correlation and image autocorrelation, object finding and classification (blob analysis), and colour space manipulations for visualisation. In addition to the algorithmic procedures, heuristic methods such as neural networks may also be used. In a preferred embodiment of the

10 invention, a dose-response relationship is established based on quantification of the responses caused by a particular influence, representative of the underlying intracellular signalling process, using the methods described above and in the examples. The dose-response relationship for the particular influence is then compared to the dose-response relationship obtained by performing the same assay in an instrument which allows

15 parallel monitoring of all wells in a microtiter plate such as a FLIPR™ or an ordinary fluorescence plate reader for microtiter plates. If a good correlation between the dose-response relationships obtained from the two different measurement systems is obtained, it can be said that the parallel measurement mode has been validated (see examples 8, 9, 10 and 11). This implies that it can be used as the primary basis for a

20 screening assay with the potential benefit of screening a significantly higher number of substances per unit of time for their influence on the response. For example, if the single experiment performed on the microscope can be run in at least 96 experimental chambers simultaneously the throughput for the person who is running the experiments increases by a factor of 96.

25

Imaging plate readers integrate the signal from each well into a single value per time point. Thus the data resulting from a single "run" of the instrument is a set of time series of single values, one for each well, with the injection of the test compound taking place at a known point in the time series. The primary advantage of this type of instrumentation is

30 that it greatly increases the number of samples that can be processed in a given amount of time (the throughput). This is of great advantage when using the assay in a screening program for new pharmaceutical lead compounds.

The first step in the data analysis is to normalise the results from each well so that they

35 can be compared with each other or with previously analysed known compounds. This

always begins with correcting the signal by subtracting the instrument bias from all data points on a well-by-well basis. From this point, either of two techniques can be followed depending on the design of the assay:

Procedure 1: The average of the signal prior to the addition of the test compound is

5 subtracted from all data points on a well-by-well basis.

Procedure 2: The data are corrected for any known background by subtracting the background value from all data points on a well-by-well basis. The resulting background-corrected data are normalised by dividing each data set by the average of the data values prior to the injection of the test compound on a well-by-well basis.

10

The corrected or normalised time series data sets are then further reduced by a technique that converts the time series to a single value. There are at least three such approaches:

For transient responses, the maximum deviation from the baseline is determined. This is  
15 also known as the "peak height" technique.

Alternatively, the signal is integrated over time between pre-defined limits. If the data were treated according to Procedure 2 above, then the offset is subtracted such that the integral of a non-response is zero within the limit of measurement error. This is also  
20 known as the "peak area" technique. If the response is a cumulative one, e.g., an exponential change to a new level, the result is taken as the either the difference or the ratio between the signal after a predetermined time and the signal prior to the addition of the test compound.

25 All of the above procedures reduce the data for a given well to one or more single values. For screening purposes, these values will be searched for those that are greater than a certain statistically determined cut-off value. For characterisation, the values represent a quantitative response, and are further treated in sets by techniques such as dose-response curve fitting.

30

In another embodiment of the invention, the measurement of redistribution is accomplished indirectly by taking advantage of the fact that in order for redistribution to occur, the probe will experience some change in its freedom, or restriction, of movement within the intracellular milieu. The degree of translocation will correlate with the amount  
35 of freely mobile luminophore in the cytoplasm. At a point in time after the test compound

has begun to have any influence it may have, the amount or fraction of restricted luminophore can be measured by disrupting or permeabilising the plasma membrane of the cells and allowing the freely mobile luminophore to diffuse away. If the detection volume of the detector is limited to the region immediately surrounding the cells, and the overall volume into which the freely mobile luminophore can diffuse is much larger, then the freely mobile luminophore essentially disappears from the detector's view and its signal is not recorded.

In one aspect of the invention, the above mentioned measurement of redistribution is made on cells with permanently permeabilised plasma membranes immersed in a solution mimicking the cytoplasmic environment. In this way the influence of compounds that can normally not enter the cytoplasm of cells can be tested.

The nucleic acid constructs used in the present invention encode in their nucleic acid sequences fusion polypeptides comprising a biologically active polypeptide that is a component of an intracellular signalling pathway, or a part thereof, and a GFP, preferably an F64L mutant of GFP, N- or C-terminally fused, optionally via a peptide linker, to the biologically active polypeptide or part thereof. In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a protein kinase or a phosphatase. In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a transcription factor or a part thereof which changes cellular localisation upon activation.

In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a protein, or a part thereof, which is associated with the cytoskeletal network and which changes cellular localisation upon activation. In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a protein kinase or a part thereof which changes cellular localisation upon activation. In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a serine/threonine protein kinase or a part thereof capable of changing intracellular localisation upon activation. In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a tyrosine protein kinase or a part thereof capable of changing intracellular localisation upon activation. In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a phospholipid-

dependent serine/threonine protein kinase or a part thereof capable of changing intracellular localisation upon activation.

In a specific embodiment the constructs listed in table 1 are used in a method for  
 5 extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed fluorescence emitted from the fluorophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or being modulated by a component which is capable of  
 10 being redistributed in a manner which is related to the degree of the influence, as a change fluorescence intensity preferably measured by an instrument designed for the measurement of changes in fluorescence intensity.

**Table 1** The fusion constructs of the invention by the names used herein as well as by reference to relevant SEQ ID NOs of sequences of DNA encoding the construct and full  
 15 amino acid sequences.

Fusion construct	DNA sequence SEQ ID NO:	Protein Sequence SEQ ID NO:
PKAcat - F64LS65TGFP	1	2
PKC $\alpha$ - F64L-S65TGFP	3	4
EGFP - Erk1	5	6
EGFP - SMAD2	7	8
SMAD2 - EGFP	9	10
EGFP - VASP	11	12
EGFP - NF $\chi$ $\beta$	13	14
NF $\chi$ $\beta$ - EGFP	15	16
EGFP - PKC $\beta$ 1	17	18

As illustrated in examples 8, 9 and 11, the redistribution of PKA, and PKC can readily be detected as a variation in fluorescence intensity, as measured e.g. in the FLIPR<sup>TM</sup> instrument.

20

In one embodiment any new luminophore determined to redistribute in response to an influence in a pattern similar to the pattern observed in the microscope for PKA or PKC (see examples 1, 2, 8 and 11), that is from an aggregated form to a dispersed form or from a dispersed form to an aggregated form of the luminophore as the redistribution  
 25 takes place, can be predicted to be detectable as a variation in light intensity as measured, for example in the FLIPR<sup>TM</sup> instrument.

In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a cAMP-dependent protein kinase or a part thereof capable of changing cellular localisation upon activation. In a preferred embodiment the biologically active polypeptide encoded by the nucleic acid construct is a PKAc-F64L-S65T-GFP fusion. In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a cGMP-dependent protein kinase or a part thereof capable of changing cellular localisation upon activation.

10 In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a calmodulin-dependent serine/threonine protein kinase or a part thereof capable of changing cellular localisation upon activation.

In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a mitogen-activated serine/threonine protein kinase or a part thereof capable of changing cellular localisation upon activation. In preferred embodiments the biologically active polypeptide encoded by the nucleic acid constructs are an ERK1-F64L-S65T-GFP fusion or an EGFP-ERK1 fusion.

20 In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a cyclin-dependent serine/threonine protein kinase or a part thereof capable of changing cellular localisation upon activation.

In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a protein phosphatase or a part thereof capable of changing cellular localisation upon activation.

In one preferred embodiment of the invention the nucleic acid constructs may be DNA constructs.

30

In one embodiment the biologically active polypeptide encoded by the nucleic acid construct. In one embodiment the gene encoding GFP in the nucleic acid construct is derived from *Aequorea victoria*. In a preferred embodiment the gene encoding GFP in the nucleic acid construct is EGFP or a GFP variant selected from F64L-GFP, F64L-Y66H-GFP and F64L-S65T-GFP.

In preferred embodiments of the invention the DNA constructs which can be identified by any of the DNA sequences shown in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15 and 17 or are variants of these sequences capable of encoding the same fusion polypeptide or a fusion polypeptide which is biologically equivalent thereto, e.g. an isoform, or a splice variant or a homologue from another species.

The present invention describes a method that may be used to establish a screening program for the identification of biologically active substances that directly or indirectly affects intracellular signalling pathways and because of this property are potentially useful as medicaments. Based on measurements in living cells of the redistribution of spatially resolved luminescence from luminophores which undergo a change in distribution upon activation or deactivation of an intracellular signalling pathway the result of the individual measurement of each substance being screened indicates its potential biological activity.

In one embodiment of the invention the screening program is used for the identification of a biologically toxic substance as defined herein that exerts its toxic effect by interfering with an intracellular signalling pathway. Based on measurements in living cells of the redistribution of spatially resolved luminescence from luminophores which undergo a change in distribution upon activation or deactivation of an intracellular signalling pathway the result of the individual measurement of each substance being screened indicates its potential biologically toxic activity. In one embodiment of a screening program a compound that modulates a component of an intracellular pathway as defined herein, can be found and the therapeutic amount of the compound estimated by a method according to the method of the invention. In a preferred embodiment the present invention leads to the discovery of a new way of treating a condition or disease related to the intracellular function of a biologically active polypeptide comprising administration to a patient suffering from said condition or disease of an effective amount of a compound which has been discovered by any method according to the invention. In another preferred embodiment of the invention a method is established for identification of a new drug target or several new drug targets among the group of biologically active polypeptides which are components of intracellular signalling pathways.

- In another embodiment of the invention an individual treatment regimen is established for the selective treatment of a selected patient suffering from an ailment where the available medicaments used for treatment of the ailment are tested on a relevant primary cell or cells obtained from said patient from one or several tissues, using a method
- 5 comprising transfecting the cell or cells with at least one DNA sequence encoding a fluorescent probe according to the invention, transferring the transfected cell or cells back the said patient, or culturing the cell or cells under conditions permitting the expression of said probes and exposing it to an array of the available medicaments, then comparing changes in fluorescence patterns or redistribution patterns of the fluorescent
- 10 probes in the intact living cells to detect the cellular response to the specific medicaments (obtaining a cellular action profile), then selecting one or more medicament or medicaments based on the desired activity and acceptable level of side effects and administering an effective amount of these medicaments to the selected patient.
- 15 The present invention describes a method that may be used to establish a screening program for back-tracking signal transduction pathways as defined herein. In one embodiment the screening program is used to establish more precisely at which level one or several compounds affect a specific signal transduction pathway by successively or in parallel testing the influence of the compound or compounds on the redistribution of
- 20 spatially resolved luminescence from several of the luminophores which undergo a change in distribution upon activation or deactivation of the intracellular signalling pathway under study.

In general, a probe, i.e. a "GeneX"-GFP fusion or a GFP-"GeneX" fusion, is constructed

25 using PCR with "GeneX"-specific primers followed by a cloning step to fuse "GeneX" in frame with GFP. The fusion may contain a short vector derived sequence between "GeneX" and GFP (e.g. part of a multiple cloning site region in the plasmid) resulting in a peptide linker between "GeneX" and GFP in the resulting fusion protein.

- 30 Some of the steps involved in the development of a probe include the following:  
Identify the sequence of the gene. This is most readily done by searching a depository of genetic information, e.g. the GenBank Sequence Database, which is widely available and routinely used by molecular biologists. In the specific examples below the GenBank Accession number of the gene in question is provided.

Design the gene-specific primers. Inspection of the sequence of the gene allows design of gene-specific primers to be used in a PCR reaction. Typically, the top-strand primer encompasses the ATG start codon of the gene and the following ca. 20 nucleotides, while the bottom-strand primer encompasses the stop codon and the ca. 20 preceding  
5 nucleotides, if the gene is to be fused behind GFP, i.e. a GFP-"GeneX" fusion. If the gene is to be fused in front of GFP, i.e. a "GeneX"-GFP fusion, a stop codon must be avoided. Optionally, the full-length sequence of GeneX may not be used in the fusion, but merely the part that localizes and redistributes like GeneX in response to a signal. In addition to gene-specific sequences, the primers contain at least one recognition  
10 sequence for a restriction enzyme, to allow subsequent cloning of the PCR product. The sites are chosen so that they are unique in the PCR product and compatible with sites in the cloning vector. Furthermore, it may be necessary to include an exact number of nucleotides between the restriction enzyme site and the gene-specific sequence in order to establish the correct reading frame of the fusion gene and/or a translation initiation  
15 consensus sequence. Lastly, the primers always contain a few nucleotides in front of the restriction enzyme site to allow efficient digestion with the enzyme.

Identify a source of the gene to be amplified. In order for a PCR reaction to produce a product with gene-specific primers, the gene-sequence must initially be present in the  
20 reaction, e.g. in the form of cDNA. Information in GenBank or the scientific literature will usually indicate in which tissue(s) the gene is expressed, and cDNA libraries from a great variety of tissues or cell types from various species are commercially available, e.g. from Clontech (Palo Alto), Stratagene (La Jolla) and Invitrogen (San Diego). Many genes are also available in cloned form from The American Type Tissue Collection (Virginia).

25

Optimise the PCR reaction. Several factors are known to influence the efficiency and specificity of a PCR reaction, including the annealing temperature of the primers, the concentration of ions, notably  $Mg^{2+}$  and  $K^+$ , present in the reaction, as well as pH of the reaction. If the result of a PCR reaction is deemed unsatisfactory, it might be because  
30 the parameters mentioned above are not optimal. Various annealing temperatures should be tested, e.g. in a PCR machine with a built-in temperature gradient, available from e.g. Stratagene (La Jolla), and/or various buffer compositions should be tried, e.g. the OptiPrime buffer system from Stratagene (La Jolla).

Clone the PCR product. The vector into which the amplified gene product will be cloned  
35 and fused with GFP will already have been taken into consideration when the primers

were designed. When choosing a vector, one should at least consider in which cell types the probe subsequently will be expressed, so that the promoter controlling expression of the probe is compatible with the cells. Most expression vectors also contain one or more selective markers, e.g. conferring resistance to a drug, which is a useful feature when  
5 one wants to make stable transfectants. The selective marker should also be compatible with the cells to be used.

The actual cloning of the PCR product should present no difficulty as it typically will be a one-step cloning of a fragment digested with two different restriction enzymes into a  
10 vector digested with the same two enzymes. If the cloning proves to be problematic, it may be because the restriction enzymes did not work well with the PCR fragment. In this case one could add longer extensions to the end of the primers to overcome a possible difficulty of digestion close to a fragment end, or one could introduce an intermediate cloning step not based on restriction enzyme digestion. Several companies offer systems  
15 for this approach, e.g. Invitrogen (San Diego) and Clontech (Palo Alto).

Once the gene has been cloned and, in the process, fused with the GFP gene, the resulting product, usually a plasmid, should be carefully checked to make sure it is as expected. The most exact test would be to obtain the nucleotide sequence of the fusion-  
20 gene.

Once a DNA construct for a probe has been generated, its functionality and usefulness may be evaluated by transfecting it into cells capable of expressing the probe. The fluorescence of the cell is inspected soon after, typically the next day. At this point, two  
25 features of cellular fluorescence are noted: the intensity and the sub-cellular localisation.

The intensity should usually be at least as strong as that of unfused GFP in the cells. If it is not, the sequence or quality of the probe-DNA might be faulty, and should be carefully checked.  
30

The sub-cellular localisation is an indication of whether the probe is likely to perform well. If it localises as expected for the gene in question, e.g. is excluded from the nucleus, it can immediately go on to a functional test. If the probe is not localised soon after the transfection procedure, it may be because of overexpression at this point in time, as the  
35 cell typically will have taken up very many copies of the plasmid, and localisation will

occur in time, e.g. within a few weeks, as plasmid copy number and expression level decreases. If localisation does not occur after prolonged time, it may be because the fusion to GFP has destroyed a localisation function, e.g. masked a protein sequence essential for interaction with its normal cellular anchor-protein. In this case the opposite fusion might work, e.g. if GeneX-GFP does not work, GFP-GeneX might, as two different parts of GeneX will be affected by the proximity to GFP. If this does not work, the proximity of GFP at either end might be a problem, and it could be attempted to increase the distance by incorporating a longer linker between GeneX and GFP in the DNA construct.

10

If there is no prior knowledge of localisation, and no localisation is observed, it may be because the probe should not be localised at this point, because such is the nature of the protein fused to GFP. It should then be subjected to a functional test.

- 15 In a functional test, the cells expressing the probe are treated with at least one compound known to perturb, usually by activating, the signalling pathway on which the probe is expected to report by redistributing itself within the cell. If the redistribution is as expected, e.g. if prior knowledge tell that it should translocate from location X to location Y, it has passed the first critical test. In this case it can go on to further characterisation and quantification of the response.

- 20 If it does not perform as expected, it may be because the cell lacks at least one component of the signalling pathway, e.g. a cell surface receptor, or there is species incompatibility, e.g. if the probe is modelled on sequence information of a human gene product, and the cell is of hamster origin. In both instances one should identify other cell types for the testing process where these potential problems would not apply.

- 25 If there is no prior knowledge about the pattern of redistribution, the analysis of the redistribution will have to be done in greater depth to identify what the essential and indicative features are, and when this is clear, it can go on to further characterisation and quantification of the response. If no feature of redistribution can be identified, the problem might be as mentioned above, and the probe should be retested under more optimal cellular conditions. If the probe does not perform under optimal cellular conditions, then it's back to the drawing board.

35

The process of developing an image-based redistribution assay begins with either the unplanned experimental observation that a redistribution phenomenon can be visualised, or the design of a probe specifically to follow a redistribution phenomenon already known to occur. In either event, the first and best exploratory technique is for a trained scientist or technician to observe the phenomenon. Even with the rapid advances in computing technology, the human eye-brain combination is still the most powerful pattern recognition system known, and requires no advance knowledge of the system in order to detect potentially interesting and useful patterns in raw data. This is especially if those data are presented in the form of images, which are the natural "data type" for human visual processing. Because human visual processing operates most effectively in a relatively narrow frequency range, i.e., we cannot see either very fast or very slow changes in our visual field, it may be necessary to record the data and play it back with either time dilation or time compression.

Some luminescence phenomena cannot be seen directly by the human eye. Examples include polarisation and fluorescence lifetime. However, with suitable filters or detectors, these signals can be recorded as images or sequences of images and displayed to the human in the fashion just described. In this way, patterns can be detected and the same methods can be applied.

20

Once the redistribution has been determined to be a reproducible phenomenon, one or more data sets are generated for the purpose of developing a procedure for extracting the quantitative information from the data. In parallel, the biological and optical conditions are determined which will give the best quality raw data for the assay. This can become an iterative process; it may be necessary to develop a quantitative procedure in order to assess the effect on the assay of manipulating the assay conditions.

The data sets are examined by a person or persons with knowledge of the biological phenomenon and skill in the application of image processing techniques. The goal of this exercise is to determine or at least propose a method that will reduce the image or sequence of images constituting the record of a "response" to a value corresponding to the degree of the response. Using either interactive image processing software or an image processing toolbox and a programming language, the method is encoded as a procedure or algorithm that takes the image or images as input and generates the

degree of response (in any units) as its output. Some of the criteria for evaluating the validity of a particular procedure are:

Does the degree of the response vary in a biologically significant fashion, i.e., does it  
5 show the known or putative dependence on the concentration of the stimulating agent or condition?

Is the degree of response reproducible, i.e., does the same concentration or level of stimulating agent or condition give the same response with an acceptable variance? Is  
10 the dynamic range of the response sufficient for the purpose of the assay? If not, can a change in the procedure or one of its parameters improve the dynamic range? Does the procedure exhibit any clear "pathologies", i.e., does it give ridiculous values for the response if there are commonly occurring imperfections in the imaging process? Can these pathologies be eliminated, controlled, or accounted for? Can the procedure deal  
15 with the normal variation in the number and/or size of cells in an image?

In some cases the method may be obvious; in others, a number of possible procedures may suggest themselves. Even if one method appears clearly superior to others, optimisation of parameters may be required. The various procedures are applied to the  
20 data set and the criteria suggested above are determined, or the single procedure is applied repeatedly with adjustment of the parameter or parameters until the most satisfactory combination of signal, noise, range, etc. are arrived at. This is equivalent to the calibration of any type of single-channel sensor.

25 The number of ways of extracting a single value from an image are extremely large, and thus an intelligent approach must be taken to the initial step of reducing this number to a small, finite number of possible procedures. This is not to say that the procedure arrived at is necessarily the best procedure - but a global search for the best procedure is simply out of the question due to the sheer number of possibilities involved.

30

Image-based assays are no different than other assay techniques in that their usefulness is characterised by parameters such as the specificity for the desired component of the sample, the dynamic range, the variance, the sensitivity, the concentration range over which the assay will work, and other such parameters. While it is not necessary to

characterise each and every one of these before using the assay, they represent the only way to compare one assay with another.

The final step is then to see whether there exists a possibility to increase the throughput of the assay to improve its utility as the basis of a screening program. In order to do this, a dose-response relationship is established based on quantification of the responses caused by a particular influence, representative of the underlying intracellular signalling process, using the methods described above and in the examples. The dose-response relationship for the particular influence is then compared to the dose-response relationship obtained by performing the same assay in an instrument which allows parallel monitoring of all wells in a microtiter plate such as a FLIPR™ or an ordinary imaging or fluorescence plate reader for microtiter plates. If a good correlation between the dose-response relationships obtained from the two different measurement systems is obtained, it can be said that the parallel measurement mode has been validated (see examples 8, 9 and 11). This implies that it can be used as the primary basis for a screening program with the potential benefit of screening a significantly higher number of substances for their influence on the response per unit of time.

In the present specification and claims, the term "an influence" covers any influence to which the cellular response comprises a redistribution. Thus, e.g., heating, cooling, pH, high pressure, low pressure, humidifying, or drying are influences on the cellular response on which the resulting redistribution can be quantified, but as mentioned above, perhaps the most important influences are the influences of contacting or incubating the cells with substances which are known or suspected to exert an influence on the cellular response involving a redistribution contribution. In another embodiment of the invention the influence could be substances from a compound drug library.

In the present context, the term "green fluorescent protein" is intended to indicate a protein which, when expressed by a cell, emits fluorescence upon exposure to light of the correct excitation wavelength (cf. [(Chalfie, M. *et al.* (1994) *Science* 263, 802-805)]). In the following, GFP in which one or more amino acids have been substituted, inserted or deleted is most often termed "modified GFP". "GFP" as used herein includes wild-type GFP derived from the jelly fish *Aequorea victoria* and modifications of GFP, such as the blue fluorescent variant of GFP disclosed by Heim *et al.* (1994). *Proc.Natl.Acad.Sci.* 91:26, pp 12501-12504, and other modifications that change the spectral properties of the GFP

fluorescence, or modifications that exhibit increased fluorescence when expressed in cells at a temperature above about 30°C described in PCT/DK96/00051, published as WO 97/11094 on 27 March 1997 and hereby incorporated by reference, and which comprises a fluorescent protein derived from *Aequorea* Green Fluorescent Protein (GFP) or any functional analogue thereof, wherein the amino acid in position 1 upstream from the chromophore has been mutated to provide an increase of fluorescence intensity when the fluorescent protein of the invention is expressed in cells. Preferred GFP variants are F64L-GFP, F64L-Y66H-GFP and F64L-S65T-GFP. An especially preferred variant of GFP for use in all the aspects of this invention is EGFP (DNA encoding EGFP which is a F64L-S65T variant with codons optimized for expression in mammalian cells is available from Clontech, Palo Alto, plasmids containing the EGFP DNA sequence, cf. GenBank Acc. Nos. U55762, U55763).

The term "intracellular signalling pathway" and "signal transduction pathway" are intended to indicate the co-ordinated intracellular processes whereby a living cell transduce an external or internal signal into cellular responses. Said signal transduction will involve an enzymatic reaction said enzymes include but are not limited to protein kinases, GTPases, ATPases, protein phosphatases, phospholipases and cyclic nucleotide phosphodiesterases. The cellular responses include but are not limited to gene transcription, secretion, proliferation, mechanical activity, metabolic activity, cell death.

The term "second messenger" is used to indicate a low molecular weight component involved in the early events of intracellular signal transduction pathways.

The term "luminophore" is used to indicate a chemical substance that has the property of emitting light either inherently or upon stimulation with chemical or physical means. This includes but is not limited to fluorescence, bioluminescence, phosphorescence, and chemiluminescence.

The term "mechanically intact living cell" is used to indicate a cell which is considered living according to standard criteria for that particular type of cell such as maintenance of normal membrane potential, energy metabolism, proliferative capability, and has not experienced any physically invasive treatment designed to introduce external substances into the cell such as microinjection.

In the present context, the term "permeabilised living cell" is used to indicate cells where a pore forming agent such as Streptolysin O or *Staphylococcus Aureus*  $\alpha$ -toxin has been applied and thereby incorporated into the plasma membrane in the cells. This creates  
5 proteinaceous pores with a defined pore size in the plasma membranes of the exposed cells. Pores could also be made by electroporation, i.e. exposing the cells to high voltage discharges, a procedure that creates small holes in the plasma membrane by coagulating integral membrane proteins. Treatment with a mild detergent such as saponin may accomplish the same thing. Common to all these treatments are that pores  
10 are formed only in the plasma membrane without affecting the integrity of cytoplasmic structural elements and organelles. The term living in this context means that the permeabilised cells bathed in a solution mimicking the intracellular milieu still have functional organelles, such as actively respiring mitochondria and endoplasmic reticulum that can take up and release calcium ions, and functional structural elements. The  
15 benefit of this method is that substances that normally can not traverse the plasma membrane, but most likely exert their influence intracellularly, can be introduced and their influence studied without cumbersome microinjection of the substances into single cells. Using this method the response to an influence can be recorded from many cells simultaneously.

20

In the present context, the term "permeabilisation" is intended to indicate the selective disruption of the plasma membrane barrier so that soluble substances freely mobile in the cytosol are lost from the cells. The permeabilisation can be achieved as described above under "permeabilised living cells" or by using other chemical detergents such as  
25 Triton X-100 or digitonin in carefully titrated amounts.

The term "physiologically relevant", when applied to an experimentally determined redistribution of an intracellular component, as measured by a change in the luminescence properties or distribution, is used to indicate that said redistribution can be  
30 explained in terms of the underlying biological phenomenon which gives rise to the redistribution.

The terms "image processing" and "image analysis" are used to describe a large family of digital data analysis techniques or combination of such techniques which reduce  
35 ordered arrays of numbers (images) to quantitative information describing those ordered

arrays of numbers. When said ordered arrays of numbers represent measured values from a physical process, the quantitative information derived is therefore a measure of the physical process.

- 5 The term "fluorescent probe" is used to indicate a fluorescent fusion polypeptide comprising a GFP or any functional part thereof which is N- or C-terminally fused to a biologically active polypeptide as defined herein, optionally via a peptide linker consisting of one or more amino acid residues, where the size of the linker peptide in itself is not critical as long as the desired functionality of the fluorescent probe is maintained. A  
10 fluorescent probe according to the invention is expressed in a cell and basically mimics the physiological behaviour of the biologically active polypeptide moiety of the fusion polypeptide.

The term "mammalian cell" is intended to indicate any living cell of mammalian origin.

- 15 The cell may be an established cell line, many of which are available from The American Type Culture Collection (ATCC, Virginia, USA) or a primary cell with a limited life span derived from a mammalian tissue, including tissues derived from a transgenic animal, or a newly established immortal cell line derived from a mammalian tissue including transgenic tissues, or a hybrid cell or cell line derived by fusing different cell types of  
20 mammalian origin e.g. hybridoma cell lines. The cells may optionally express one or more non-native gene products, e.g. receptors, enzymes, enzyme substrates, prior to or in addition to the fluorescent probe. Preferred cell lines include but are not limited to those of fibroblast origin, e.g. BHK, CHO, BALB, or of endothelial origin, e.g. HUVEC, BAE (bovine artery endothelial), CPAE (cow pulmonary artery endothelial), HLMVEC  
25 (human lung microvascular endothelial cells) or of pancreatic origin, e.g. RIN, INS-1, MIN6, bTC3, aTC6, bTC6, HIT, or of hematopoietic origin, e.g. primary isolated human monocytes, macrophages, neutrophils, basophils, eosinophils and lymphocyte populations, AML-193, HL-60, RBL-1, adipocyte origin, e.g. 3T3-L1, neuronal/neuroendocrine origin, e.g. AtT20, PC12, GH3, muscle origin, e.g. SKMC, A10,  
30 C2C12, renal origin, e.g. HEK 293, LLC-PK1.

- The term "hybrid polypeptide" is intended to indicate a polypeptide which is a fusion of at least a portion of each of two proteins, in this case at least a portion of the green fluorescent protein, and at least a portion of a catalytic and/or regulatory domain of a  
35 protein kinase. Furthermore a hybrid polypeptide is intended to indicate a fusion

polypeptide comprising a GFP or at least a portion of the green fluorescent protein that contains a functional fluorophore, and at least a portion of a biologically active polypeptide. Thus, GFP may be N- or C-terminally tagged to a biologically active polypeptide, optionally via a linker portion or linker peptide consisting of a sequence of  
5 one or more amino acids. The hybrid polypeptide or fusion polypeptide may act as a fluorescent probe in intact living cells carrying a DNA sequence encoding the hybrid polypeptide under conditions permitting expression of said hybrid polypeptide.

The term "kinase" is intended to indicate an enzyme that is capable of phosphorylating a  
10 cellular component.

The term "protein kinase" is intended to indicate an enzyme that is capable of phosphorylating serine and/or threonine and/or tyrosine in peptides and/or proteins.

15 The term "phosphatase" is intended to indicate an enzyme that is capable of dephosphorylating phosphoserine and/or phosphothreonine and/or phosphotyrosine in peptides and/or proteins.

The term "cyclic nucleotide phosphodiesterase" is intended to indicate an enzyme that is  
20 capable of inactivating the second messengers cAMP and cGMP by hydrolysis of their 3'-ester bond.

In the present context, the term "biologically active polypeptide" is intended to indicate a polypeptide affecting intracellular processes upon activation, such as an enzyme which  
25 is active in intracellular processes or a portion thereof comprising a desired amino acid sequence which has a biological function or exerts a biological effect in a cellular system.

In the polypeptide one or several amino acids may have been deleted, inserted or replaced to alter its biological function, e.g. by rendering a catalytic site inactive.

Preferably, the biologically active polypeptide is selected from the group consisting of  
30 proteins taking part in an intracellular signalling pathway, such as enzymes involved in the intracellular phosphorylation and dephosphorylation processes including kinases, protein kinases and phosphorylases as defined herein, but also proteins making up the cytoskeleton play important roles in intracellular signal transduction and are therefore included in the meaning of "biologically active polypeptide" herein. More preferably, the  
35 biologically active polypeptide is a protein which according to its state as activated or

non-activated changes localisation within the cell, preferably as an intermediary component in a signal transduction pathway. Included in this preferred group of biologically active polypeptides are cAMP dependent protein kinase A.

- 5 The term "a substance having biological activity" is intended to indicate any sample that has a biological function or exerts a biological effect in a cellular system. The sample may be a sample of a biological material such as a sample of a body fluid including blood, plasma, saliva, milk, urine, or a microbial or plant extract, an environmental sample containing pollutants including heavy metals or toxins, or it may be a sample  
10 containing a compound or mixture of compounds prepared by organic synthesis or genetic techniques.

The phrase "any change in fluorescence" means any change in absorption properties, such as wavelength and intensity, or any change in spectral properties of the emitted  
15 light, such as a change of wavelength, fluorescence lifetime, intensity or polarisation, or any change in the intracellular localisation of the fluorophore. It may thus be localised to a specific cellular component (e.g. organelle, membrane, cytoskeleton, molecular structure) or it may be evenly distributed throughout the cell or parts of the cell.

- 20 The term "organism" as used herein indicates any unicellular or multicellular organism preferably originating from the animal kingdom including protozoans, but also organisms that are members of the plant kingdoms, such as algae, fungi, bryophytes, and vascular plants are included in this definition.

- 25 The term "nucleic acid" is intended to indicate any type of poly- or oligonucleic acid sequence, such as a DNA sequence, a cDNA sequence, or an RNA sequence.

The term "biologically equivalent" as it relates to proteins is intended to mean that a first protein is equivalent to a second protein if the cellular functions of the two proteins may  
30 substitute for each other, e.g. if the two proteins are closely related isoforms encoded by different genes, if they are splicing variants, or allelic variants derived from the same gene, if they perform identical cellular functions in different cell types, or in different species. The term "biologically equivalent" as it relates to DNA is intended to mean that a first DNA sequence encoding a polypeptide is equivalent to a second DNA sequence

encoding a polypeptide if the functional proteins encoded by the two genes are biologically equivalent.

The term "higher throughput" is intended to mean an increased number of experiments  
5 per time unit per person performing the actual experiments.

- The term "high throughput screening assay" as used herein is intended to mean the process of performing a screening assay with at least 100 individual experiments where compounds are tested for their influence on the redistribution of a luminophore in one  
10 working day for one person skilled in the art. In a preferred embodiment the high throughput screening assay involves at least 500 individual experiments such as 750, 1000, 2000, 5000, or even 10.000 individual experiments in one working day for a person skilled in the art.
- 15 The phrase "back-tracking of a signal transduction pathway" is intended to indicate a process for defining more precisely at what level a signal transduction pathway is affected, either by the influence of chemical compounds or a disease state in an organism. Consider a specific signal transduction pathway represented by the bioactive polypeptides A - B - C - D, with signal transduction from A towards D. When investigating  
20 all components of this signal transduction pathway compounds or disease states that influence the activity or redistribution of only D can be considered to act on C or downstream of C whereas compounds or disease states that influence the activity or redistribution of C and D, but not of A and B can be considered to act downstream of B.
- 25 The term "fixed cells" is used to mean cells treated with a cytological fixative such as glutaraldehyde or formaldehyde, treatments that serve to chemically cross-link and stabilise soluble and insoluble proteins within the structure of the cell. Once in this state, such proteins cannot be lost from the structure of the now-dead cell.
- 30 In the present context a "screening assay" is intended to mean any measurement protocol, including materials, cells, instruments, chemicals, reagents, detection units, calibration and quantification procedures used to measure a response from mechanically intact or permeabilised living cells relevant to influences on an intracellular pathway.

The term "dose-response relationship" and "screening programme" is in the present context intended to mean a clear correlation between the quantified response of cells in a screening assay to application of an influence, such as a compound, and the concentration of the applied influence. The response to the influence may be both an up-  
5 regulation and a down-regulation of the quantified parameter used in the screening assay.

In the present context, the term "physiology" is intended to mean the normal function of biological and biochemical processes inside cells, between cells and in the whole  
10 organism or animal.

## BRIEF DESCRIPTION OF THE DRAWINGS

- Figure 1. CHO cells expressing the PKAc-F64L-S65T-GFP hybrid protein have been treated in HAM's F12 medium with 50  $\mu$ M forskolin at 37°C. The images of the GFP  
15 fluorescence in these cells have been taken at different time intervals after treatment, which were: a) 40 seconds b) 60 seconds c) 70 seconds d) 80 seconds. The fluorescence changes from a punctate to a more even distribution within the (non-nuclear) cytoplasm.
- 20 Figure 2. Time-lapse analysis of forskolin induced PKAc-F64L-S65T-GFP redistribution. CHO cells, expressing the PKAc-F64L-S65T-GFP fusion protein were analysed by time-lapse fluorescence microscopy. Fluorescence micrographs were acquired at regular intervals from 2 min before to 8 min after the addition of agonist. The cells were challenged with 1  $\mu$ M forskolin immediately after the upper left image was acquired (t=0).  
25 Frames were collected at the following times: i) 0, ii) 1, iii) 2, iv) 3, v) 4 and vi) 5 minutes. Scale bar 10  $\mu$ m.

Figure 3. Time-lapse analyses of PKAc-F64L-S65T-GFP redistribution in response to various agonists. The effects of 1  $\mu$ M forskolin (A), 50  $\mu$ M forskolin (B), 1mM dbcAMP  
30 (C) and 100  $\mu$ M IBMX (D) (additions indicated by open arrows) on the localisation of the PKAc-F64L-S65T-GFP fusion protein were analysed by time-lapse fluorescence microscopy of CHO/PKAc-F64L-S65T-GFP cells. The effect of addition of 10  $\mu$ M forskolin (open arrow), followed shortly by repeated washing with buffer (solid arrow), on the localisation of the PKAc-F64L-S65T-GFP fusion protein was analysed in the same

cells (E). In a parallel experiment, the effect of adding 10  $\mu$ M forskolin and 100  $\mu$ M IBMX (open arrow) followed by repeated washing with buffer containing 100  $\mu$ M IBMX (solid arrow) was analysed (F). Removing forskolin caused PKAc-F64L-S65T-GFP fusion protein to return to the cytoplasmic aggregates while this is prevented by the continued presence of IBMX (F). The effect of 100 nM glucagon (Fig 3G, open arrow) on the localisation of the PKAc-F64L-S65T-GFP fusion protein is also shown for BHK/GR, PKAc-F64L-S65T-GFP cells. The effect of 10  $\mu$ M norepinephrine (H), solid arrow, on the localisation of the PKAc-F64L-S65T-GFP fusion protein was analysed similarly, in transiently transfected CHO, PKAc-F64L-S65T-GFP cells, pretreated with 10  $\mu$ M forskolin, open arrow, to increase [cAMP]. N.B. in Fig 3H the x-axis counts the image numbers, with 12 seconds between images. The raw data of each experiment consisted of 60 fluorescence micrographs acquired at regular intervals including several images acquired before the addition of buffer or agonist. The charts (A-G) each show a quantification of the response seen through all the 60 images, performed as described in analysis method 2. The change in total area of the highly fluorescent aggregates, relative to the initial area of fluorescent aggregates is plotted as the ordinate in all graphs in Figure 3, versus time for each experiment. Scale bar 10  $\mu$ m.

Figure 4. Dose-response curve (two experiments) for forskolin-induced redistribution of the PKAc-F64L-S65T-GFP fusion.

Figure 5. Time from initiation of a response to half maximal ( $t_{1/2max}$ ) and maximal ( $t_{max}$ ) PKAc-F64L-S65T-GFP redistribution. The data was extracted from curves such as that shown in "Figure 2." All  $t_{1/2max}$  and  $t_{max}$  values are given as mean $\pm$ SD and are based on a total of 26-30 cells from 2-3 independent experiments for each forskolin concentration. Since the observed redistribution is sustained over time, the  $t_{max}$  values were taken as the earliest time point at which complete redistribution is reached. Note that the values do not relate to the degree of redistribution.

Figure 6. Parallel dose-response analyses of forskolin induced cAMP elevation and PKAc-F64L-S65T-GFP redistribution. The effects of buffer or 5 increasing concentrations of forskolin on the localisation of the PKAc-F64L-S65T-GFP fusion protein in CHO/PKAc-F64L-S65T-GFP cells, grown in a 96 well plate, were analysed as described above. Computing the ratio of the SD's of fluorescence micrographs taken of the same field of cells, prior to and 30 min after the addition of forskolin, gave a reproducible measure of

PKAc-F64L-S65T-GFP redistribution. The graph shows the individual 48 measurements and a trace of their mean  $\pm$  s.e.m at each forskolin concentration. For comparison, the effects of buffer or 8 increasing concentrations of forskolin on  $[cAMP]_i$  was analysed by a scintillation proximity assay of cells grown under the same conditions. The graph shows  
 5 a trace of the mean  $\pm$  s.e.m of 4 experiments expressed in arbitrary units.

Figure 7. BHK cells stably transfected with the human muscarinic (hM1) receptor and the PKC $\alpha$ -F64L-S65T-GFP fusion. Carbachol (100  $\mu$ M added at 1.0 second) induced a transient redistribution of PKC $\alpha$ -F64L-S65T-GFP from the cytoplasm to the plasma  
 10 membrane. Images were taken at the following times: a) 1 second before carbachol addition, b) 8.8 seconds after addition and c) 52.8 seconds after addition.

Figure 8. BHK cells stably transfected with the hM1 receptor and PKC $\alpha$ -F64L-S65T-GFP fusion were treated with carbachol (1  $\mu$ M, 10  $\mu$ M, 100  $\mu$ M). In single cells intracellular  
 15  $[Ca^{2+}]$  was monitored simultaneously with the redistribution of PKC $\alpha$ -F64L-S65T-GFP. Dashed line indicates the addition times of carbachol. The top panel shows changes in the intracellular  $Ca^{2+}$  concentration of individual cells with time for each treatment. The middle panel shows changes in the average cytoplasmic GFP fluorescence for individual cells against time for each treatment. The bottom panel shows changes in the  
 20 fluorescence of the periphery of single cells, within regions that specifically include the circumferential edge of a cell as seen in normal projection, the best regions for monitoring changes in the fluorescence intensity of the plasma membrane.

Figure 9. The hERK1-F64L-S65T-GFP fusion expressed in HEK293 cells treated with  
 25 100  $\mu$ M of the MEK1 inhibitor PD98059 in HAM F-12 (without serum) for 30 minutes at 37 °C. The nuclei empty of fluorescence during this treatment. The same cells as in (a) following treatment with 10 % foetal calf serum for 15 minutes at 37 °C.

Time profiles for the redistribution of GFP fluorescence in HEK293 cells following treatment with various concentrations of EGF in Hepes buffer (HAM F-12 replaced with  
 30 Hepes buffer directly before the experiment). Redistribution of fluorescence is expressed as the change in the ratio value between areas in nucleus and cytoplasm of single cells. Each time profile is the mean for the changes seen in six single cells.

Bar chart for the end-point measurements, 600 seconds after start of EGF treatments, of fluorescence change (nucleus:cytoplasm) following various concentrations of EGF.

Figure 10. The SMAD2-EGFP fusion expressed in HEK293 cells starved of serum overnight in HAM F-12. HAM F-12 was then replaced with Hepes buffer pH 7.2 immediately before the experiment. Scale bar is 10  $\mu$ m.

HEK 293 cells expressing the SMAD2-EGFP fusion were treated with various

5 concentration of TGF-beta as indicated, and the redistribution of fluorescence monitored against time. The time profile plots represent increases in fluorescence within the nucleus, normalised to starting values in each cell measured. Each trace is the time profile for a single cell nucleus.

A bar chart representing the end-point change in fluorescence within nuclei (after 850  
10 seconds of treatment) for different concentrations of TGF-beta. Each bar is the value for a single nucleus in each treatment.

Figure 11. The VASP-F64L-S65T-GFP fusion in CHO cells stably transfected with the human insulin receptor. The cells were starved for two hours in HAM F-12 without  
15 serum, then treated with 10% foetal calf serum. The image shows the resulting redistribution of fluorescence after 15 minutes of treatment. GFP fluorescence becomes localised in structures identified as focal adhesions along the length of actin stress fibres.

Figure 12. Dose-response relationship for the translocation of PKC $\alpha$ -GFP in BHKhM1  
20 cells stimulated with the muscarinic agonist carbamylcholine using a FLIPR™ to do the actual experiments.

Figure 13. Dose-response relationship for the translocation of PKA $\epsilon$ -GFP in CHO/PKA $\epsilon$ -F64L-S65T-GFP cells stimulated with forskolin using a FLIPR™ to do the actual  
25 experiments.

Figure 14. CHO cells stably expressing the human insulin receptor and mouse cPKA labeled with S65T-GFP were more thoroughly investigated in the FLIPR™ instrument. A forskolin (a substance that increases Adenylate cyclase production of cAMP in the cells)  
30 dose-response was created where six separate wells were imaged over time for each concentration. The changes in fluorescence were calculated as AUC (area under the curve) for 9 min of stimulation.

Conclusion: Redistribution of mouse cPKA - BioST can be detected in the FLIPR™ despite the fact that the whole wells, containing around 50-100 000 cells, are illuminated  
35 and imaged simultaneously with a spatial resolution that is far from capable of resolving

single cells or subcellular events. The method can be used as a real time measurement of cAMP levels in the cells and as a screening assay to measure effects of ligands to G-protein coupled receptors linked to Gi and Gq type G-proteins.

- 5 Figure 15. Dose-response relationship for the disappearance of fluorescence from permeabilised CHO/PKAc-F64L-S65T-GFP when previously exposed to different doses of forskolin.

Figure 16. CHO cells stably expressing the human insulin receptor and human PKC beta

- 10 1 labeled with EGFP were investigated in the microscope. A dose-response was created where a set of cells were imaged over time for each concentration. The changes in fluorescence were calculated as AUC for 4 min of stimulation. From the images the following data were extracted:

Whole image : Just analysing the change in intensity in the whole images taking both  
15 cells and background.

Single cell: 5 separate cells were analysed after background compensation. The analysis was made on the entire cell.

Cytoplasm: The same 5 cells as above were analysed after background compensation. the analysis was made on a small region in the cytoplasm close to the nucleus.

- 20 Conclusion: Redistribution of human PKC beta 1 – EGFP can only be detected if a subregion of each cell is analysed. The event is clearly visible when the image series is viewed as a movie but if the whole image change in fluorescence or the change in fluorescence in entire cells are analysed the redistribution cannot be detected.

- 25 Figure 17. CHO cells stably expressing the human insulin receptor and human PKC beta 1 labeled with EGFP were investigated in the FLIPR™. A dose-response was created where six separate wells were imaged over time for each concentration. The changes in fluorescence were calculated as AUC for 5 min of stimulation.

Conclusion: Redistribution of human PKC beta 1 – EGFP can be detected in the

- 30 FLIPR™ despite the fact that the whole wells, containing around 50-100 000 cells, are illuminated and imaged by a detector that has a resolution far below that needed to resolve single cells or subcellular structures. This phenomenon can clearly not be predicted from the microscope data in Figure 16.

Figure 18 CHO cells stably expressing the insulin receptor and a human NFkB – GFP protein hybrid were stimulated with different concentrations of IL-1 for 1 h, then washed with a hypoosmotic buffer (TRIS-base 10mM, MgCl<sub>2</sub> 2mM, PMSF(Phenyl methyl sulfonyl fluoride) 0.5mM, pH 7.4) and placed on the microscope. A sequence of images were

- 5 acquired during the addition of 0.05% Triton X-100 and subsequent gentle mixing after a short incubation period. The treatment causes the cell membranes to rupture leaving the fraction of NFkB-GFP that has translocated to the nucleus behind whereas the cytoplasmic amount of the probe leaves the cells more quickly and immediately becomes infinitely diluted in the surrounding medium (out of focus - this part of the total
- 10 fluorescence from the probe is thereby lost). At a defined time point before and after this treatment a total intensity value for the whole image was extracted. To normalize each experiment, the after value was divided by the before value. meaning that a higher ratio was found in cells where more NFkB had translocated to the nucleus and thereby contributed to the total fluorescence after permeabilisation.

- 15 Conclusion: the present protocol is a good example of the possibility of revealing translocation of a fluorescent probe from the cytosol to the nucleus or translocation from the nucleus to the cytosol.

## EXAMPLES

### **EXAMPLE 1 Construction, testing and implementation of an assay for cAMP based on PKA activation.**

- 5 Useful for monitoring the activity of signalling pathways that lead to altered concentrations of cAMP, e.g. activation of G-protein coupled receptors which couple to G-proteins of the G<sub>s</sub> or G<sub>i</sub> class.

The catalytic subunit of the murine cAMP dependent protein kinase (PKAc) was fused C-terminally to a F64L-S65T derivative of GFP. The resulting fusion (PKAc-F64L-S65T-

- 10 GFP) was used for monitoring *in vivo* the translocation and thereby the activation of PKA.

To construct the PKAc-F64L-S65T-GFP fusion, convenient restriction endonuclease sites were introduced into the cDNAs encoding murine PKAc (Gen Bank Accession number: M12303) and F64L-S65T-GFP (sequence disclosed in WO 97/11094) by

- 15 polymerase chain reaction (PCR). The PCR reactions were performed according to standard protocols with the following primers:

5'PKAc:

TTggACACAAgCTTTggACACCCTCAggATATgggCAACgCCgCCgCCgCCAAg,

3'PKAc:

- 20 gTCATCTTCTCgAgTCTTTCAggCgCgCCCAAACCTCAgTAAACTCCTTgCCACAC

5'GFP:

TTggACACAAgCTTTggACACggCgCgCCATgAgTAAAgg.AgAAgAACTTTTC

3'GFP:

gTCATCTTCTCgAgTCTTACTCCTgAggTTTgTATAgTTCATCCATgCCATgT.

25

The PKAc amplification product was then digested with HindIII+Ascl and the F64L-S65T-GFP product with Ascl+XhoI. The two digested PCR products were subsequently ligated with a HindIII+XhoI digested plasmid (pZeoSV® mammalian expression vector, Invitrogen, San Diego, CA, USA). The resulting fusion construct (SEQ ID NO:1 and 2)

- 30 was under control of the SV40 promoter.

Transfection and cell culture conditions:

- Chinese hamster ovary cells (CHO), were transfected with the plasmid containing the PKAc-F64L-S65T-GFP fusion using the calcium phosphate precipitate method in HEPES-buffered saline (Sambrook *et al.*, 1989). Stable transfectants were selected using 1000  $\mu$ g Zeocin/ml (Invitrogen) in the growth medium (DMEM with 1000 mg glucose/l, 10 % fetal bovine serum (FBS), 100  $\mu$ g penicillin-streptomycin mixture ml<sup>-1</sup>, 2 mM L-glutamine purchased from Life Technologies Inc., Gaithersburg, MD, USA).
- Untransfected CHO cells were used as the control. To assess the effect of glucagon on fusion protein translocation, the PKAc-F64L-S65T-GFP fusion was stably expressed in baby hamster kidney cells overexpressing the human glucagon receptor (BHK/GR cells).
- 10 Untransfected BHK/GR cells were used as the control. Expression of GR was maintained with 500  $\mu$ g G418/ml (*Neo* marker) and PKAc-F64L-S65T-GFP was maintained with 500  $\mu$ g Zeocin/ml (*Sh ble* marker). CHO cells were also simultaneously co-transfected with vectors containing the PKAc-F64L-S65T-GFP fusion and the human  $\alpha$ 2a adrenoceptor (hAR $\alpha$ 2a).
- 15 For fluorescence microscopy, cells were allowed to adhere to Lab-Tek chambered coverglasses (Nalge Nunc Int., Naperville, IL, USA) for at least 24 hours and cultured to about 80% confluence. Prior to experiments, the cells were cultured over night without selection pressure in HAM F-12 medium with glutamax (Life Technologies), 100  $\mu$ g penicillin-streptomycin mixture ml<sup>-1</sup> and 0.3 % FBS. This medium has low
- 20 autofluorescence enabling fluorescence microscopy of cells straight from the incubator.

Monitoring activity of PKA activity in real time:

- Image aquisition of live cells were gathered using a Zeiss Axiovert 135M fluorescence microscope fitted with a Fluar 40X, NA: 1.3 oil immersion objective and coupled to a
- 25 Photometrics CH250 charged coupled device (CCD) camera. The cells were illuminated with a 100 W HBO arc lamp. In the light path was a 470 $\pm$ 20 nm excitation filter, a 510 nm dichroic mirror and a 515 $\pm$ 15 nm emission filter for minimal image background. The cells were maintained at 37°C with a custom built stage heater.

Images were processed and analysed in the following manner:

- 30 Method 1: Stepwise procedure for quantitation of translocation of PKA:
- The image was corrected for dark current by performing a pixel-by-pixel subtraction of a dark image (an image taken under the same conditions as the actual image, except the camera shutter is not allowed to open).

The image was corrected for non-uniformity of the illumination by performing a pixel-by-pixel ratio with a flat field correction image (an image taken under the same conditions as the actual image of a uniformly fluorescent specimen).

5 The image histogram, i.e., the frequency of occurrence of each intensity value in the image, was calculated.

A smoothed, second derivative of the histogram was calculated and the second zero is determined. This zero corresponds to the inflection point of the histogram on the high side of the main peak representing the bulk of the image pixel values.

10 The value determined in step 4 was subtracted from the image. All negative values were discarded.

The variance (square of the standard deviation) of the remaining pixel values was determined. This value represents the "response" for that image.

Scintillation proximity assay (SPA) for independent quantitation of cAMP.

15 Method 2: Alternative method for quantitation of PKA redistribution:

The fluorescent aggregates are segmented from each image using an automatically found threshold based on the maximisation of the information measure between the object and background. The *a priori* entropy of the image histogram is used as the information measure.

20 The area of each image occupied by the aggregates is calculated by counting pixels in the segmented areas.

The value obtained in step 2 for each image in a series, or treatment pair, is normalised to the value found for the first (unstimulated) image collected. A value of zero (0) indicates no redistribution of fluorescence from the starting condition. A value of one (1)  
25 by this method equals full redistribution.

Cells were cultured in HAM F-12 medium as described above, but in 96-well plates. The medium was exchanged with  $\text{Ca}^{2+}$ -HEPES buffer including 100  $\mu\text{M}$  IBMX and the cells were stimulated with different concentrations of forskolin for 10 min. Reactions were stopped with addition of NaOH to 0.14 M and the amount of cAMP produced was  
30 measured with the cAMP-SPA kit, RPA538 (Amersham) as described by the manufacturer.

Manipulating intracellular levels of cAMP to test the PKAc-F64L-S65T-GFP fusion.

The following compounds were used to vary cAMP levels: Forskolin, an activator of adenylate cyclase; dbcAMP, a membrane permeable cAMP analog which is not degraded by phosphodiesterase; IBMX, an inhibitor of phosphodiesterase.

CHO cells stably expressing the PKAc-F64L-S65T-GFP, showed a dramatic

- 5 translocation of the fusion protein from a punctate distribution to an even distribution throughout the cytoplasm following stimulation with 1  $\mu$ M forskolin (n=3), 10  $\mu$ M forskolin (n=4) and 50  $\mu$ M forskolin (n=4) (Fig 1), or dbcAMP at 1mM (n=6).

Fig. 2 shows the progression of response in time following treatment with 1  $\mu$ M forskolin.

- Fig. 3 gives a comparison of the average temporal profiles of fusion protein redistribution  
10 and a measure of the extent of each response to the three forskolin concentrations (Fig. 3A, E, B), and to 1 mM dbcAMP (fig 3C) which caused a similar but slower response, and to addition of 100  $\mu$ M IBMX (n=4, Fig. 3D) which also caused a slow response, even in the absence of adenylate cyclase stimulation. Addition of buffer (n=2) had no effect (data not shown).

- 15 As a control for the behaviour of the fusion protein, F64L-S65T-GFP alone was expressed in CHO cells and these were also given 50  $\mu$ M forskolin (n=5); the uniform diffuse distribution characteristic of GFP in these cells was unaffected by such treatment (data not shown).

- The forskolin-induced translocation of PKAc-F64L-S65T-GFP showed a dose-response  
20 relationship (Fig 4 and 6), see quantitative procedures above.

Reversibility of PKAc-F64L-S65T-GFP translocation.

The release of the PKAc probe from its cytoplasmic anchoring hotspots was reversible.

Washing the cells repeatedly (5-8 times) with buffer after 10 $\mu$ M forskolin treatment

- 25 completely restored the punctate pattern within 2-5 min (n=2, Fig. 3E). In fact the fusion protein returned to a pattern of fluorescent cytoplasmic aggregates virtually indistinguishable from that observed before forskolin stimulation.

To test whether the return of fusion protein to the cytoplasmic aggregates reflected a

decreased [cAMP]<sub>i</sub>, cells were treated with a combination of 10  $\mu$ M forskolin and 100  $\mu$ M

- 30 IBMX (n=2) then washed repeatedly (5-8 times) with buffer containing 100  $\mu$ M IBMX (Fig. 3F). In these experiments, the fusion protein did not return to its prestimulatory localisation after removal of forskolin.

Testing the PKA-F64L-S65T-GFP probe with physiologically relevant agents.

To test the probe's response to receptor activation of adenylate cyclase, BHK cells stably transfected with the glucagon receptor and the PKA-F64L-S65T-GFP probe were exposed to glucagon stimulation. The glucagon receptor is coupled to a  $G_s$  protein which activates adenylate cyclase, thereby increasing the cAMP level. In these cells, addition of 100 nM glucagon ( $n=2$ ) caused the release of the PKA-F64L-S65T-GFP probe from the cytoplasmic aggregates and a resulting translocation of the fusion protein to a more even cytoplasmic distribution within 2-3 min (Fig. 3G). Similar but less pronounced effects were seen at lower glucagon concentrations ( $n=2$ , data not shown). Addition of buffer ( $n=2$ ) had no effect over time (data not shown).

- 10 Transiently transfected CHO cells expressing hAR $\alpha$ 2a and the PKA-F64L-S65T-GFP probe were treated with 10  $\mu$ M forskolin for 7.5 minutes, then, in the continued presence of forskolin, exposed to 10  $\mu$ M norepinephrine to stimulate the exogenous adrenoreceptors, which couple to a  $G_i$  protein, which inhibit adenylate cyclase. This treatment led to reappearance of fluorescence in the cytoplasmic aggregates indicative of a decrease in  $[cAMP]_i$  (Fig. 3H).

Fusion protein translocation correlated with  $[cAMP]_i$

- As described above, the time it took for a response to come to completion was dependent on the forskolin dose (Fig. 5) In addition the degree of responses was also dose-dependent. To test the PKA-F64L-S65T-GFP fusion protein translocation in a semi high through-put system, CHO cells stably transfected with the PKA-F64L-S65T-GFP fusion was stimulated with buffer and 5 increasing doses of forskolin ( $n=8$ ). Using the image analysis algorithm described above (Method 1), a dose-response relationship was observed in the range from 0.01-50  $\mu$ M forskolin (Fig. 6). A half-maximal stimulation was observed at about 2  $\mu$ M forskolin. In parallel, cells were stimulated with buffer and 8 increasing concentrations of forskolin ( $n=4$ ) in the range 0.01-50  $\mu$ M. The amount of cAMP produced was measured in an SPA assay. A steep increase was observed between 1 and 5  $\mu$ M forskolin coincident with the steepest part of the curve for fusion protein translocation (also Fig. 6).

30

### **EXAMPLE 2 Probe for detection of PKC activity**

Construction of PKC-GFP fusion:

The probe was constructed by ligating two restriction enzyme treated polymerase chain reaction (PCR) amplification products of the cDNA for murine PKC $\alpha$  (GenBank

Accession number: M25811) and F64L-S65T-GFP (sequence disclosed in WO 97/11094) respectively. Taq® polymerase and the following oligonucleotide primers were used for PCR;

5'mPKC $\alpha$ :

5 TTggACACAAgCTTTggACACCCTCAggATATggCTgACgTTTACCCggCCAACg

3'mPKC $\alpha$ :

gTCATCTTCTCgAgTCTTTCAGgCgCgCCCTACTgCACTTTgCAAgATTgggTgC,

5'F64L-S65T-GFP:

TTggACACAAgCTTTggACACggCgCgCCATgAgTAAAggAgAAgAACTTTTC,

10 3'F64L-S65T-GFP:

gTCATCTTCTCgAgTCTTACTCCTgAggTTTgTATAgTTCATCCATgCCATgT.

The hybrid DNA strand was inserted into the pZeoSV® mammalian expression vector as a HindIII-XhoI cassette as described in example 1.

- 15 BHK cells expressing the human M1 receptor under the control of the inducible metallothionine promoter and maintained with the dihydrofolate reductase marker were transfected with the PKC $\alpha$ -F64L-S65T-GFP probe using the calcium phosphate precipitate method in HEPES buffered saline (HBS [pH 7.10]). Stable transfectants were selected using 1000  $\mu$ g Zeocin®/ml in the growth medium (DMEM with 1000 mg
- 20 glucose/l, 10 % foetal bovine serum (FBS), 100  $\mu$ g penicillin-streptomycin mixture ml<sup>-1</sup>, 2 mM l-glutamine). The hM1 receptor and PKC $\alpha$ -F64L-S65T-GFP fusion protein were maintained with 500 nM methotrexate and 500  $\mu$ g Zeocin®/ml respectively. 24 hours prior to any experiment, the cells were transferred to HAM F-12 medium with glutamax, 100  $\mu$ g penicillin-streptomycin mixture ml<sup>-1</sup> and 0.3 % FBS. This medium relieves
- 25 selection pressure, gives a low induction of signal transduction pathways and has a low autofluorescence at the relevant wavelength enabling fluorescence microscopy of cells straight from the incubator.

Method 1: Monitoring the PKC $\alpha$  activity in real time:

- 30 Digital images of live cells were gathered using a Zeiss Axiovert 135M fluorescence microscope fitted with a 40X, NA: 1.3 oil immersion objective and coupled to a Photometrics CH250 charged coupled device (CCD) camera. The cells were illuminated with a 100 W arc lamp. In the light path was a 470 $\pm$ 20 nm excitation filter, a 510 nm dichroic mirror and a 515 $\pm$ 15 nm emission filter for minimal image background. The cells
- 35 were kept and monitored to be at 37°C with a custom built stage heater.

Images were analyzed using the IPLab software package for Macintosh.

Upon stimulation of the M1-BHK cells, stably expressing the PKC $\alpha$ -F64L-S65T-GFP fusion, with carbachol we observed a dose-dependent transient translocation from the cytoplasm to the plasma membrane (Fig. 7a,b,c). Simultaneous measurement of the  
5 cytosolic free calcium concentration shows that the carbachol-induced calcium mobilisation precedes the translocation (Fig. 8).

Stepwise procedure for quantification of translocation of PKC $\alpha$ :

The image was corrected for dark current by performing a pixel-by-pixel subtraction of a dark image (an image taken under the same conditions as the actual image, except the  
10 camera shutter is not allowed to open).

The image was corrected for non-uniformity of the illumination by performing a pixel-by-pixel ratio with a flat field correction image (an image taken under the same conditions as the actual image of a uniformly fluorescent specimen).

A copy of the image was made in which the edges are identified. The edges in the image  
15 are found by a standard edge-detection procedure – convolving the image with a kernel which removes any large-scale unchanging components (i.e., background) and accentuates any small-scale changes (i.e., sharp edges). This image was then converted to a binary image by thresholding. Objects in the binary image which are too small to represent the edges of cells were discarded. A dilation of the binary image was  
20 performed to close any gaps in the image edges. Any edge objects in the image which were in contact with the borders of the image are discarded. This binary image represents the edge mask.

Another copy of image was made via the procedure in step 3. This copy was further processed to detect objects which enclose “holes” and setting all pixels inside the holes  
25 to the binary value of the edge, i.e., one. This image represents the whole cell mask.

The original image was masked with the edge mask from step 3 and the sum total of all pixel values is determined.

The original image was masked with the whole cell mask from step 4 and the sum total of all pixel values was determined.

30 The value from step 5 was divided by the value from step 6 to give the final result, the fraction of fluorescence intensity in the cells which was localized in the edges.

**EXAMPLE 3 Probes for detection of mitogen activated protein kinase Erk1 redistribution.**

Useful for monitoring signalling pathways involving MAPK, e.g. to identify compounds which modulate the activity of the pathway in living cells.

- 5 Erk1, a serine/threonine protein kinase, is a component of a signalling pathway that is activated by e.g. many growth factors.

Probes for detection of ERK-1 activity in real time within living cells:

The extracellular signal regulated kinase (ERK-1, a mitogen activated protein kinase, MAPK) is fused N- or C-terminally to a derivative of GFP. The resulting fusions

- 10 expressed in different mammalian cells are used for monitoring *in vivo* the nuclear translocation, and thereby the activation, of ERK1 in response to stimuli that activate the MAPK pathway.

The human Erk1 gene (GenBank Accession number: X60188) was amplified using PCR according to standard protocols with primers

- 15 Erk1-top

5'-TAGAATTCAACCATGGCGGCGGCGGCGGCG-3'

and Erk1-bottom/+stop

5'-TAGGATCCCTAGGGGGCCTCCAGCACTCC-3'.

- 20 The PCR product was digested with restriction enzymes EcoR1 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with EcoR1 and BamH1. This produces an EGFP-Erk1 fusion (SEQ ID NOs: 5 and 6) under the control of a CMV promoter.

- The plamid containing the EGFP-Erk1 fusion was transfected into HEK293 cells employing the FUGENE transfection reagent (Boehringer Mannheim). Prior to  
25 experiments the cells were grown to 80%-90% confluency 8 well chambers in DMEM with 10% FCS. The cells were washed in plain HAM F-12 medium (without FCS), and then incubated for 30-60 minutes in plain HAM F-12 (without FCS) with 100 micromolar PD98059, an inhibitor of MEK1, a kinase which activates Erk1; this step effectively empties the nucleus of EGFP-Erk1. Just before starting the experiment, the HAM F-12  
30 was replaced with Hepes buffer following a wash with Hepes buffer. This removes the PD98059 inhibitor; if blocking of MEK1 is still wanted (e.g. in control experiments), the inhibitor is included in the Hepes buffer.

The experimental setup of the microscope was as described in example 1.

- 60 images were collected with 10 seconds between each, and with the test compound  
35 added after image number 10.

Addition of EGF (1-100 nM) caused within minutes a redistribution of EGFP-Erk1 from the cytoplasm into the nucleus (Fig. 9a,b).

The response was quantitated as described below and a dose-dependent relationship between EGF concentration and nuclear translocation of EGFP-Erk1 was found (Fig.

- 5 9c,d). Redistribution of GFP fluorescence is expressed in this example as the change in the ratio value between areas in nuclear versus cytoplasmic compartments of the cell. Each time profile is the average of nuclear to cytoplasmic ratios from six cells in each treatment.

#### 10 **EXAMPLE 4 Probes for detection of Smad2 redistribution.**

Useful for monitoring signalling pathways activated by some members of the transforming growth factor-beta family, e.g. to identify compounds which modulate the activity of the pathway in living cells.

- 15 Smad 2, a signal transducer, is a component of a signalling pathway that is induced by some members of the TGFbeta family of cytokines.

a) The human Smad2 gene (GenBank Accession number: AF027964) was amplified using PCR according to standard protocols with primers

Smad2-top

5'-GTGAATTCGACCATGTCGTCCATCTTGCCATTC-3'

- 20 and Smad2-bottom/+stop

5'-GTGGTACCTTATGACATGCTTGAGCAACGCAC-3'.

- The PCR product was digested with restriction enzymes EcoR1 and Acc65I, and ligated into pEGFP-C1 (Clontech; Palo Alto; GenBank Accession number U55763) digested with EcoR1 and Acc65I. This produces an EGFP-Smad2 fusion (SEQ ID NOs: 7 and 8) under  
25 the control of a CMV promoter.

b) The human Smad2 gene (GenBank Accession number: AF027964) was amplified using PCR according to standard protocols with primers

Smad2-top

5'-GTGAATTCGACCATGTCGTCCATCTTGCCATTC-3'

- 30 and Smad2-bottom/-stop

5'-GTGGTACCCATGACATGCTTGAGCAACGCAC-3'.

- The PCR product was digested with restriction enzymes EcoR1 and Acc65I, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with EcoR1 and Acc65I. This produces a Smad2-EGFP fusion (SEQ ID NOs:9 and 10) under  
35 the control of a CMV promoter.

The plasmid containing the EGFP-Smad2 fusion was transfected into HEK293 cells, where it showed a cytoplasmic distribution. Prior to experiments the cells were grown in 8 well Nunc chambers in DMEM with 10% FCS to 80% confluence and starved overnight in HAM F-12 medium without FCS.

- 5 For experiments, the HAM F-12 medium was replaced with Hepes buffer pH 7.2. The experimental setup of the microscope was as described in example 1. 90 images were collected with 10 seconds between each, and with the test compound added after image number 5.

After serum starvation of cells, each nucleus contains less GFP fluorescence than the surrounding cytoplasm (Fig. 10a). Addition of TGFbeta caused within minutes a redistribution of EGFP-Smad2 from the cytoplasm into the nucleus (Fig. 10b).

The redistribution of fluorescence within the treated cells was quantified simply as the fractional increase in nuclear fluorescence normalised to the starting value of GFP fluorescence in the nucleus of each unstimulated cell and displayed a dose dependent

- 15 change in response to TGFβ (fig. 10c).

#### ***EXAMPLE 5 Probes for detection of VASP redistribution.***

Useful for monitoring signalling pathways involving rearrangement of cytoskeletal elements, e.g. to identify compounds which modulate the activity of the pathway in living cells. VASP, a phosphoprotein, is a component of cytoskeletal structures, which

- 20 redistributes in response to signals that affect focal adhesions.

The human VASP gene (GenBank Accession number: Z46389) was amplified using PCR according to standard protocols with primers

VASP-top

5'-GGGAAGCTTCCATGAGCGAGACGGTCATC-3'

- 25 and VASP-bottom/+stop

5'-CCCGGATCCTCAGGGAGAACCCCGCTTC-3'.

The PCR product was digested with restriction enzymes Hind3 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Hind3 and BamH1. This produces an EGFP-VASP fusion (SEQ ID NOs:11 and 12) under

- 30 the control of a CMV promoter.

The resulting plasmid was transfected into CHO cells expressing the human insulin receptor using the calcium-phosphate transfection method. Prior to experiments, cells were grown in 8 well Nunc chambers and starved overnight in medium without FCS.

Experiments are performed in a microscope setup as described in example 1. 10% FCS

- 35 was added to the cells and images were collected. The EGFP-VASP fusion was

redistributed from a somewhat even distribution near the periphery into more localised structures, identified as focal adhesion points (Fig. 11).

**EXAMPLE 7 Probes for detection of NFkappaB redistribution.**

- 5 Useful for monitoring signalling pathways leading to activation of NFkappaB, e.g. to identify compounds which modulate the activity of the pathway in living cells.  
NFkappaB, an activator of transcription, is a component of signalling pathways that are responsive to a variety of inducers including cytokines, lymphokines, and some immunosuppressive agents.
- 10 a) The human NFkappaB p65 subunit gene (GenBank Accession number: M62399) is amplified using PCR according to standard protocols with primers  
NFkappaB-top  
5'-GTCTCGAGCCATGGACGAACTGTTCCCCCTCATC-3'  
and NFkappaB-bottom/+stop
- 15 5'-GTGGATCCTTAGGAGCTGATCTGACTCAGCAG-3'.  
The PCR product is digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Xho1 and BamH1. This produces an EGFP-NFkappaB fusion (SEQ ID NOs: 13 and 14) under the control of a CMV promoter.
- 20 b) The human NFkappaB p65 subunit gene (GenBank Accession number: M62399) is amplified using PCR according to standard protocols with primers  
NFkappaB-top  
5'-GTCTCGAGCCATGGACGAACTGTTCCCCCTCATC-3'  
and NFkappaB-bottom/-stop
- 25 5'-GTGGATCCAAGGAGCTGATCTGACTCAGCAG-3'.  
The PCR product is digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with Xho1 and BamH1. This produces an NFkappaB-EGFP fusion (SEQ ID NOs: 15 and 16) under the control of a CMV promoter.
- 30 The resulting plasmids are transfected into a suitable cell line, e.g. Jurkat, in which the EGFP-NFkappaB probe and/or the NFkappaB-EGFP probe should change its cellular distribution from cytoplasmic to nuclear in response to activation of the signalling pathway with e.g. IL-1.

CHO cells stably expressing the insulin receptor and a human NFkB – GFP protein hybrid were stimulated with different concentrations of IL-1 for 1 hour, then washed with a hypoosmotic buffer (TRIS-base 10mM, MgCl<sub>2</sub> 2mM, PMSF(Phenyl methyl sulfonyl fluoride) 0.5mM, pH 7.4) and placed on the microscope. A sequence of images were  
 5 acquired during the addition of 0.05% Triton X-100 and subsequent gentle mixing after a short incubation period. The treatment causes the cell membranes to rupture leaving the fraction of NFkB-GFP that has translocated to the nucleus behind whereas the cytoplasmic amount of the probe leaves the cells more quickly and immediately becomes infinitely diluted in the surrounding medium (out of focus - this part of the total  
 10 fluorescence from the probe is thereby lost). At a defined time point before and after this treatment a total intensity value for the whole image was extracted. To normalize each experiment, the after value was divided by the before value, meaning that a higher ratio was found in cells where more NFkB had translocated to the nucleus and thereby contributed to the total fluorescence after permeabilisation. the actual data from such an  
 15 experiment run in duplicate is shown in Figure 18.

Conclusion: the present protocol is a good example of the possibility of revealing translocation of a fluorescent probe from the cytosol to the nucleus or translocation from the nucleus to the cytosol by using a measurement immediately before and after plasma membrane permeabilisation recorded as an image sequence.

20

### ***EXAMPLE 8 real-time redistribution of protein kinase C $\alpha$***

Measurement of the real-time redistribution of protein kinase C  $\alpha$  isoform-GFP fusion (PKC $\alpha$ -GFP, SEQ ID NOs: 3 and 4) in response to carbamylcholine stimulation of the muscarinic M1 receptor; 96 parallel redistribution measurements in microtiter plates.

25 BHK cells were stably expressing a recombinant human muscarinic type 1 receptor, under the selection with 500  $\mu$ g/ml Methotrexate, and also a PKC $\alpha$ -GFP construct (K $\alpha$ A 048), under the selection of 500 nM Zeocin. The cells were grown in 96-well plates (Packard ViewPlate, black with transparent bottom), washed and preincubated in a Hank's Buffered Salt solution (HBSS) without phenol red, with 20 mM HEPES and 5.5  
 30 mM glucose.

The plate was measured in a FLIPR™ (Fluorescence Imaging Plate Reader) from Molecular Devices. The 488 nm emission line from an argon ion laser, run at between 0.4 and 0.8 W output, was used to excite fluorescence from the GFP. Emission wavelengths were collected through a 510 to 565 nm band pass filter.

The cells were challenged with three doses of carbamylcholine, an M1 receptor agonist known from previous studies to give a microscopically detectable redistribution of the PKC $\alpha$ -GFP construct [(Almholt *et al.* 1997)]. Measurements were made every 10 seconds for 5 minutes. After data handling including normalisation of baseline  
5 fluorescence for the different wells, background subtraction and averaging the 6 wells used for each concentration the data presented in figure 14 were obtained. It can clearly be seen (Fig 12) that carbamylcholine gave a time- and dose-dependent, and transient, decrease in fluorescence very similar to the time- and dose-dependent profile seen in microscopic fluorescence measurements [(see Almholt *et al.* 1997)]. This experiment  
10 was repeated twice on the same batch of cells with similar results.

**EXAMPLE 9 real-time redistribution of cyclic-AMP dependent protein kinase catalytic subunit-GFP fusion**

Measurement of the real-time redistribution of cyclic-AMP dependent protein kinase  
15 catalytic subunit-GFP fusion (C-GFP<sup>LT</sup> SEQ ID NOs: 1 and 2) in response to forskolin stimulation of the adenylate cyclase; 96 parallel redistribution measurements in microtiter plates.

CHO cells were stably transfected with hybrid DNA for the PKA catalytic subunit-F64L+S65T GFP (C-GFP<sup>LT</sup>) fusion protein, and were typically under continuous selection  
20 with 1000  $\mu$ g/ml zeocin (Invitrogen). The cells were grown without selection for 2 days in 96-well plates (Packard ViewPlate, black with transparent bottom), washed and preincubated in a Hank's Buffered Salt solution (HBSS) without phenol red, with 20 mM HEPES and 5.5 mM glucose.

The plate was measured in a FLIPR<sup>TM</sup> (Fluorescence Imaging Plate Reader) from  
25 Molecular Devices. The 488 nm emission line from an argon ion laser, run at between 0.4 and 0.8 W output, was used to excite fluorescence from the GFP. Emission wavelengths were collected through a 510 to 565 nm band pass filter.

The cells were challenged with three doses of forskolin (Fig 13), an adenylate cyclase agonist known from previous studies to give a microscopically detectable redistribution of  
30 the C-GFP<sup>LT</sup> construct. Measurements were made every 10 seconds for over 6 minutes from the point of addition of forskolin. After data handling including normalisation of baseline fluorescence for the different wells, background subtraction and averaging the 6 wells used for each concentration the data presented below were obtained. It can clearly be seen in figure 15 that forskolin gave a time- and dose-dependent decrease in  
35 fluorescence very similar to the time- and dose-dependent profile seen in microscopic

fluorescence measurements. This experiment was repeated twice on the same batch of cells with similar results. As can be seen in figure 14, a more extensive dose-response test gives at hand that this method is both sensitive and reproducible enough to use as the basis for a high throughput screening assay.

**5 EXAMPLE 10 cyclic-AMP dependent protein kinase catalytic subunit-GFP fusion**

Measurement of the redistribution response of cyclic-AMP dependent protein kinase catalytic subunit-GFP fusion (C-GFP<sup>LT</sup> SEQ ID NOs: 1 and 2) after forskolin stimulation of the adenylate cyclase; measurement of the change in total fluorescence upon

10 permeabilisation of agonist-treated cells.

CHO cells were stably transfected with hybrid DNA for the PKA catalytic subunit-F64L+S65T GFP (C-GFP<sup>LT</sup>) fusion protein, and were typically under continuous selection with 1000 µg/ml zeocin (Invitrogen). For the experiments reported here, cells were grown without selection to 90% confluence in 8-well tissue culture-treated Lab-Tek®

15 chambered coverglass units (chambers, obtained from Nunc, Inc. Illinois, USA).

Immediately prior to the experiment growth medium was washed from the cells and replaced with 200 µl HEPES buffer per well.

For the results reported here, chambers were measured using a cooled CCD camera (KAF1400 chip, Photometrics Ltd., USA) attached to an inverted microscope (Diaphot  
20 300, Nikon, Japan) equipped with a x40 oil-immersion Fluor lens, NA 1.4. Cells were illuminated with 450-490 nm light from a 50 W HBO lamp, and emitted light collected between 510-560 nm.

The cells were challenged with four doses of forskolin, an adenylate cyclase agonist known from previous studies to give a microscopically detectable redistribution of the C-

25 GFP<sup>LT</sup> construct. Images were collected at 10-second intervals for a period of 10 minutes for each treatment. Six minutes after the addition of forskolin or buffer control, Triton-X100 was added to a final concentration of 0.1%. The detergent releases freely mobile C-GFP<sup>LT</sup> from the cells. The change in fluorescence resulting from this loss was measured after 1 minute of equilibration. After data handling including background

30 subtraction and normalisation to pre-detergent values, the data presented in figure 16 were obtained. Permeabilisation caused decreases in fluorescence, the magnitude of which were dependent on the forskolin treatments. This experiment was repeated twice on the same batch of cells with similar results.

**EXAMPLE 11 Prob s for detection of PKC $\beta$ 1 redistribution.**

Useful for monitoring signalling pathways involving Protein Kinase C, e.g. to identify compounds which modulate the activity of the pathway in living cells.

PKC $\beta$ 1, a serine/threonine protein kinase, is closely related to PKC $\alpha$  and

- 5 PKC $\beta$ 2 but not identical; it is a component of a signalling pathway which is activated by elevation of intracellular calcium concomitant with an increase in diacylglycerol species.

a) The human PKC $\beta$ 1 gene (GenBank Accession number: X06318) was amplified

- 10 using PCR according to standard protocols with primers

PKC $\beta$ 1-top

GTCTCGAGGCAAGATGGCTGACCC

and PKC $\beta$ 1-bottom

GTGGATCCCTACACATTAATGACAACTCTGGG.

- 15 The PCR product was digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Xho1 and BamH1. This produces an EGFP-PKC $\beta$ 1 fusion (SEQ ID NOs: 17 and 18) under the control of a CMV promoter.

b) CHO cells stably expressing the human insulin receptor and human PKC  $\beta$  1

- 20 labeled with EGFP were investigated in the microscope. A dose-response was created where a set of cells were imaged over time for each concentration. The changes in fluorescence were calculated as AUC for 4 min of stimulation.

It can be seen in figure 16 that using microscopic measurements, redistribution of human PKC  $\beta$  1 – EGFP can only be detected if a subregion of each cell is analysed. The

- 25 event is clearly visible when the image series is viewed as a movie but if the whole image changes in fluorescence or the changes in fluorescence in entire cells are analysed the redistribution cannot be detected.

CHO cells stably expressing the human insulin receptor and human PKC  $\beta$  1 labelled with EGFP were investigated in the FLIPR<sup>TM</sup>. A dose-response was created where six

- 30 separate wells were imaged over time for each concentration. The changes in fluorescence were calculated as AUC for 5 min of stimulation. As shown in figure 17 redistribution of human PKC  $\beta$  1 – EGFP can be detected in the FLIPR<sup>TM</sup> instrument despite the fact that the whole wells, containing around 50-100 000 cells, are illuminated and imaged with a resolution far below what is needed to resolve single cells or
- 35 subcellular compartments. This phenomenon can clearly not be predicted from the

microscope data in Figure 16. Based on these observations it is clear that a screening assay can be established in the FLIPR™ instrument. It might even be possible to establish a high throughput screening assay with further optimisation.

**REFERENCES:**

- Adams, S.R., Harootunian, A.T., Buechler, Y.J., Taylor, S.S. & Tsien, R.Y. (1991) *Nature* **349**, 694-697.
- Barak, L.S., Ferguson, S.S.G., Zhang, J. & Caron, M.G. (1997) *J. Biol. Chem.* **272**:44,  
5 27497-27500.
- Bastiaens, P.I.H. & Jovin, T.M. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 8407-8412.
- Beals, C.R., Clipstone, N.A., Ho, S.N. & Crabtree, G.R. (1998) *Genes and Development* **11**:7, 824-834.
- Blobe, G.C., Stribling, D.S., Fabbro, D., Stabel, S & Hannun, Y.A. (1996) *J. Biol. Chem.*  
10 **271**, 15823-15830.
- Carey, K.L., Richards, S.A., Lounsbury, K.M. & Macara, I.G. (1996) *J. Cell Biol.* **133**: 5, 985-996.
- Chalfie, M., Tu, Y., Euskirchen, G., Ward, W.W. & Prasher, D.C. (1994) *Science* **263**, 802-805.
- 15 Cossette, L.J., Hoglinger, O., Mou, L.J. & Shen, S.H. (1997) *Exp. Cell Res.* **223**, 459-466.
- DeBernardi, M.A. & Brooker, G. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 4577-4582.
- Farese, R.V. (1992) *Biochem. J.* **288**, 319-323.
- Fulop Jr., T., Leblanc, C., Lacombe, G. & Dupuis, G. (1995) *FEBS Lett.* **375**, 69-74.
- 20 Georget, V., Lobaccaro, J.M., Terouanne, B., Mangeat, P., Nicolas, J.C. & Sultan, C. (1997) *Mol. Cell. Endocrinol.* **129**:1, 17-26.
- Godson, C., Masliah, E., Balboa, M.A., Ellisman, M.H. & Insel, P.A. (1996) *Biochem. Biophys. Acta* **1313**, 63-71.
- Guiliano, K.A., DeBiasio, R, Dunlay, R.T., Gough, A., Volosky, J.M., Zock, J., Pavlakis, G.N. & Taylor, D.L. (1997) *J. Biomol. Screening* **2**:4, 249-259.
- 25 Khalil, R.A., Lajoie, C., Resnick, M.S. & Morgan, K.G. (1992) *Am. J. Physiol.* **263** (Cell Physiol. 32) C714-C719.
- Oancea, E., Teruel, M.N., Quest, A.F.G. & Meyer, T. (1998) *J. Cell Biol.* **140**:3, 485-498.
- Sano, M., Kohno, M. & Iwanaga, M. (1995) *Brain Res.* **688**, 213-218.
- 30 Sakai, N., Sasaki, K., Hasegawa, C., Ohkura, M., Sumioka, K., Shirai, Y. & Saito, N. (1996) *Soc. Neuroscience* **22**, 69P (Abstract).
- Sakai, N., Sakai, K., Hasegawa, C., Ohkura, M., Sumioka, K., Shirai, Y., & Naoaki, S. (1997) *Japanese Journal of Pharmacology* **73**, 69P (Abstract of a meeting held 22-23 March).
- 35 Schmidt, D.J., Ikebe, M., Kitamura, K. & Fay, F.S. (1997) *FASEB J.* **11**, 2924 (Abstract).

Schroeder, K. & Neagle, B.J. (1996) *Biomolecular Screening* 1, 75-80.

Silverman, L., Campbell, R. & Broach, J.R. (1998) *Current Opinion in Chemical Biology* 2:3, 397-403.

Stauffer, T.P., Ahn, S. & Meyer, T. (1998) *Current Biol.* 8:6, 343-346.

## CLAIMS

1. A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising  
5 recording variation in spatially distributed light emitted from a luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a component which is capable of being redistributed in a manner which is related to the degree of the influence, as a change in light intensity measured by an instrument  
10 designed for the measurement of changes in fluorescence intensity.
2. A method according to claim 1, wherein the quantitative information which is indicative of the degree of the cellular response to the influence or the result of the influence on the subcellular component is extracted from the recorded variation according to a  
15 predetermined calibration based on responses or results, recorded in the same manner, to known degrees of a relevant specific influence.
3. A method according to claims 1 or 2, wherein the influence comprises contact between the mechanically intact or permeabilised living cells and a chemical substance and/or incubation of the mechanically intact or permeabilised living cells with a chemical  
20 substance.
4. A method according to any of claims 1-3, wherein the cells comprise a group of cells contained within a spatial limitation.
5. A method according to any of claims 1-4, wherein the cells comprise multiple groups of cells contained within multiple spatial limitations.
- 25 6. A method according to any of claims 1-5, wherein the cells comprise multiple groups of cells that are qualitatively the same but are subjected to different influences.
7. A method according to any of claims 1-5, wherein the cells comprise multiple groups of cells that are qualitatively different but are subjected to the same influence.
8. A method according to any of claims 1-7, wherein multiple spatial limitations are  
30 measured simultaneously by means of a one- or two-dimensional array detector, whereby the multiple spatial limitations are imaged onto the array detector such that

discrete subsets of the detecting units (pixels) in the array detector measure the signal from one and only one of the multiple spatial limitations, the signal from any one spatial limitation being the combined signal from those pixels that receive the image from one of the spatial limitations.

- 5 9. A method according to claim 8, wherein the detector is a linear diode array.
10. A method according to claim 8, wherein the detector is a video camera.
11. A method according to claim 8, wherein the detector is a charge transfer device.
12. A method according to claim 8, wherein the charge transfer device is a charge-coupled device.
- 10 13. A method according to any of claims 1-12, wherein all of the multiple spatial limitations are simultaneously illuminated during the measurement operation.
14. A method according to any of claims 1-12, wherein the individual spatial limitations are singly illuminated only during the time period in which they are being measured.
15. A method according to any of claims 1-14, wherein the illumination is provided by a  
15 laser which is scanned in a raster fashion over some or all of the spatial limitations being measured, the scanning taking place at a rate substantially faster than the measurement process such that the illumination appears to the measurement process to be continuous in time and spatially uniform over the region being measured.
16. A method according to any of claims 1-15, wherein the spatial limitations are spatial  
20 limitations arranged in one or more arrays on a common carrier.
17. A method according to claim 16, wherein the spatial limitations are wells in a plate of microtiter type.
18. A method according to any of claims 1-17, wherein the spatial limitations are domains defined on a substrate on which the cells are present.
- 25 19. A method according to claim 18, wherein the domains are domains established by the presence of the cells on the substrate in a pattern defining the domains.
20. A method according to claim 18, wherein the domains are domains established by the spatial pattern of the influence as it is applied to or contacted with the cells.

21. A method according to any of claims 1-20, wherein the recording is performed at a series of points in time, in which the application of the influence occurs at some time after the first time point in the series of recordings, the recording being performed, e.g., with a predetermined time spacing of from 0.1 seconds to 1 hour, preferably from 1 to 60  
5 seconds, more preferably from 1 to 30 seconds, in particular from 1 to 10 seconds, over a time span of from 1 second to 12 hours, such as from 10 seconds to 12 hours, e.g., from 10 seconds to one hour, such as from 60 seconds to 30 minutes or 20 minutes.
22. A method according to claim 21, wherein the recording is made at two points in time, one point being before, and the other point being after the application of the influence.
- 10 23. A method according to any of claims 1-22, wherein the cells are fixed at a point in time after the application of the influence at which the response has been predetermined to be significant, and the recording is made at an arbitrary later time.
24. A method according to any of claims 1-23, wherein the redistribution results in quenching of fluorescence, the quenching being measured as a decrease in the intensity  
15 of the fluorescence.
25. A method according to any of claims 1-24, wherein the redistribution results in energy transfer, the energy transfer being measured as a change in the intensity of the luminescence.
26. A method according to any of claims 1-24, wherein the illumination necessary to  
20 excite fluorescence is non-homogeneous such that the redistribution results in a greater or lesser number of fluorescent molecules being excited, the result being measured as a change in fluorescent intensity.
27. A method according to any of claims 1-24, wherein the intensity of the light being recorded is a function of the fluorescence lifetime, polarisation, wavelength shift, or other  
25 property which is modulated as a result of the underlying cellular response.
28. A method according to any of claims 1-27, wherein the light to be measured passes through a filter which selects the desired component of the light to be measured and rejects other components.

29. A method according to any of claims 1-28, wherein the fluorescence comes from a fluorophore encoded by and expressed from a nucleotide sequence harboured in the cells.

30. A method according to any of claims 1-28, wherein the fluorescence comes from a fluorophore introduced into the cells by any or various techniques for the bulk loading of material into cells such as transfection, incubation, scrape loading, electroporation.

31. A method according to any of the preceding claims, wherein the fluorescence comes from a luminescent polypeptide, such as GFP.

32. A method according to any of claims 1-31, wherein the cells are selected from the group consisting of fungal cells, such as yeast cells; invertebrate cells including insect cells; and vertebrate cells, such as mammalian cells.

33. A method according to claim 32, wherein the mechanically intact or permeabilised living cells are mammalian cells which, during the time period over which the influence is observed, are incubated at a temperature of 30°C or above, preferably at a temperature of from 32°C to 39°C, more preferably at a temperature of from 35°C to 38°C, and most preferably at a temperature of about 37°C.

34. A method according to any of the preceding claims, wherein the nucleic acid construct is a DNA construct with a sequence selected from the group consisting of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15 and 17 or is a variant thereof capable of encoding the same fusion polypeptide or a fusion polypeptide which is biologically equivalent thereto.

35. A method according to any of claims 1-34, used as a screening program.

36. A method according claim 35, wherein the method is a screening program for the identification of a biologically active substance that directly or indirectly affects an intracellular signalling pathway and is potentially useful as a medicament, wherein the result of the individual measurement of each substance being screened which indicates its potential biological activity is based on measurement of the redistribution of spatially resolved luminescence in living cells and which undergoes a change in distribution upon activation of an intracellular signalling pathway.

37. A method according to claim 35, wherein the method is a screening program for the identification of a biologically toxic substance as defined herein that exerts its toxic effect

by interfering with an intracellular signalling pathway, wherein the result of the individual measurement of each substance being screened which indicates its potential biologically toxic activity is based on measurement of the redistribution of said fluorescent probe in living cells and which undergoes a change in distribution upon activation of an

5 intracellular signalling pathway.

38. A method according to any of claims 1-37 wherein a fluorescent probe is used in back-tracking of signal transduction pathways as defined herein.

39. A set of data relating to an influence on a cellular response in mechanically intact or permeabilised living cells, obtained by recording variation in spatially distributed light

10 emitted from a luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a component which is capable of being redistributed in a manner which is related to the degree of the influence, as a change in light intensity measured by an instrument designed for the measurement of changes in

15 fluorescence intensity.

1/18

Figure 1




Fig. 1 a




Fig. 1 b




Fig. 1 c




Fig. 1 d

Fig. 1

2/18




Fig. 2 i




Fig. 2 ii




Fig. 2 iii




Fig. 2 iv



Fig. 2 v




Fig. 2 vi

Fig. 2

SUBSTITUTE SHEET (RULE 26)

3/18




Fig. 3 A




Fig. 3 B




Fig. 3 C




Fig. 3 D




Fig. 3 E




Fig. 3 F




Fig. 3 G





Fig. 3 H

Fig. 3

SUBSTITUTE SHEET (RULE 26)

4/18

**Fig. 4**

SUBSTITUTE SHEET (RULE 26)

**5/18**

[forskolin] $\mu$ M	$t_{1/2\max}$ / s	$t_{\max}$ / s
1	115 $\pm$ 21	310 $\pm$ 31
10	69 $\pm$ 14	224 $\pm$ 47
50	47 $\pm$ 10	125 $\pm$ 28

**Fig. 5**

6/18




Fig. 6

7/18



Fig. 7 a



Fig. 7 b



Fig. 7 c

**Fig. 7**

SUBSTITUTE SHEET (RULE 26)

8/18




Fig. 8


**9/18**




**Fig. 9 a**



**Fig. 9 b**



**Fig. 9 c**



**Fig. 9 d**

**Fig. 9**

**SUBSTITUTE SHEET (RULE 26)**

10/18

Fig. 10 a




Fig. 10 b






Fig. 10 c




**Fig. 10**  
SUBSTITUTE SHEET (RULE 26)

11/18



**Fig. 11**  
SUBSTITUTE SHEET (RULE 26)

12/18

**Fig. 12**

SUBSTITUTE SHEET (RULE 26)

13/18






Fig. 13

14/18


**Fig. 14**

15/18




**Fig. 15**  
SUBSTITUTE SHEET (RULE 26)

16/18


**Fig. 16**

SUBSTITUTE SHEET (RULE 26)

17/18

**Fig. 17**

18/18

**Fig. 18**

## SEQUENCE LISTING

<110> BioImage A/S

<120> AN IMPROVED METHOD FOR EXTRACTING  
QUANTITATIVE INFORMATION RELATING TO AN INFLUENCE ON A  
CELLULAR RESPONSE.

<130> 22129PC1

<160> 18

<170> FastSEQ for Windows Version 3.0

$\langle 210 \rangle$  1

<211> 1788

<212> DNA

<213> Aequorea victoria and mouse

<220>

<221> CDS

<222> (1) ... (1788)

<400> 1

atg ggc aac gcc gcc gcc gcc aag aag ggc agc gag cag gag agc gtg 48  
Met Gly Asn Ala Ala Ala Ala Lys Lys Gly Ser Glu Gln Glu Ser Val  
1 5 10 15

aaa gag ttc cta gcc aaa gcc aag gaa gat ttc ctg aaa aaa tgg gaa 96  
Lys Glu Phe Leu Ala Lys Ala Lys Glu Asp Phe Leu Lys Lys Trp Glu  
20 25 30

gac ccc tct cag aat aca gcc cag ttg gat cag ttt gat aga atc aag 144  
Asp Pro Ser Gln Asn Thr Ala Gln Leu Asp Gln Phe Asp Arg Ile Lys  
35 40 45

acc ctt ggc acc ggc tcc ttt ggg cga gtg atg ctg gtg aag cac aag 192  
Thr Leu Gly Thr Gly Ser Phe Gly Arg Val Met Leu Val Lys His Lys  
50 55 60

gag agt ggg aac cac tac gcc atg aag atc tta gac aag cag aag gtg 240  
Glu Ser Gly Asn His Tyr Ala Met Lys Ile Leu Asp Lys Gln Lys Val  
65 70 75 80

gtg aag cta aag cag atc gag cac act ctg aat gag aag cgc atc ctg 288  
Val Lys Leu Lys Gln Ile Glu His Thr Leu Asn Glu Lys Arg Ile Leu  
85 90 95

cag gcc gtc aac ttc ccg ttc ctg gtc aaa ctt gaa ttc tcc ttc aag 336  
Gln Ala Val Asn Phe Pro Phe Leu Val Lys Leu Glu Phe Ser Phe Lys  
100 105 110

gac aac tca aac ctg tac atg gtc atg gag tat gta gct ggt ggc gag 384  
Asp Asn Ser Asn Leu Tyr Met Val Met Glu Tyr Val Ala Gly Gly Glu  
115 120 125

atg ttc tcc cac cta cgg cgg att gga agg ttc agc gag ccc cat gcc 432  
Met Phe Ser His Leu Arg Arg Ile Gly Arg Phe Ser Glu Pro His Ala  
130 135 140

cgt ttc tac gcg gcg cag atc gtc ctg acc ttt gag tat ctg cac tcc 480  
Arg Phe Tyr Ala Ala Gln Ile Val Leu Thr Phe Glu Tyr Leu His Ser  
145 150 155 160

ctg gac ctc atc tac cgg gac ctg aag ccc gag aat ctt ctc atc gac 528  
Leu Asp Leu Ile Tyr Arg Asp Leu Lys Pro Glu Asn Leu Leu Ile Asp  
165 170 175

cag cag ggc tat att cag gtg aca gac ttc ggt ttt gcc aag cgt gtg 576  
Gln Gln Gly Tyr Ile Gln Val Thr Asp Phe Gly Phe Ala Lys Arg Val  
180 185 190

aaa ggc cgt act tgg acc ttg tgt ggg acc cct gag tac ttg gcc ccc 624  
Lys Gly Arg Thr Trp Thr Leu Cys Gly Thr Pro Glu Tyr Leu Ala Pro  
195 200 205

gag att atc ctg agc aaa ggc tac aac aag gct gtg gac tgg tgg gct 672  
Glu Ile Ile Leu Ser Lys Gly Tyr Asn Lys Ala Val Asp Trp Trp Ala  
210 215 220

ctc gga gtc ctc atc tac gag atg gct gct ggt tac cca ccc ttc ttc 720  
 Leu Gly Val Leu Ile Tyr Glu Met Ala Ala Gly Tyr Pro Pro Phe Phe  
 225 230 235 240

gct gac cag cct atc cag atc tat gag aaa atc gtc tct ggg aag gtg 768  
 Ala Asp Gln Pro Ile Gln Ile Tyr Glu Lys Ile Val Ser Gly Lys Val  
 245 250 255

cgg ttc cca tcc cac ttc agc tct gac ttg aag gac ctg ctg cgg aac 816  
 Arg Phe Pro Ser His Phe Ser Ser Asp Leu Lys Asp Leu Leu Arg Asn  
 260 265 270

ctt ctg caa gtg gat cta acc aag cgc ttt gga aac ctc aag gac ggg 864  
 Leu Leu Gln Val Asp Leu Thr Lys Arg Phe Gly Asn Leu Lys Asp Gly  
 275 280 285

gtc aat gac atc aag aac cac aag tgg ttt gcc acg act gac tgg att 912  
 Val Asn Asp Ile Lys Asn His Lys Trp Phe Ala Thr Thr Asp Trp Ile  
 290 295 300

gcc atc tat cag aga aag gtg gaa gct ccc ttc ata cca aag ttt aaa 960  
 Ala Ile Tyr Gln Arg Lys Val Glu Ala Pro Phe Ile Pro Lys Phe Lys  
 305 310 315 320

ggc cct ggg gac acg agt aac ttt gac gac tat gag gag gaa gag atc 1008  
 Gly Pro Gly Asp Thr Ser Asn Phe Asp Asp Tyr Glu Glu Glu Glu Ile  
 325 330 335

cgg gtc tcc atc aat gag aag tgt ggc aag gag ttt act gag ttt ggg 1056  
 Arg Val Ser Ile Asn Glu Lys Cys Gly Lys Glu Phe Thr Glu Phe Gly  
 340 345 350

cgc gcc atg agt aaa gga gaa gaa ctt ttc act gga gtt gtc cca att 1104  
 Arg Ala Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile  
 355 360 365

ctt gtt gaa tta gat ggc gat gtt aat ggg caa aaa ttc tct gtt agt 1152  
 Leu Val Glu Leu Asp Gly Asp Val Asn Gly Gln Lys Phe Ser Val Ser  
 370 375 380

gga gag ggt gaa ggt gat gca aca tac gga aaa ctt acc ctt aaa ttt	1200
Gly Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe	
385 390 395 400	
att tgc act act ggg aag cta cct gtt cca tgg cca acg ctt gtc act	1248
Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr	
405 410 415	
act ctc act tat ggt gtt caa tgc ttt tct aga tac cca gat cat atg	1296
Thr Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met	
420 425 430	
aaa cag cat gac ttt ttc aag agt gcc atg ccc gaa ggt tat gta cag	1344
Lys Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln	
435 440 445	
gaa aga act ata ttt tac aaa gat gac ggg aac tac aag aca cgt gct	1392
Glu Arg Thr Ile Phe Tyr Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala	
450 455 460	
gaa gtc aag ttt gaa ggt gat acc ctt gtt aat aga atc gag tta aaa	1440
Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys	
465 470 475 480	
ggt att gat ttt aaa gaa gat gga aac att ctt gga cac aaa atg gaa	1488
Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Met Glu	
485 490 495	
tac aat tat aac tca cat aat gta tac atc atg gca gac aaa cca aag	1536
Tyr Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Pro Lys	
500 505 510	
aat ggc atc aaa gtt aac ttc aaa att aga cac aac att aaa gat gga	1584
Asn Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Lys Asp Gly	
515 520 525	
agc gtt caa tta gca gac cat tat caa caa aat act cca att ggc gat	1632
Ser Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp	
530 535 540	

ggc cct gtc ctt tta cca gac aac cat tac ctg tcc acg caa tct gcc 1680  
 Gly Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala  
 545 550 555 560

ctt tcc aaa gat ccc aac gaa aag aga gat cac atg atc ctt ctt gag 1728  
 Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Ile Leu Leu Glu  
 565 570 575

ttt gta aca gct gct ggg att aca cat ggc atg gat gaa cta tac aaa 1776  
 Phe Val Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys  
 580 585 590

cct cag gag taa 1788  
 Pro Gln Glu \*  
 595

<210> 2

<211> 595

<212> PRT

<213> Aequorea victoria and mouse

<400> 2

Met Gly Asn Ala Ala Ala Ala Lys Lys Gly Ser Glu Gln Glu Ser Val  
 1 5 10 15  
 Lys Glu Phe Leu Ala Lys Ala Lys Glu Asp Phe Leu Lys Lys Trp Glu  
 20 25 30  
 Asp Pro Ser Gln Asn Thr Ala Gln Leu Asp Gln Phe Asp Arg Ile Lys  
 35 40 45  
 Thr Leu Gly Thr Gly Ser Phe Gly Arg Val Met Leu Val Lys His Lys  
 50 55 60  
 Glu Ser Gly Asn His Tyr Ala Met Lys Ile Leu Asp Lys Gln Lys Val  
 65 70 75 80  
 Val Lys Leu Lys Gln Ile Glu His Thr Leu Asn Glu Lys Arg Ile Leu  
 85 90 95  
 Gln Ala Val Asn Phe Pro Phe Leu Val Lys Leu Glu Phe Ser Phe Lys  
 100 105 110  
 Asp Asn Ser Asn Leu Tyr Met Val Met Glu Tyr Val Ala Gly Gly Glu  
 115 120 125

Met Phe Ser His Leu Arg Arg Ile Gly Arg Phe Ser Glu Pro His Ala  
 130 135 140  
 Arg Phe Tyr Ala Ala Gln Ile Val Leu Thr Phe Glu Tyr Leu His Ser  
 145 150 155 160  
 Leu Asp Leu Ile Tyr Arg Asp Leu Lys Pro Glu Asn Leu Leu Ile Asp  
 165 170 175  
 Gln Gln Gly Tyr Ile Gln Val Thr Asp Phe Gly Phe Ala Lys Arg Val  
 180 185 190  
 Lys Gly Arg Thr Trp Thr Leu Cys Gly Thr Pro Glu Tyr Leu Ala Pro  
 195 200 205  
 Glu Ile Ile Leu Ser Lys Gly Tyr Asn Lys Ala Val Asp Trp Trp Ala  
 210 215 220  
 Leu Gly Val Leu Ile Tyr Glu Met Ala Ala Gly Tyr Pro Pro Phe Phe  
 225 230 235 240  
 Ala Asp Gln Pro Ile Gln Ile Tyr Glu Lys Ile Val Ser Gly Lys Val  
 245 250 255  
 Arg Phe Pro Ser His Phe Ser Ser Asp Leu Lys Asp Leu Leu Arg Asn  
 260 265 270  
 Leu Leu Gln Val Asp Leu Thr Lys Arg Phe Gly Asn Leu Lys Asp Gly  
 275 280 285  
 Val Asn Asp Ile Lys Asn His Lys Trp Phe Ala Thr Thr Asp Trp Ile  
 290 295 300  
 Ala Ile Tyr Gln Arg Lys Val Glu Ala Pro Phe Ile Pro Lys Phe Lys  
 305 310 315 320  
 Gly Pro Gly Asp Thr Ser Asn Phe Asp Asp Tyr Glu Glu Glu Glu Ile  
 325 330 335  
 Arg Val Ser Ile Asn Glu Lys Cys Gly Lys Glu Phe Thr Glu Phe Gly  
 340 345 350  
 Arg Ala Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile  
 355 360 365  
 Leu Val Glu Leu Asp Gly Asp Val Asn Gly Gln Lys Phe Ser Val Ser  
 370 375 380  
 Gly Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe  
 385 390 395 400  
 Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr  
 405 410 415  
 Thr Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met  
 420 425 430  
 Lys Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln  
 435 440 445

Glu Arg Thr Ile Phe Tyr Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala  
 450 455 460  
 Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys  
 465 470 475 480  
 Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Met Glu  
 485 490 495  
 Tyr Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Pro Lys  
 500 505 510  
 Asn Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Lys Asp Gly  
 515 520 525  
 Ser Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp  
 530 535 540  
 Gly Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala  
 545 550 555 560  
 Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Ile Leu Leu Glu  
 565 570 575  
 Phe Val Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys  
 580 585 590  
 Pro Gln Glu  
 595

&lt;210&gt; 3

&lt;211&gt; 2751

&lt;212&gt; DNA

&lt;213&gt; Aequorea victoria and mouse

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(2751)

&lt;400&gt; 3

atg gct gac gtt tac ccg gcc aac gac tcc acg gcg tct cag gac gtg 48  
 Met Ala Asp Val Tyr Pro Ala Asn Asp Ser Thr Ala Ser Gln Asp Val  
 1 5 10 15  
  
 gcc aac cgc ttc gcc cgc aaa ggg gcg ctg agg cag aag aac gtg cat 96  
 Ala Asn Arg Phe Ala Arg Lys Gly Ala Leu Arg Gln Lys Asn Val His  
 20 25 30  
  
 gag gtg aaa gac cac aaa ttc atc gcc cgc ttc ttc aag caa ccc acc 144

Glu Val Lys Asp His Lys Phe Ile Ala Arg Phe Phe Lys Gln Pro Thr	
35 40 45	
ttc tgc agc cac tgc acc gac ttc atc tgg ggg ttt ggg aaa caa ggc	192
Phe Cys Ser His Cys Thr Asp Phe Ile Trp Gly Phe Gly Lys Gln Gly	
50 55 60	
ttc cag tgc caa gtt tgc tgt ttt gtg gtt cat aag agg tgc cat gag	240
Phe Gln Cys Gln Val Cys Cys Phe Val Val His Lys Arg Cys His Glu	
65 70 75 80	
ttc gtt acg ttc tct tgt ccg ggt gcg gat aag gga cct gac act gac	288
Phe Val Thr Phe Ser Cys Pro Gly Ala Asp Lys Gly Pro Asp Thr Asp	
85 90 95	
gac ccc agg agc aag cac aag ttc aaa atc cac aca tac gga agc cct	336
Asp Pro Arg Ser Lys His Lys Phe Lys Ile His Thr Tyr Gly Ser Pro	
100 105 110	
acc ttc tgt gat cac tgt ggg tcc ctg ctc tat gga ctt atc cac caa	384
Thr Phe Cys Asp His Cys Gly Ser Leu Leu Tyr Gly Leu Ile His Gln	
115 120 125	
ggg atg aaa tgt gac acc tgc gac atg aat gtt cac aac cag tgt gtg	432
Gly Met Lys Cys Asp Thr Cys Asp Met Asn Val His Asn Gln Cys Val	
130 135 140	
atc aat gac cct agc ctc tgc gga atg gat cac aca gag aag agg ggg	480
Ile Asn Asp Pro Ser Leu Cys Gly Met Asp His Thr Glu Lys Arg Gly	
145 150 155 160	
cgg att tat ctg aag gct gag gtc act gat gaa aag ctc cac gtc acg	528
Arg Ile Tyr Leu Lys Ala Glu Val Thr Asp Glu Lys Leu His Val Thr	
165 170 175	
gta cga gat gca aaa aat cta atc cct atg gat cca aat ggg ctt tcg	576
Val Arg Asp Ala Lys Asn Leu Ile Pro Met Asp Pro Asn Gly Leu Ser	
180 185 190	
gat cct tat gtg aag ctg aaa cta atc cct gac ccc aag aat gag agc	624

Asp	Pro	Tyr	Val	Lys	Leu	Lys	Leu	Ile	Pro	Asp	Pro	Lys	Asn	Glu	Ser		
195				200				205									
aaa	cag	aaa	acc	aaa	acc	atc	cgc	tcc	aac	ctg	aat	cct	cag	tgg	aat	672	
Lys	Gln	Lys	Thr	Lys	Thr	Ile	Arg	Ser	Asn	Leu	Asn	Pro	Gln	Trp	Asn		
210				215				220									
gag	tcc	ttc	acg	ttc	aaa	tta	aaa	cct	tca	gac	aaa	gac	cgg	cga	ctg	720	
Glu	Ser	Phe	Thr	Phe	Lys	Leu	Lys	Pro	Ser	Asp	Lys	Asp	Arg	Arg	Leu		
225					230				235				240				
tct	gta	gaa	atc	tgg	gac	tgg	gat	cgg	acg	act	cgg	aat	gac	ttc	atg	768	
Ser	Val	Glu	Ile	Trp	Asp	Trp	Asp	Arg	Thr	Thr	Arg	Asn	Asp	Phe	Met		
				245				250				255					
gga	tcc	ctt	tcc	ttt	ggt	gtc	tca	gag	cta	atg	aag	atg	ccg	gcc	agt	816	
Gly	Ser	Leu	Ser	Phe	Gly	Val	Ser	Glu	Leu	Met	Lys	Met	Pro	Ala	Ser		
				260				265				270					
gga	tgg	tat	aaa	gct	cac	aac	caa	gaa	gag	ggc	gaa	tat	tac	aac	gtg	864	
Gly	Trp	Tyr	Lys	Ala	His	Asn	Gln	Glu	Glu	Gly	Glu	Tyr	Tyr	Asn	Val		
				275				280				285					
ccc	att	cca	gaa	gga	gat	gaa	gaa	ggc	aac	atg	gaa	ctc	agg	cag	aag	912	
Pro	Ile	Pro	Glu	Gly	Asp	Glu	Glu	Gly	Asn	Met	Glu	Leu	Arg	Gln	Lys		
				290				295				300					
ttt	gag	aaa	gcc	aag	cta	ggt	cct	gtt	ggt	aac	aaa	gtc	atc	agc	cct	960	
Phe	Glu	Lys	Ala	Lys	Leu	Gly	Pro	Val	Gly	Asn	Lys	Val	Ile	Ser	Pro		
305					310				315				320				
tca	gaa	gac	aga	aag	caa	cca	tcc	aac	aac	ctg	gac	aga	gtg	aaa	ctc	1008	
Ser	Glu	Asp	Arg	Lys	Gln	Pro	Ser	Asn	Asn	Leu	Asp	Arg	Val	Lys	Leu		
				325				330				335					
aca	gac	ttc	aac	ttc	ctc	atg	gtg	ctg	ggg	aag	ggg	agt	ttt	ggg	aag	1056	
Thr	Asp	Phe	Asn	Phe	Leu	Met	Val	Leu	Gly	Lys	Gly	Ser	Phe	Gly	Lys		
				340				345				350					
gtg	atg	ctt	gct	qac	aqq	aag	gga	acq	gag	gaa	ctg	tac	gcc	atc	aag	1104	

Val Met Leu Ala Asp Arg Lys Gly Thr Glu Glu Leu Tyr Ala Ile Lys	
355 360 365	
atc ctg aag aag gac gtg gtg atc cag gac gac gac gtg gag tgc acc	1152
Ile Leu Lys Lys Asp Val Val Ile Gln Asp Asp Asp Val Glu Cys Thr	
370 375 380	
atg gtg gag aag cgc gtg ctg gcc ctg ctg gac aag ccg cca ttt ctg	1200
Met Val Glu Lys Arg Val Leu Ala Leu Leu Asp Lys Pro Pro Phe Leu	
385 390 395 400	
aca cag ctg cac tcc tgc ttc cag aca gtg gac cgg ctg tac ttc gtc	1248
Thr Gln Leu His Ser Cys Phe Gln Thr Val Asp Arg Leu Tyr Phe Val	
405 410 415	
atg gaa tac gtc aac ggc ggg gat ctt atg tac cac att cag caa gtc	1296
Met Glu Tyr Val Asn Gly Gly Asp Leu Met Tyr His Ile Gln Gln Val	
420 425 430	
ggg aaa ttt aag gag cca caa gca gta ttc tac gca gcc gag atc tcc	1344
Gly Lys Phe Lys Glu Pro Gln Ala Val Phe Tyr Ala Ala Glu Ile Ser	
435 440 445	
atc gga ctg ttc ttc ctt cat aaa aga ggg atc att tac agg gat ctg	1392
Ile Gly Leu Phe Phe Leu His Lys Arg Gly Ile Ile Tyr Arg Asp Leu	
450 455 460	
aag ctg aac aat gtc atg ctg aac tca gaa ggg cac atc aaa atc gcc	1440
Lys Leu Asn Asn Val Met Leu Asn Ser Glu Gly His Ile Lys Ile Ala	
465 470 475 480	
gac ttc ggg atg tgc aag gaa cac atg atg gat gga gtc acg acc agg	1488
Asp Phe Gly Met Cys Lys Glu His Met Met Asp Gly Val Thr Thr Arg	
485 490 495	
acc ttc tgc gga act ccg gac tac att gcc cca gag ata atc gct tac	1536
Thr Phe Cys Gly Thr Pro Asp Tyr Ile Ala Pro Glu Ile Ile Ala Tyr	
500 505 510	
cag ccg tac ggg aag tct gta gat tgg tgg gcg tac ggt gtg ctg ctg	1584

Gln	Pro	Tyr	Gly	Lys	Ser	Val	Asp	Trp	Trp	Ala	Tyr	Gly	Val	Leu	Leu		
			515				520					525					
tac	gag	atg	cta	gcc	ggg	cag	cct	ccg	ttt	gat	ggt	gaa	gat	gaa	gat	1632	
Tyr	Glu	Met	Leu	Ala	Gly	Gln	Pro	Pro	Phe	Asp	Gly	Glu	Asp	Glu	Asp		
		530				535					540						
gaa	ctg	ttt	cag	tct	ata	atg	gag	cac	aac	gtg	tcc	tac	ccc	aaa	tcc	1680	
Glu	Leu	Phe	Gln	Ser	Ile	Met	Glu	His	Asn	Val	Ser	Tyr	Pro	Lys	Ser		
545					550					555					560		
ttg	tcc	aag	gaa	gcc	gtc	tcc	atc	tgc	aaa	gga	ctt	atg	acc	aaa	cag	1728	
Leu	Ser	Lys	Glu	Ala	Val	Ser	Ile	Cys	Lys	Gly	Leu	Met	Thr	Lys	Gln		
				565					570					575			
cct	gcc	aag	cga	ctg	ggc	tgc	ggg	ccc	gag	gga	gag	agg	gat	gtc	aga	1776	
Pro	Ala	Lys	Arg	Leu	Gly	Cys	Gly	Pro	Glu	Gly	Glu	Arg	Asp	Val	Arg		
			580				585						590				
gag	cat	gcc	ttc	ttc	agg	agg	atc	gac	tgg	gag	aaa	ctg	gag	aac	agg	1824	
Glu	His	Ala	Phe	Phe	Arg	Arg	Ile	Asp	Trp	Glu	Lys	Leu	Glu	Asn	Arg		
		595				600						605					
gag	atc	caa	cca	cca	ttc	aag	ccc	aaa	gtg	tgt	ggc	aaa	gga	gca	gaa	1872	
Glu	Ile	Gln	Pro	Pro	Phe	Lys	Pro	Lys	Val	Cys	Gly	Lys	Gly	Ala	Glu		
		610				615					620						
aac	ttt	gac	aag	ttc	ttc	acg	cga	gga	cag	cct	gtc	tta	aca	cca	cca	1920	
Asn	Phe	Asp	Lys	Phe	Phe	Thr	Arg	Gly	Gln	Pro	Val	Leu	Thr	Pro	Pro		
625					630					635					640		
gat	cag	ctg	gtc	att	gct	aac	ata	gac	caa	tct	gat	ttt	gaa	ggg	ttc	1968	
Asp	Gln	Leu	Val	Ile	Ala	Asn	Ile	Asp	Gln	Ser	Asp	Phe	Glu	Gly	Phe		
				645					650					655			
tcg	tat	gtc	aac	ccc	cag	ttt	gtg	cac	cca	atc	ttg	caa	agt	gca	gta	2016	
Ser	Tyr	Val	Asn	Pro	Gln	Phe	Val	His	Pro	Ile	Leu	Gln	Ser	Ala	Val		
			660					665						670			
ggg	cgc	gcc	atg	agt	aaa	gga	gaa	gaa	ctt	ttc	act	gga	gtt	gtc	cca	2064	

Gly Arg Ala Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro	
675 680 685	
att ctt gtt gaa tta gat ggc gat gtt aat ggg caa aaa ttc tct gtt	2112
Ile Leu Val Glu Leu Asp Gly Asp Val Asn Gly Gln Lys Phe Ser Val	
690 695 700	
agt gga gag ggt gaa ggt gat gca aca tac gga aaa ctt acc ctt aaa	2160
Ser Gly Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys	
705 710 715 720	
ttt att tgc act act ggg aag cta cct gtt cca tgg cca acg ctt gtc	2208
Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val	
725 730 735	
act act ctc act tat ggt gtt caa tgc ttt tct aga tac cca gat cat	2256
Thr Thr Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His	
740 745 750	
atg aaa cag cat gac ttt ttc aag agt gcc atg ccc gaa ggt tat gta	2304
Met Lys Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val	
755 760 765	
cag gaa aga act ata ttt tac aaa gat gac ggg aac tac aag aca cgt	2352
Gln Glu Arg Thr Ile Phe Tyr Lys Asp Asp Gly Asn Tyr Lys Thr Arg	
770 775 780	
gct gaa gtc aag ttt gaa ggt gat acc ctt gtt aat aga atc gag tta	2400
Ala Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu	
785 790 795 800	
aaa ggt att gat ttt aaa gaa gat gga aac att ctt gga cac aaa atg	2448
Lys Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Met	
805 810 815	
gaa tac aat tat aac tca cat aat gta tac atc atg gca gac aaa cca	2496
Glu Tyr Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Pro	
820 825 830	
aag aat ggc atc aaa gtt aac ttc aaa att aga cac aac att aaa gat	2544

Lys Asn Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Lys Asp  
 835 840 845

gga agc gtt caa tta gca gac cat tat caa caa aat act cca att ggc 2592  
 Gly Ser Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly  
 850 855 860

gat ggc cct gtc ctt tta cca gac aac cat tac ctg tcc acg caa tct 2640  
 Asp Gly Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser  
 865 870 875 880

gcc ctt tcc aaa gat ccc aac gaa aag aga gat cac atg atc ctt ctt 2688  
 Ala Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Ile Leu Leu  
 885 890 895

gag ttt gta aca gct gct ggg att aca cat ggc atg gat gaa cta tac 2736  
 Glu Phe Val Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr  
 900 905 910

aaa cct cag gag taa 2751  
 Lys Pro Gln Glu \*  
 915

<210> 4  
 <211> 916  
 <212> PRT  
 <213> Aequorea victoria and mouse

<400> 4

Met Ala Asp Val Tyr Pro Ala Asn Asp Ser Thr Ala Ser Gln Asp Val  
 1 5 10 15  
 Ala Asn Arg Phe Ala Arg Lys Gly Ala Leu Arg Gln Lys Asn Val His  
 20 25 30  
 Glu Val Lys Asp His Lys Phe Ile Ala Arg Phe Phe Lys Gln Pro Thr  
 35 40 45  
 Phe Cys Ser His Cys Thr Asp Phe Ile Trp Gly Phe Gly Lys Gln Gly  
 50 55 60  
 Phe Gln Cys Gln Val Cys Cys Phe Val Val His Lys Arg Cys His Glu  
 65 70 75 80

Phe Val Thr Phe Ser Cys Pro Gly Ala Asp Lys Gly Pro Asp Thr Asp  
                     85                    90                    95  
 Asp Pro Arg Ser Lys His Lys Phe Lys Ile His Thr Tyr Gly Ser Pro  
                     100                    105                    110  
 Thr Phe Cys Asp His Cys Gly Ser Leu Leu Tyr Gly Leu Ile His Gln  
                     115                    120                    125  
 Gly Met Lys Cys Asp Thr Cys Asp Met Asn Val His Asn Gln Cys Val  
                     130                    135                    140  
 Ile Asn Asp Pro Ser Leu Cys Gly Met Asp His Thr Glu Lys Arg Gly  
 145                    150                    155                    160  
 Arg Ile Tyr Leu Lys Ala Glu Val Thr Asp Glu Lys Leu His Val Thr  
                     165                    170                    175  
 Val Arg Asp Ala Lys Asn Leu Ile Pro Met Asp Pro Asn Gly Leu Ser  
                     180                    185                    190  
 Asp Pro Tyr Val Lys Leu Lys Leu Ile Pro Asp Pro Lys Asn Glu Ser  
                     195                    200                    205  
 Lys Gln Lys Thr Lys Thr Ile Arg Ser Asn Leu Asn Pro Gln Trp Asn  
                     210                    215                    220  
 Glu Ser Phe Thr Phe Lys Leu Lys Pro Ser Asp Lys Asp Arg Arg Leu  
 225                    230                    235                    240  
 Ser Val Glu Ile Trp Asp Trp Asp Arg Thr Thr Arg Asn Asp Phe Met  
                     245                    250                    255  
 Gly Ser Leu Ser Phe Gly Val Ser Glu Leu Met Lys Met Pro Ala Ser  
                     260                    265                    270  
 Gly Trp Tyr Lys Ala His Asn Gln Glu Glu Gly Glu Tyr Tyr Asn Val  
                     275                    280                    285  
 Pro Ile Pro Glu Gly Asp Glu Glu Gly Asn Met Glu Leu Arg Gln Lys  
                     290                    295                    300  
 Phe Glu Lys Ala Lys Leu Gly Pro Val Gly Asn Lys Val Ile Ser Pro  
 305                    310                    315                    320  
 Ser Glu Asp Arg Lys Gln Pro Ser Asn Asn Leu Asp Arg Val Lys Leu  
                     325                    330                    335  
 Thr Asp Phe Asn Phe Leu Met Val Leu Gly Lys Gly Ser Phe Gly Lys  
                     340                    345                    350  
 Val Met Leu Ala Asp Arg Lys Gly Thr Glu Glu Leu Tyr Ala Ile Lys  
                     355                    360                    365  
 Ile Leu Lys Lys Asp Val Val Ile Gln Asp Asp Asp Val Glu Cys Thr  
                     370                    375                    380  
 Met Val Glu Lys Arg Val Leu Ala Leu Leu Asp Lys Pro Pro Phe Leu  
 385                    390                    395                    400

Thr	Gln	Leu	His	Ser	Cys	Phe	Gln	Thr	Val	Asp	Arg	Leu	Tyr	Phe	Val			
				405					410					415				
Met	Glu	Tyr	Val	Asn	Gly	Gly	Asp	Leu	Met	Tyr	His	Ile	Gln	Gln	Val			
			420					425					430					
Gly	Lys	Phe	Lys	Glu	Pro	Gln	Ala	Val	Phe	Tyr	Ala	Ala	Glu	Ile	Ser			
		435					440					445						
Ile	Gly	Leu	Phe	Phe	Leu	His	Lys	Arg	Gly	Ile	Ile	Tyr	Arg	Asp	Leu			
	450					455					460							
Lys	Leu	Asn	Asn	Val	Met	Leu	Asn	Ser	Glu	Gly	His	Ile	Lys	Ile	Ala			
465					470				475					480				
Asp	Phe	Gly	Met	Cys	Lys	Glu	His	Met	Met	Asp	Gly	Val	Thr	Thr	Arg			
			485					490					495					
Thr	Phe	Cys	Gly	Thr	Pro	Asp	Tyr	Ile	Ala	Pro	Glu	Ile	Ile	Ala	Tyr			
			500					505					510					
Gln	Pro	Tyr	Gly	Lys	Ser	Val	Asp	Trp	Trp	Ala	Tyr	Gly	Val	Leu	Leu			
	515					520						525						
Tyr	Glu	Met	Leu	Ala	Gly	Gln	Pro	Pro	Phe	Asp	Gly	Glu	Asp	Glu	Asp			
	530					535				540								
Glu	Leu	Phe	Gln	Ser	Ile	Met	Glu	His	Asn	Val	Ser	Tyr	Pro	Lys	Ser			
545					550				555					560				
Leu	Ser	Lys	Glu	Ala	Val	Ser	Ile	Cys	Lys	Gly	Leu	Met	Thr	Lys	Gln			
			565					570					575					
Pro	Ala	Lys	Arg	Leu	Gly	Cys	Gly	Pro	Glu	Gly	Glu	Arg	Asp	Val	Arg			
		580						585					590					
Glu	His	Ala	Phe	Phe	Arg	Arg	Ile	Asp	Trp	Glu	Lys	Leu	Glu	Asn	Arg			
	595					600						605						
Glu	Ile	Gln	Pro	Pro	Phe	Lys	Pro	Lys	Val	Cys	Gly	Lys	Gly	Ala	Glu			
	610					615					620							
Asn	Phe	Asp	Lys	Phe	Phe	Thr	Arg	Gly	Gln	Pro	Val	Leu	Thr	Pro	Pro			
625					630				635					640				
Asp	Gln	Leu	Val	Ile	Ala	Asn	Ile	Asp	Gln	Ser	Asp	Phe	Glu	Gly	Phe			
			645					650					655					
Ser	Tyr	Val	Asn	Pro	Gln	Phe	Val	His	Pro	Ile	Leu	Gln	Ser	Ala	Val			
		660						665				670						
Gly	Arg	Ala	Met	Ser	Lys	Gly	Glu	Glu	Leu	Phe	Thr	Gly	Val	Val	Pro			
	675					680						685						
Ile	Leu	Val	Glu	Leu	Asp	Gly	Asp	Val	Asn	Gly	Gln	Lys	Phe	Ser	Val			
	690					695					700							
Ser	Gly	Glu	Gly	Glu	Gly	Asp	Ala	Thr	Tyr	Gly	Lys	Leu	Thr	Leu	Lys			
705					710				715					720				

16

Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val  
                             725                            730                            735  
 Thr Thr Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His  
                             740                            745                            750  
 Met Lys Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val  
                             755                            760                            765  
 Gln Glu Arg Thr Ile Phe Tyr Lys Asp Asp Gly Asn Tyr Lys Thr Arg  
                             770                            775                            780  
 Ala Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu  
 785                            790                            795                            800  
 Lys Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Met  
                             805                            810                            815  
 Glu Tyr Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Pro  
                             820                            825                            830  
 Lys Asn Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Lys Asp  
                             835                            840                            845  
 Gly Ser Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly  
                             850                            855                            860  
 Asp Gly Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser  
 865                            870                            875                            880  
 Ala Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Ile Leu Leu  
                             885                            890                            895  
 Glu Phe Val Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr  
                             900                            905                            910  
 Lys Pro Gln Glu  
                             915

&lt;210&gt; 5

&lt;211&gt; 1896

&lt;212&gt; DNA

&lt;213&gt; Aequorea victoria and human

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(1896)

&lt;400&gt; 5

atg gtg agc aag ggc gag gag ctg ttc acc ggg gtg gtg ccc atc ctg  
 Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu  
 1                            5                            10                            15

48

gtc gag ctg gac ggc gac gta aac ggc cac aag ttc agc gtg tcc ggc	96
Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly	
20 25 30	
gag ggc gag ggc gat gcc acc tac ggc aag ctg acc ctg aag ttc atc	144
Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile	
35 40 45	
tgc acc acc ggc aag ctg ccc gtg ccc tgg ccc acc ctc gtg acc acc	192
Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr	
50 55 60	
ctg acc tac ggc gtg cag tgc ttc agc cgc tac ccc gac cac atg aag	240
Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys	
65 70 75 80	
cag cac gac ttc ttc aag tcc gcc atg ccc gaa ggc tac gtc cag gag	288
Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu	
85 90 95	
cgc acc atc ttc ttc aag gac gac ggc aac tac aag acc cgc gcc gag	336
Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu	
100 105 110	
gtg aag ttc gag ggc gac acc ctg gtg aac cgc atc gag ctg aag ggc	384
Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly	
115 120 125	
atc gac ttc aag gag gac ggc aac atc ctg ggg cac aag ctg gag tac	432
Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr	
130 135 140	
aac tac aac agc cac aac gtc tat atc atg gcc gac aag cag aag aac	480
Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn	
145 150 155 160	
ggc atc aag gtg aac ttc aag atc cgc cac aac atc gag gac ggc agc	528
Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser	
165 170 175	

gtg cag ctc gcc gac cac tac cag cag aac acc ccc atc ggc gac ggc	576
Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly	
180 185 190	
ccc gtg ctg ctg ccc gac aac cac tac ctg agc acc cag tcc gcc ctg	624
Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu	
195 200 205	
agc aaa gac ccc aac gag aag cgc gat cac atg gtc ctg ctg gag ttc	672
Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe	
210 215 220	
gtg acc gcc gcc ggg atc act ctc ggc atg gac gag ctg tac aag tcc	720
Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser	
225 230 235 240	
gga ctc aga tct cga gct caa gct tcg aat tca acc atg gcg gcg gcg	768
Gly Leu Arg Ser Arg Ala Gln Ala Ser Asn Ser Thr Met Ala Ala Ala	
245 250 255	
gcg gct cag ggg ggc ggg ggc ggg gag ccc cgt aga acc gag ggg gtc	816
Ala Ala Gln Gly Gly Gly Gly Gly Glu Pro Arg Arg Thr Glu Gly Val	
260 265 270	
ggc ccg ggg gtc ccg ggg gag gtg gag atg gtg aag ggg cag ccg ttc	864
Gly Pro Gly Val Pro Gly Glu Val Glu Met Val Lys Gly Gln Pro Phe	
275 280 285	
gac gtg ggc ccg cgc tac acg cag ttg cag tac atc ggc gag ggc gcg	912
Asp Val Gly Pro Arg Tyr Thr Gln Leu Gln Tyr Ile Gly Glu Gly Ala	
290 295 300	
tac ggc atg gtc agc tcg gcc tat gac cac gtg cgc aag act cgc gtg	960
Tyr Gly Met Val Ser Ser Ala Tyr Asp His Val Arg Lys Thr Arg Val	
305 310 315 320	
gcc atc aag aag atc agc ccc ttc gaa cat cag acc tac tgc cag cgc	1008
Ala Ile Lys Lys Ile Ser Pro Phe Glu His Gln Thr Tyr Cys Gln Arg	
325 330 335	

acg ctc cgg gag atc cag atc ctg ctg cgc ttc cgc cat gag aat gtc 1056  
 Thr Leu Arg Glu Ile Gln Ile Leu Leu Arg Phe Arg His Glu Asn Val  
 340 345 350

atc ggc atc cga gac att ctg cgg gcg tcc acc ctg gaa gcc atg aga 1104  
 Ile Gly Ile Arg Asp Ile Leu Arg Ala Ser Thr Leu Glu Ala Met Arg  
 355 360 365

gat gtc tac att gtg cag gac ctg atg gag act gac ctg tac aag ttg 1152  
 Asp Val Tyr Ile Val Gln Asp Leu Met Glu Thr Asp Leu Tyr Lys Leu  
 370 375 380

ctg aaa agc cag cag ctg agc aat gac cat atc tgc tac ttc ctc tac 1200  
 Leu Lys Ser Gln Gln Leu Ser Asn Asp His Ile Cys Tyr Phe Leu Tyr  
 385 390 395 400

cag atc ctg cgg ggc ctc aag tac atc cac tcc gcc aac gtg ctc cac 1248  
 Gln Ile Leu Arg Gly Leu Lys Tyr Ile His Ser Ala Asn Val Leu His  
 405 410 415

cga gat cta aag ccc tcc aac ctg ctc agc aac acc acc tgc gac ctt 1296  
 Arg Asp Leu Lys Pro Ser Asn Leu Leu Ser Asn Thr Thr Cys Asp Leu  
 420 425 430

aag att tgt gat ttc ggc ctg gcc cgg att gcc gat cct gag cat gac 1344  
 Lys Ile Cys Asp Phe Gly Leu Ala Arg Ile Ala Asp Pro Glu His Asp  
 435 440 445

cac acc ggc ttc ctg acg gag tat gtg gct acg cgc tgg tac cgg gcc 1392  
 His Thr Gly Phe Leu Thr Glu Tyr Val Ala Thr Arg Trp Tyr Arg Ala  
 450 455 460

cca gag atc atg ctg aac tcc aag ggc tat acc aag tcc atc gac atc 1440  
 Pro Glu Ile Met Leu Asn Ser Lys Gly Tyr Thr Lys Ser Ile Asp Ile  
 465 470 475 480

tgg tct gtg ggc tgc att ctg gct gag atg ctc tct aac cgg ccc atc 1488  
 Trp Ser Val Gly Cys Ile Leu Ala Glu Met Leu Ser Asn Arg Pro Ile  
 485 490 495

ttc cct ggc aag cac tac ctg gat cag ctc aac cac att ctg ggc atc	1536
Phe Pro Gly Lys His Tyr Leu Asp Gln Leu Asn His Ile Leu Gly Ile	
500 505 510	
ctg ggc tcc cca tcc cag gag gac ctg aat tgt atc atc aac atg aag	1584
Leu Gly Ser Pro Ser Gln Glu Asp Leu Asn Cys Ile Ile Asn Met Lys	
515 520 525	
gcc cga aac tac cta cag tct ctg ccc tcc aag acc aag gtg gct tgg	1632
Ala Arg Asn Tyr Leu Gln Ser Leu Pro Ser Lys Thr Lys Val Ala Trp	
530 535 540	
gcc aag ctt ttc ccc aag tca gac tcc aaa gcc ctt gac ctg ctg gac	1680
Ala Lys Leu Phe Pro Lys Ser Asp Ser Lys Ala Leu Asp Leu Leu Asp	
545 550 555 560	
cgg atg tta acc ttt aac ccc aat aaa cgg atc aca gtg gag gaa gcg	1728
Arg Met Leu Thr Phe Asn Pro Asn Lys Arg Ile Thr Val Glu Glu Ala	
565 570 575	
ctg gct cac ccc tac ctg gag cag tac tat gac ccg acg gat gag cca	1776
Leu Ala His Pro Tyr Leu Glu Gln Tyr Tyr Asp Pro Thr Asp Glu Pro	
580 585 590	
gtg gcc gag gag ccc ttc acc ttc gcc atg gag ctg gat gac cta cct	1824
Val Ala Glu Glu Pro Phe Thr Phe Ala Met Glu Leu Asp Asp Leu Pro	
595 600 605	
aag gag cgg ctg aag gag ctc atc ttc cag gag aca gca cgc ttc cag	1872
Lys Glu Arg Leu Lys Glu Leu Ile Phe Gln Glu Thr Ala Arg Phe Gln	
610 615 620	
ccc gga gtg ctg gag gcc ccc tag	1896
Pro Gly Val Leu Glu Ala Pro *	
625 630	

&lt;210&gt; 6

&lt;211&gt; 631

&lt;212&gt; PRT

&lt;213&gt; Aequorea victoria and human

&lt;400&gt; 6

```

Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu
 1              5              10              15
Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly
      20              25              30
Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile
      35              40              45
Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr
      50              55              60
Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys
65              70              75              80
Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu
      85              90              95
Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu
      100             105             110
Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly
      115             120             125
Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr
      130             135             140
Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn
145             150             155             160
Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser
      165             170             175
Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly
      180             185             190
Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu
      195             200             205
Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe
      210             215             220
Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser
225             230             235             240
Gly Leu Arg Ser Arg Ala Gln Ala Ser Asn Ser Thr Met Ala Ala Ala
      245             250             255
Ala Ala Gln Gly Gly Gly Gly Gly Glu Pro Arg Arg Thr Glu Gly Val
      260             265             270
Gly Pro Gly Val Pro Gly Glu Val Glu Met Val Lys Gly Gln Pro Phe
      275             280             285

```

Asp Val Gly Pro Arg Tyr Thr Gln Leu Gln Tyr Ile Gly Glu Gly Ala  
 290 295 300  
 Tyr Gly Met Val Ser Ser Ala Tyr Asp His Val Arg Lys Thr Arg Val  
 305 310 315 320  
 Ala Ile Lys Lys Ile Ser Pro Phe Glu His Gln Thr Tyr Cys Gln Arg  
 325 330 335  
 Thr Leu Arg Glu Ile Gln Ile Leu Leu Arg Phe Arg His Glu Asn Val  
 340 345 350  
 Ile Gly Ile Arg Asp Ile Leu Arg Ala Ser Thr Leu Glu Ala Met Arg  
 355 360 365  
 Asp Val Tyr Ile Val Gln Asp Leu Met Glu Thr Asp Leu Tyr Lys Leu  
 370 375 380  
 Leu Lys Ser Gln Gln Leu Ser Asn Asp His Ile Cys Tyr Phe Leu Tyr  
 385 390 395 400  
 Gln Ile Leu Arg Gly Leu Lys Tyr Ile His Ser Ala Asn Val Leu His  
 405 410 415  
 Arg Asp Leu Lys Pro Ser Asn Leu Leu Ser Asn Thr Thr Cys Asp Leu  
 420 425 430  
 Lys Ile Cys Asp Phe Gly Leu Ala Arg Ile Ala Asp Pro Glu His Asp  
 435 440 445  
 His Thr Gly Phe Leu Thr Glu Tyr Val Ala Thr Arg Trp Tyr Arg Ala  
 450 455 460  
 Pro Glu Ile Met Leu Asn Ser Lys Gly Tyr Thr Lys Ser Ile Asp Ile  
 465 470 475 480  
 Trp Ser Val Gly Cys Ile Leu Ala Glu Met Leu Ser Asn Arg Pro Ile  
 485 490 495  
 Phe Pro Gly Lys His Tyr Leu Asp Gln Leu Asn His Ile Leu Gly Ile  
 500 505 510  
 Leu Gly Ser Pro Ser Gln Glu Asp Leu Asn Cys Ile Ile Asn Met Lys  
 515 520 525  
 Ala Arg Asn Tyr Leu Gln Ser Leu Pro Ser Lys Thr Lys Val Ala Trp  
 530 535 540  
 Ala Lys Leu Phe Pro Lys Ser Asp Ser Lys Ala Leu Asp Leu Leu Asp  
 545 550 555 560  
 Arg Met Leu Thr Phe Asn Pro Asn Lys Arg Ile Thr Val Glu Glu Ala  
 565 570 575  
 Leu Ala His Pro Tyr Leu Glu Gln Tyr Tyr Asp Pro Thr Asp Glu Pro  
 580 585 590  
 Val Ala Glu Glu Pro Phe Thr Phe Ala Met Glu Leu Asp Asp Leu Pro  
 595 600 605

## 23

Lys Glu Arg Leu Lys Glu Leu Ile Phe Gln Glu Thr Ala Arg Phe Gln  
 610 615 620  
 Pro Gly Val Leu Glu Ala Pro  
 625 630

<210> 7

<211> 2160

<212> DNA

<213> Aequorea victoria and human

<220>

<221> CDS

<222> (1)...(2160)

<400> 7

atg gtg agc aag ggc gag gag ctg ttc acc ggg gtg gtg ccc atc ctg 48  
 Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu  
 1 5 10 15

gtc gag ctg gac ggc gac gta aac ggc cac aag ttc agc gtg tcc ggc 96  
 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly  
 20 25 30

gag ggc gag ggc gat gcc acc tac ggc aag ctg acc ctg aag ttc atc 144  
 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile  
 35 40 45

tgc acc acc ggc aag ctg ccc gtg ccc tgg ccc acc ctc gtg acc acc 192  
 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr  
 50 55 60

ctg acc tac ggc gtg cag tgc ttc agc cgc tac ccc gac cac atg aag 240  
 Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys  
 65 70 75 80

cag cac gac ttc ttc aag tcc gcc atg ccc gaa ggc tac gtc cag gag 288  
 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu  
 85 90 95

cgc acc atc ttc ttc aag gac gac ggc aac tac aag acc cgc gcc gag 336

Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu	
100 105 110	
gtg aag ttc gag ggc gac acc ctg gtg aac cgc atc gag ctg aag ggc	384
Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly	
115 120 125	
atc gac ttc aag gag gac ggc aac atc ctg ggg cac aag ctg gag tac	432
Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr	
130 135 140	
aac tac aac agc cac aac gtc tat atc atg gcc gac aag cag aag aac	480
Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn	
145 150 155 160	
ggc atc aag gtg aac ttc aag atc cgc cac aac atc gag gac ggc agc	528
Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser	
165 170 175	
gtg cag ctc gcc gac cac tac cag cag aac acc ccc atc ggc gac ggc	576
Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly	
180 185 190	
ccc gtg ctg ctg ccc gac aac cac tac ctg agc acc cag tcc gcc ctg	624
Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu	
195 200 205	
agc aaa gac ccc aac gag aag cgc gat cac atg gtc ctg ctg gag ttc	672
Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe	
210 215 220	
gtg acc gcc gcc ggg atc act ctc ggc atg gac gag ctg tac aag tcc	720
Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser	
225 230 235 240	
gga ctc aga tct cga gct caa gct tcg aat tcg acc atg tcg tcc atc	768
Gly Leu Arg Ser Arg Ala Gln Ala Ser Asn Ser Thr Met Ser Ser Ile	
245 250 255	
ttg cca ttc acg ccg cca gtt gtg aag aga ctg ctg gga tgg aag aag	816

## 25

Leu	Pro	Phe	Thr	Pro	Pro	Val	Val	Lys	Arg	Leu	Leu	Gly	Trp	Lys	Lys		
			260					265					270				
tca	gct	ggt	ggg	tct	gga	gga	gca	ggc	gga	gga	gag	cag	aat	ggg	cag		864
Ser	Ala	Gly	Gly	Ser	Gly	Gly	Ala	Gly	Gly	Gly	Glu	Gln	Asn	Gly	Gln		
			275					280					285				
gaa	gaa	aag	tgg	tgt	gag	aaa	gca	gtg	aaa	agt	ctg	gtg	aag	aag	cta		912
Glu	Glu	Lys	Trp	Cys	Glu	Lys	Ala	Val	Lys	Ser	Leu	Val	Lys	Lys	Leu		
			290					295				300					
aag	aaa	aca	gga	cga	tta	gat	gag	ctt	gag	aaa	gcc	atc	acc	act	caa		960
Lys	Lys	Thr	Gly	Arg	Leu	Asp	Glu	Leu	Glu	Lys	Ala	Ile	Thr	Thr	Gln		
305						310				315					320		
aac	tgt	aat	act	aaa	tgt	gtt	acc	ata	cca	agc	act	tgc	tct	gaa	att		1008
Asn	Cys	Asn	Thr	Lys	Cys	Val	Thr	Ile	Pro	Ser	Thr	Cys	Ser	Glu	Ile		
				325					330					335			
tgg	gga	ctg	agt	aca	cca	aat	acg	ata	gat	cag	tgg	gat	aca	aca	ggc		1056
Trp	Gly	Leu	Ser	Thr	Pro	Asn	Thr	Ile	Asp	Gln	Trp	Asp	Thr	Thr	Gly		
				340					345					350			
ctt	tac	agc	ttc	tct	gaa	caa	acc	agg	tct	ctt	gat	ggt	cgt	ctc	cag		1104
Leu	Tyr	Ser	Phe	Ser	Glu	Gln	Thr	Arg	Ser	Leu	Asp	Gly	Arg	Leu	Gln		
			355					360					365				
gta	tcc	cat	cga	aaa	gga	ttg	cca	cat	gtt	ata	tat	tgc	cga	tta	tgg		1152
Val	Ser	His	Arg	Lys	Gly	Leu	Pro	His	Val	Ile	Tyr	Cys	Arg	Leu	Trp		
			370				375					380					
cgc	tgg	cct	gat	ctt	cac	agt	cat	cat	gaa	ctc	aag	gca	att	gaa	aac		1200
Arg	Trp	Pro	Asp	Leu	His	Ser	His	His	Glu	Leu	Lys	Ala	Ile	Glu	Asn		
385						390				395					400		
tgc	gaa	tat	gct	ttt	aat	ctt	aaa	aag	gat	gaa	gta	tgt	gta	aac	cct		1248
Cys	Glu	Tyr	Ala	Phe	Asn	Leu	Lys	Lys	Asp	Glu	Val	Cys	Val	Asn	Pro		
				405					410					415			
tac	cac	tat	cag	aga	gtt	gag	aca	cca	gtt	ttg	cct	cca	gta	tta	gtg		1296

Tyr His Tyr Gln Arg Val Glu Thr Pro Val Leu Pro Pro Val Leu Val	
420	425 430
ccc cga cac acc gag atc cta aca gaa ctt ccg cct ctg gat gac tat	1344
Pro Arg His Thr Glu Ile Leu Thr Glu Leu Pro Pro Leu Asp Asp Tyr	
435	440 445
act cac tcc att cca gaa aac act aac ttc cca gca gga att gag cca	1392
Thr His Ser Ile Pro Glu Asn Thr Asn Phe Pro Ala Gly Ile Glu Pro	
450	455 460
cag agt aat tat att cca gaa acg cca cct cct gga tat atc agt gaa	1440
Gln Ser Asn Tyr Ile Pro Glu Thr Pro Pro Pro Gly Tyr Ile Ser Glu	
465	470 475 480
gat gga gaa aca agt gac caa cag ttg aat caa agt atg gac aca ggc	1488
Asp Gly Glu Thr Ser Asp Gln Gln Leu Asn Gln Ser Met Asp Thr Gly	
485	490 495
tct cca gca gaa cta tct cct act act ctt tcc cct gtt aat cat agc	1536
Ser Pro Ala Glu Leu Ser Pro Thr Thr Leu Ser Pro Val Asn His Ser	
500	505 510
ttg gat tta cag cca gtt act tac tca gaa cct gca ttt tgg tgt tca	1584
Leu Asp Leu Gln Pro Val Thr Tyr Ser Glu Pro Ala Phe Trp Cys Ser	
515	520 525
ata gca tat tat gaa tta aat cag agg gtt gga gaa acc ttc cat gca	1632
Ile Ala Tyr Tyr Glu Leu Asn Gln Arg Val Gly Glu Thr Phe His Ala	
530	535 540
tca cag ccc tca ctc act gta gat ggc ttt aca gac cca tca aat tca	1680
Ser Gln Pro Ser Leu Thr Val Asp Gly Phe Thr Asp Pro Ser Asn Ser	
545	550 555 560
gag agg ttc tgc tta ggt tta ctc tcc aat gtt aac cga aat gcc acg	1728
Glu Arg Phe Cys Leu Gly Leu Leu Ser Asn Val Asn Arg Asn Ala Thr	
565	570 575
gta gaa atg aca aga agg cat ata gga aga gga gtg cgc tta tac tac	1776

<213> Aequorea victoria and human

&lt;400&gt; 8

Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu  
 1 5 10 15  
 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly  
 20 25 30  
 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile  
 35 40 45  
 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr  
 50 55 60  
 Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys  
 65 70 75 80  
 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu  
 85 90 95  
 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu  
 100 105 110  
 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly  
 115 120 125  
 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr  
 130 135 140  
 Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn  
 145 150 155 160  
 Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser  
 165 170 175  
 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly  
 180 185 190  
 Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu  
 195 200 205  
 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe  
 210 215 220  
 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser  
 225 230 235 240  
 Gly Leu Arg Ser Arg Ala Gln Ala Ser Asn Ser Thr Met Ser Ser Ile  
 245 250 255  
 Leu Pro Phe Thr Pro Pro Val Val Lys Arg Leu Leu Gly Trp Lys Lys  
 260 265 270  
 Ser Ala Gly Gly Ser Gly Gly Ala Gly Gly Gly Glu Gln Asn Gly Gln  
 275 280 285  
 Glu Glu Lys Trp Cys Glu Lys Ala Val Lys Ser Leu Val Lys Lys Leu  
 290 295 300

Lys Lys Thr Gly Arg Leu Asp Glu Leu Glu Lys Ala Ile Thr Thr Gln  
 305 310 315 320  
 Asn Cys Asn Thr Lys Cys Val Thr Ile Pro Ser Thr Cys Ser Glu Ile  
 325 330 335  
 Trp Gly Leu Ser Thr Pro Asn Thr Ile Asp Gln Trp Asp Thr Thr Gly  
 340 345 350  
 Leu Tyr Ser Phe Ser Glu Gln Thr Arg Ser Leu Asp Gly Arg Leu Gln  
 355 360 365  
 Val Ser His Arg Lys Gly Leu Pro His Val Ile Tyr Cys Arg Leu Trp  
 370 375 380  
 Arg Trp Pro Asp Leu His Ser His His Glu Leu Lys Ala Ile Glu Asn  
 385 390 395 400  
 Cys Glu Tyr Ala Phe Asn Leu Lys Lys Asp Glu Val Cys Val Asn Pro  
 405 410 415  
 Tyr His Tyr Gln Arg Val Glu Thr Pro Val Leu Pro Pro Val Leu Val  
 420 425 430  
 Pro Arg His Thr Glu Ile Leu Thr Glu Leu Pro Pro Leu Asp Asp Tyr  
 435 440 445  
 Thr His Ser Ile Pro Glu Asn Thr Asn Phe Pro Ala Gly Ile Glu Pro  
 450 455 460  
 Gln Ser Asn Tyr Ile Pro Glu Thr Pro Pro Pro Gly Tyr Ile Ser Glu  
 465 470 475 480  
 Asp Gly Glu Thr Ser Asp Gln Gln Leu Asn Gln Ser Met Asp Thr Gly  
 485 490 495  
 Ser Pro Ala Glu Leu Ser Pro Thr Thr Leu Ser Pro Val Asn His Ser  
 500 505 510  
 Leu Asp Leu Gln Pro Val Thr Tyr Ser Glu Pro Ala Phe Trp Cys Ser  
 515 520 525  
 Ile Ala Tyr Tyr Glu Leu Asn Gln Arg Val Gly Glu Thr Phe His Ala  
 530 535 540  
 Ser Gln Pro Ser Leu Thr Val Asp Gly Phe Thr Asp Pro Ser Asn Ser  
 545 550 555 560  
 Glu Arg Phe Cys Leu Gly Leu Leu Ser Asn Val Asn Arg Asn Ala Thr  
 565 570 575  
 Val Glu Met Thr Arg Arg His Ile Gly Arg Gly Val Arg Leu Tyr Tyr  
 580 585 590  
 Ile Gly Gly Glu Val Phe Ala Glu Cys Leu Ser Asp Ser Ala Ile Phe  
 595 600 605  
 Val Gln Ser Pro Asn Cys Asn Gln Arg Tyr Gly Trp His Pro Ala Thr  
 610 615 620



Ile Thr Thr Gln Asn Cys Asn Thr Lys Cys Val Thr Ile Pro Ser Thr	
65                               70                               75                               80	
tgc tct gaa att tgg gga ctg agt aca cca aat acg ata gat cag tgg	288
Cys Ser Glu Ile Trp Gly Leu Ser Thr Pro Asn Thr Ile Asp Gln Trp	
85                               90                               95	
gat aca aca ggc ctt tac agc ttc tct gaa caa acc agg tct ctt gat	336
Asp Thr Thr Gly Leu Tyr Ser Phe Ser Glu Gln Thr Arg Ser Leu Asp	
100                               105                               110	
ggt cgt ctc cag gta tcc cat cga aaa gga ttg cca cat gtt ata tat	384
Gly Arg Leu Gln Val Ser His Arg Lys Gly Leu Pro His Val Ile Tyr	
115                               120                               125	
tgc cga tta tgg cgc tgg cct gat ctt cac agt cat cat gaa ctc aag	432
Cys Arg Leu Trp Arg Trp Pro Asp Leu His Ser His His Glu Leu Lys	
130                               135                               140	
gca att gaa aac tgc gaa tat gct ttt aat ctt aaa aag gat gaa gta	480
Ala Ile Glu Asn Cys Glu Tyr Ala Phe Asn Leu Lys Lys Asp Glu Val	
145                               150                               155                               160	
tgt gta aac cct tac cac tat cag aga gtt gag aca cca gtt ttg cct	528
Cys Val Asn Pro Tyr His Tyr Gln Arg Val Glu Thr Pro Val Leu Pro	
165                               170                               175	
cca gta tta gtg ccc cga cac acc gag atc cta aca gaa ctt ccg cct	576
Pro Val Leu Val Pro Arg His Thr Glu Ile Leu Thr Glu Leu Pro Pro	
180                               185                               190	
ctg gat gac tat act cac tcc att cca gaa aac act aac ttc cca gca	624
Leu Asp Asp Tyr Thr His Ser Ile Pro Glu Asn Thr Asn Phe Pro Ala	
195                               200                               205	
gga att gag cca cag agt aat tat att cca gaa acg cca cct cct gga	672
Gly Ile Glu Pro Gln Ser Asn Tyr Ile Pro Glu Thr Pro Pro Pro Gly	
210                               215                               220	
tat atc agt gaa gat gga gaa aca agt gac caa cag ttg aat caa agt	720





Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln  
 545 550 555 560

cac gac ttc ttc aag tcc gcc atg ccc gaa ggc tac gtc cag gag cgc 1728  
 His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg  
 565 570 575

acc atc ttc ttc aag gac gac ggc aac tac aag acc cgc gcc gag gtg 1776  
 Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val  
 580 585 590

aag ttc gag ggc gac acc ctg gtg aac cgc atc gag ctg aag ggc atc 1824  
 Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile  
 595 600 605

gac ttc aag gag gac ggc aac atc ctg ggg cac aag ctg gag tac aac 1872  
 Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn  
 610 615 620

tac aac agc cac aac gtc tat atc atg gcc gac aag cag aag aac ggc 1920  
 Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly  
 625 630 635 640

atc aag gtg aac ttc aag atc cgc cac aac atc gag gac ggc agc gtg 1968  
 Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val  
 645 650 655

cag ctc gcc gac cac tac cag cag aac acc ccc atc ggc gac ggc ccc 2016  
 Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro  
 660 665 670

gtg ctg ctg ccc gac aac cac tac ctg agc acc cag tcc gcc ctg agc 2064  
 Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser  
 675 680 685

aaa gac ccc aac gag aag cgc gat cac atg gtc ctg ctg gag ttc gtg 2112  
 Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val  
 690 695 700

acc gcc gcc ggg atc act ctc ggc atg gac gag ctg tac aag taa 2157

Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys \*  
 705 710 715

<210> 10

<211> 718

<212> PRT

<213> Aequorea victoria and human

<400> 10

Met Ser Ser Ile Leu Pro Phe Thr Pro Pro Val Val Lys Arg Leu Leu  
 1 5 10 15  
 Gly Trp Lys Lys Ser Ala Gly Gly Ser Gly Gly Ala Gly Gly Gly Glu  
 20 25 30  
 Gln Asn Gly Gln Glu Glu Lys Trp Cys Glu Lys Ala Val Lys Ser Leu  
 35 40 45  
 Val Lys Lys Leu Lys Lys Thr Gly Arg Leu Asp Glu Leu Glu Lys Ala  
 50 55 60  
 Ile Thr Thr Gln Asn Cys Asn Thr Lys Cys Val Thr Ile Pro Ser Thr  
 65 70 75 80  
 Cys Ser Glu Ile Trp Gly Leu Ser Thr Pro Asn Thr Ile Asp Gln Trp  
 85 90 95  
 Asp Thr Thr Gly Leu Tyr Ser Phe Ser Glu Gln Thr Arg Ser Leu Asp  
 100 105 110  
 Gly Arg Leu Gln Val Ser His Arg Lys Gly Leu Pro His Val Ile Tyr  
 115 120 125  
 Cys Arg Leu Trp Arg Trp Pro Asp Leu His Ser His His Glu Leu Lys  
 130 135 140  
 Ala Ile Glu Asn Cys Glu Tyr Ala Phe Asn Leu Lys Lys Asp Glu Val  
 145 150 155 160  
 Cys Val Asn Pro Tyr His Tyr Gln Arg Val Glu Thr Pro Val Leu Pro  
 165 170 175  
 Pro Val Leu Val Pro Arg His Thr Glu Ile Leu Thr Glu Leu Pro Pro  
 180 185 190  
 Leu Asp Asp Tyr Thr His Ser Ile Pro Glu Asn Thr Asn Phe Pro Ala  
 195 200 205  
 Gly Ile Glu Pro Gln Ser Asn Tyr Ile Pro Glu Thr Pro Pro Pro Gly  
 210 215 220  
 Tyr Ile Ser Glu Asp Gly Glu Thr Ser Asp Gln Gln Leu Asn Gln Ser  
 225 230 235 240

Met Asp Thr Gly Ser Pro Ala Glu Leu Ser Pro Thr Thr Leu Ser Pro  
 245 250 255  
 Val Asn His Ser Leu Asp Leu Gln Pro Val Thr Tyr Ser Glu Pro Ala  
 260 265 270  
 Phe Trp Cys Ser Ile Ala Tyr Tyr Glu Leu Asn Gln Arg Val Gly Glu  
 275 280 285  
 Thr Phe His Ala Ser Gln Pro Ser Leu Thr Val Asp Gly Phe Thr Asp  
 290 295 300  
 Pro Ser Asn Ser Glu Arg Phe Cys Leu Gly Leu Leu Ser Asn Val Asn  
 305 310 315 320  
 Arg Asn Ala Thr Val Glu Met Thr Arg Arg His Ile Gly Arg Gly Val  
 325 330 335  
 Arg Leu Tyr Tyr Ile Gly Gly Glu Val Phe Ala Glu Cys Leu Ser Asp  
 340 345 350  
 Ser Ala Ile Phe Val Gln Ser Pro Asn Cys Asn Gln Arg Tyr Gly Trp  
 355 360 365  
 His Pro Ala Thr Val Cys Lys Ile Pro Pro Gly Cys Asn Leu Lys Ile  
 370 375 380  
 Phe Asn Asn Gln Glu Phe Ala Ala Leu Leu Ala Gln Ser Val Asn Gln  
 385 390 395 400  
 Gly Phe Glu Ala Val Tyr Gln Leu Thr Arg Met Cys Thr Ile Arg Met  
 405 410 415  
 Ser Phe Val Lys Gly Trp Gly Ala Glu Tyr Arg Arg Gln Thr Val Thr  
 420 425 430  
 Ser Thr Pro Cys Trp Ile Glu Leu His Leu Asn Gly Pro Leu Gln Trp  
 435 440 445  
 Leu Asp Lys Val Leu Thr Gln Met Gly Ser Pro Ser Val Arg Cys Ser  
 450 455 460  
 Ser Met Ser Trp Val Pro Arg Ala Arg Asp Pro Pro Val Ala Thr Met  
 465 470 475 480  
 Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val  
 485 490 495  
 Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu  
 500 505 510  
 Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys  
 515 520 525  
 Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu  
 530 535 540  
 Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln  
 545 550 555 560

His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg  
 565 570 575  
 Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val  
 580 585 590  
 Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile  
 595 600 605  
 Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn  
 610 615 620  
 Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly  
 625 630 635 640  
 Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val  
 645 650 655  
 Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro  
 660 665 670  
 Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser  
 675 680 685  
 Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val  
 690 695 700  
 Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys  
 705 710 715

&lt;210&gt; 11

&lt;211&gt; 1908

&lt;212&gt; DNA

<213> *Aequorea victoria* and human

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(1908)

&lt;400&gt; 11

atg gtg agc aag ggc gag gag ctg ttc acc ggg gtg gtg ccc atc ctg 48  
 Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu  
 1 5 10 15  
 gtc gag ctg gac ggc gac gta aac ggc cac aag ttc agc gtg tcc ggc 96  
 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly  
 20 25 30  
 gag ggc gag ggc gat gcc acc tac ggc aag ctg acc ctg aag ttc atc 144

Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile  
 35 40 45

tgc acc acc ggc aag ctg ccc gtg ccc tgg ccc acc ctc gtg acc acc 192  
 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr  
 50 55 60

ctg acc tac ggc gtg cag tgc ttc agc cgc tac ccc gac cac atg aag 240  
 Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys  
 65 70 75 80

cag cac gac ttc ttc aag tcc gcc atg ccc gaa ggc tac gtc cag gag 288  
 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu  
 85 90 95

cgc acc atc ttc ttc aag gac gac ggc aac tac aag acc cgc gcc gag 336  
 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu  
 100 105 110

gtg aag ttc gag ggc gac acc ctg gtg aac cgc atc gag ctg aag ggc 384  
 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly  
 115 120 125

atc gac ttc aag gag gac ggc aac atc ctg ggg cac aag ctg gag tac 432  
 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr  
 130 135 140

aac tac aac agc cac aac gtc tat atc atg gcc gac aag cag aag aac 480  
 Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn  
 145 150 155 160

ggc atc aag gtg aac ttc aag atc cgc cac aac atc gag gac ggc agc 528  
 Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser  
 165 170 175

gtg cag ctc gcc gac cac tac cag cag aac acc ccc atc ggc gac ggc 576  
 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly  
 180 185 190

ccc gtg ctg ctg ccc gac aac cac tac ctg agc acc cag tcc gcc ctg 624

Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu  
 195 200 205

agc aaa gac ccc aac gag aag cgc gat cac atg gtc ctg ctg gag ttc 672  
 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe  
 210 215 220

gtg acc gcc gcc ggg atc act ctc ggc atg gac gag ctg tac aag tcc 720  
 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser  
 225 230 235 240

gga ctc aga tct cga gct caa gct tcc atg agc gag acg gtc atc atg 768  
 Gly Leu Arg Ser Arg Ala Gln Ala Ser Met Ser Glu Thr Val Ile Met  
 245 250 255

agc gag acg gtc atc tgt tcc agc cgg gcc act gtg atg ctt tat gat 816  
 Ser Glu Thr Val Ile Cys Ser Ser Arg Ala Thr Val Met Leu Tyr Asp  
 260 265 270

gat ggc aac aag cga tgg ctc cct gct ggc acg ggt ccc cag gcc ttc 864  
 Asp Gly Asn Lys Arg Trp Leu Pro Ala Gly Thr Gly Pro Gln Ala Phe  
 275 280 285

agc cgc gtc cag atc tac cac aac ccc acg gcc aat tcc ttt cgc gtc 912  
 Ser Arg Val Gln Ile Tyr His Asn Pro Thr Ala Asn Ser Phe Arg Val  
 290 295 300

gtg ggc cgg aag atg cag ccc gac cag cag gtg gtc atc aac tgt gcc 960  
 Val Gly Arg Lys Met Gln Pro Asp Gln Gln Val Val Ile Asn Cys Ala  
 305 310 315 320

atc gtc cgg ggt gtc aag tat aac cag gcc acc ccc aac ttc cat cag 1008  
 Ile Val Arg Gly Val Lys Tyr Asn Gln Ala Thr Pro Asn Phe His Gln  
 325 330 335

tgg cgc gac gct cgc cag gtc tgg ggc ctc aac ttc ggc agc aag gag 1056  
 Trp Arg Asp Ala Arg Gln Val Trp Gly Leu Asn Phe Gly Ser Lys Glu  
 340 345 350

gat gcg gcc cag ttt gcc gcc ggc atg gcc agt gcc cta gag gcg ttg 1104

Asp Ala Ala Gln Phe Ala Ala Gly Met Ala Ser Ala Leu Glu Ala Leu  
 355 360 365

gaa gga ggt ggg ccc cct cca ccc cca gca ctt ccc acc tgg tcg gtc 1152  
 Glu Gly Gly Gly Pro Pro Pro Pro Pro Ala Leu Pro Thr Trp Ser Val  
 370 375 380

ccg aac ggc ccc tcc ccg gag gag gtg gag cag cag aaa agg cag cag 1200  
 Pro Asn Gly Pro Ser Pro Glu Glu Val Glu Gln Gln Lys Arg Gln Gln  
 385 390 395 400

ccc ggc ccg tcg gag cac ata gag cgc cgg gtc tcc aat gca gga ggc 1248  
 Pro Gly Pro Ser Glu His Ile Glu Arg Arg Val Ser Asn Ala Gly Gly  
 405 410 415

cca cct gct ccc ccc gct ggg ggt cca ccc cca cca cca gga cct ccc 1296  
 Pro Pro Ala Pro Pro Ala Gly Gly Pro Pro Pro Pro Pro Gly Pro Pro  
 420 425 430

cct cct cca ggt ccc ccc cca ccc cca ggt ttg ccc cct tcg ggg gtc 1344  
 Pro Pro Pro Gly Pro Pro Pro Pro Pro Gly Leu Pro Pro Ser Gly Val  
 435 440 445

cca gct gca gcg cac gga gca ggg gga gga cca ccc cct gca ccc cct 1392  
 Pro Ala Ala Ala His Gly Ala Gly Gly Gly Pro Pro Pro Ala Pro Pro  
 450 455 460

ctc ccg gca gca cag ggc cct ggt ggt ggg gga gct ggg gcc cca ggc 1440  
 Leu Pro Ala Ala Gln Gly Pro Gly Gly Gly Gly Ala Gly Ala Pro Gly  
 465 470 475 480

ctg gcc gca gct att gct gga gcc aaa ctc agg aaa gtc agc aag cag 1488  
 Leu Ala Ala Ala Ile Ala Gly Ala Lys Leu Arg Lys Val Ser Lys Gln  
 485 490 495

gag gag gcc tca ggg ggg ccc aca gcc ccc aaa gct gag agt ggt cga 1536  
 Glu Glu Ala Ser Gly Gly Pro Thr Ala Pro Lys Ala Glu Ser Gly Arg  
 500 505 510

agc gga ggt ggg gga ctc atg gaa gag atg aac gcc atg ctg gcc cgg 1584

Ser Gly Gly Gly Gly Leu Met Glu Glu Met Asn Ala Met Leu Ala Arg  
 515 520 525  
 aga agg aaa gcc acg caa gtt ggg gag aaa acc ccc aag gat gaa tct 1632  
 Arg Arg Lys Ala Thr Gln Val Gly Glu Lys Thr Pro Lys Asp Glu Ser  
 530 535 540  
 gcc aat cag gag gag cca gag gcc aga gtc ccg gcc cag agt gaa tct 1680  
 Ala Asn Gln Glu Glu Pro Glu Ala Arg Val Pro Ala Gln Ser Glu Ser  
 545 550 555 560  
 gtg cgg aga ccc tgg gag aag aac agc aca acc ttg cca agg atg aag 1728  
 Val Arg Arg Pro Trp Glu Lys Asn Ser Thr Thr Leu Pro Arg Met Lys  
 565 570 575  
 tcg tct tct tcg gtg acc act tcc gag acc caa ccc tgc acg ccc agc 1776  
 Ser Ser Ser Ser Val Thr Thr Ser Glu Thr Gln Pro Cys Thr Pro Ser  
 580 585 590  
 tcc agt gat tac tcg gac cta cag agg gtg aaa cag gag ctt ctg gaa 1824  
 Ser Ser Asp Tyr Ser Asp Leu Gln Arg Val Lys Gln Glu Leu Leu Glu  
 595 600 605  
 gag gtg aag aag gaa ttg cag aaa gtg aaa gag gaa atc att gaa gcc 1872  
 Glu Val Lys Lys Glu Leu Gln Lys Val Lys Glu Glu Ile Ile Glu Ala  
 610 615 620  
 ttc gtc cag gag ctg agg aag cgg ggt tct ccc tga 1908  
 Phe Val Gln Glu Leu Arg Lys Arg Gly Ser Pro \*  
 625 630 635

&lt;210&gt; 12

&lt;211&gt; 635

&lt;212&gt; PRT

&lt;213&gt; Aequorea victoria and human

&lt;400&gt; 12

Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu

1

5

10

15

Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly  
 20 25 30  
 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile  
 35 40 45  
 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr  
 50 55 60  
 Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys  
 65 70 75 80  
 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu  
 85 90 95  
 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu  
 100 105 110  
 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly  
 115 120 125  
 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr  
 130 135 140  
 Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn  
 145 150 155 160  
 Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser  
 165 170 175  
 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly  
 180 185 190  
 Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu  
 195 200 205  
 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe  
 210 215 220  
 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser  
 225 230 235 240  
 Gly Leu Arg Ser Arg Ala Gln Ala Ser Met Ser Glu Thr Val Ile Met  
 245 250 255  
 Ser Glu Thr Val Ile Cys Ser Ser Arg Ala Thr Val Met Leu Tyr Asp  
 260 265 270  
 Asp Gly Asn Lys Arg Trp Leu Pro Ala Gly Thr Gly Pro Gln Ala Phe  
 275 280 285  
 Ser Arg Val Gln Ile Tyr His Asn Pro Thr Ala Asn Ser Phe Arg Val  
 290 295 300  
 Val Gly Arg Lys Met Gln Pro Asp Gln Gln Val Val Ile Asn Cys Ala  
 305 310 315 320  
 Ile Val Arg Gly Val Lys Tyr Asn Gln Ala Thr Pro Asn Phe His Gln  
 325 330 335

## 43

Trp Arg Asp Ala Arg Gln Val Trp Gly Leu Asn Phe Gly Ser Lys Glu  
 340 345 350  
 Asp Ala Ala Gln Phe Ala Ala Gly Met Ala Ser Ala Leu Glu Ala Leu  
 355 360 365  
 Glu Gly Gly Gly Pro Pro Pro Pro Pro Ala Leu Pro Thr Trp Ser Val  
 370 375 380  
 Pro Asn Gly Pro Ser Pro Glu Glu Val Glu Gln Gln Lys Arg Gln Gln  
 385 390 395 400  
 Pro Gly Pro Ser Glu His Ile Glu Arg Arg Val Ser Asn Ala Gly Gly  
 405 410 415  
 Pro Pro Ala Pro Pro Ala Gly Gly Pro Pro Pro Pro Pro Gly Pro Pro  
 420 425 430  
 Pro Pro Pro Gly Pro Pro Pro Pro Pro Gly Leu Pro Pro Ser Gly Val  
 435 440 445  
 Pro Ala Ala Ala His Gly Ala Gly Gly Gly Pro Pro Pro Ala Pro Pro  
 450 455 460  
 Leu Pro Ala Ala Gln Gly Pro Gly Gly Gly Gly Ala Gly Ala Pro Gly  
 465 470 475 480  
 Leu Ala Ala Ala Ile Ala Gly Ala Lys Leu Arg Lys Val Ser Lys Gln  
 485 490 495  
 Glu Glu Ala Ser Gly Gly Pro Thr Ala Pro Lys Ala Glu Ser Gly Arg  
 500 505 510  
 Ser Gly Gly Gly Gly Leu Met Glu Glu Met Asn Ala Met Leu Ala Arg  
 515 520 525  
 Arg Arg Lys Ala Thr Gln Val Gly Glu Lys Thr Pro Lys Asp Glu Ser  
 530 535 540  
 Ala Asn Gln Glu Glu Pro Glu Ala Arg Val Pro Ala Gln Ser Glu Ser  
 545 550 555 560  
 Val Arg Arg Pro Trp Glu Lys Asn Ser Thr Thr Leu Pro Arg Met Lys  
 565 570 575  
 Ser Ser Ser Ser Val Thr Thr Ser Glu Thr Gln Pro Cys Thr Pro Ser  
 580 585 590  
 Ser Ser Asp Tyr Ser Asp Leu Gln Arg Val Lys Gln Glu Leu Leu Glu  
 595 600 605  
 Glu Val Lys Lys Glu Leu Gln Lys Val Lys Glu Glu Ile Ile Glu Ala  
 610 615 620  
 Phe Val Gln Glu Leu Arg Lys Arg Gly Ser Pro  
 625 630 635

&lt;211&gt; 2394

&lt;212&gt; DNA

&lt;213&gt; Aequorea victoria and human

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(2394)

&lt;400&gt; 13

atg gtg agc aag ggc gag gag ctg ttc acc ggg gtg gtg ccc atc ctg	48
Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu	
1 5 10 15	
gtc gag ctg gac ggc gac gta aac ggc cac aag ttc agc gtg tcc ggc	96
Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly	
20 25 30	
gag ggc gag ggc gat gcc acc tac ggc aag ctg acc ctg aag ttc atc	144
Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile	
35 40 45	
tgc acc acc ggc aag ctg ccc gtg ccc tgg ccc acc ctc gtg acc acc	192
Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr	
50 55 60	
ctg acc tac ggc gtg cag tgc ttc agc cgc tac ccc gac cac atg aag	240
Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys	
65 70 75 80	
cag cac gac ttc ttc aag tcc gcc atg ccc gaa ggc tac gtc cag gag	288
Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu	
85 90 95	
cgc acc atc ttc ttc aag gac gac ggc aac tac aag acc cgc gcc gag	336
Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu	
100 105 110	
gtg aag ttc gag ggc gac acc ctg gtg aac cgc atc gag ctg aag ggc	384
Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly	
115 120 125	

atc gac ttc aag gag gac ggc aac atc ctg ggg cac aag ctg gag tac	432
Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr	
130 135 140	
aac tac aac agc cac aac gtc tat atc atg gcc gac aag cag aag aac	480
Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn	
145 150 155 160	
ggc atc aag gtg aac ttc aag atc cgc cac aac atc gag gac ggc agc	528
Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser	
165 170 175	
gtg cag ctc gcc gac cac tac cag cag aac acc ccc atc ggc gac ggc	576
Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly	
180 185 190	
ccc gtg ctg ctg ccc gac aac cac tac ctg agc acc cag tcc gcc ctg	624
Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu	
195 200 205	
agc aaa gac ccc aac gag aag cgc gat cac atg gtc ctg ctg gag ttc	672
Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe	
210 215 220	
gtg acc gcc gcc ggg atc act ctc ggc atg gac gag ctg tac aag tcc	720
Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser	
225 230 235 240	
gga ctc aga tct cga gcc atg gac gaa ctg ttc ccc ctc atc ttc ccg	768
Gly Leu Arg Ser Arg Ala Met Asp Glu Leu Phe Pro Leu Ile Phe Pro	
245 250 255	
gca gag cca gcc cag gcc tct ggc ccc tat gtg gag atc att gag cag	816
Ala Glu Pro Ala Gln Ala Ser Gly Pro Tyr Val Glu Ile Ile Glu Gln	
260 265 270	
ccc aag cag cgg ggc atg cgc ttc cgc tac aag tgc gag ggc cgc tcc	864
Pro Lys Gln Arg Gly Met Arg Phe Arg Tyr Lys Cys Glu Gly Arg Ser	
275 280 285	

gcg ggc agc atc cca ggc gag agg agc aca gat acc acc aag acc cac	912
Ala Gly Ser Ile Pro Gly Glu Arg Ser Thr Asp Thr Thr Lys Thr His	
290 295 300	
ccc acc atc aag atc aat ggc tac aca gga cca ggg aca gtg cgc atc	960
Pro Thr Ile Lys Ile Asn Gly Tyr Thr Gly Pro Gly Thr Val Arg Ile	
305 310 315 320	
tcc ctg gtc acc aag gac cct cct cac cgg cct cac ccc cac gag ctt	1008
Ser Leu Val Thr Lys Asp Pro Pro His Arg Pro His Pro His Glu Leu	
325 330 335	
gta gga aag gac tgc cgg gat ggc ttc tat gag gct gag ctc tgc ccg	1056
Val Gly Lys Asp Cys Arg Asp Gly Phe Tyr Glu Ala Glu Leu Cys Pro	
340 345 350	
gac cgc tgc atc cac agt ttc cag aac ctg gga atc cag tgt gtg aag	1104
Asp Arg Cys Ile His Ser Phe Gln Asn Leu Gly Ile Gln Cys Val Lys	
355 360 365	
aag cgg gac ctg gag cag gct atc agt cag cgc atc cag acc aac aac	1152
Lys Arg Asp Leu Glu Gln Ala Ile Ser Gln Arg Ile Gln Thr Asn Asn	
370 375 380	
aac ccc ttc caa gtt cct ata gaa gag cag cgt ggg gac tac gac ctg	1200
Asn Pro Phe Gln Val Pro Ile Glu Glu Gln Arg Gly Asp Tyr Asp Leu	
385 390 395 400	
aat gct gtg cgg ctc tgc ttc cag gtg aca gtg cgg gac cca tca ggc	1248
Asn Ala Val Arg Leu Cys Phe Gln Val Thr Val Arg Asp Pro Ser Gly	
405 410 415	
agg ccc ctc cgc ctg ccg cct gtc ctt cct cat ccc atc ttt gac aat	1296
Arg Pro Leu Arg Leu Pro Pro Val Leu Pro His Pro Ile Phe Asp Asn	
420 425 430	
cgt gcc ccc aac act gcc gag ctc aag atc tgc cga gtg aac cga aac	1344
Arg Ala Pro Asn Thr Ala Glu Leu Lys Ile Cys Arg Val Asn Arg Asn	
435 440 445	

tct ggc agc tgc ctc ggt ggg gat gag atc ttc cta ctg tgt gac aag	1392
Ser Gly Ser Cys Leu Gly Gly Asp Glu Ile Phe Leu Leu Cys Asp Lys	
450 455 460	
gtg cag aaa gag gac att gag gtg tat ttc acg gga cca ggc tgg gag	1440
Val Gln Lys Glu Asp Ile Glu Val Tyr Phe Thr Gly Pro Gly Trp Glu	
465 470 475 480	
gcc cga ggc tcc ttt tcg caa gct gat gtg cac cga caa gtg gcc att	1488
Ala Arg Gly Ser Phe Ser Gln Ala Asp Val His Arg Gln Val Ala Ile	
485 490 495	
gtg ttc cgg acc cct ccc tac gca gac ccc agc ctg cag gct cct gtg	1536
Val Phe Arg Thr Pro Pro Tyr Ala Asp Pro Ser Leu Gln Ala Pro Val	
500 505 510	
cgt gtc tcc atg cag ctg cgg cgg cct tcc gac cgg gag ctc agt gag	1584
Arg Val Ser Met Gln Leu Arg Arg Pro Ser Asp Arg Glu Leu Ser Glu	
515 520 525	
ccc atg gaa ttc cag tac ctg cca gat aca gac gat cgt cac cgg att	1632
Pro Met Glu Phe Gln Tyr Leu Pro Asp Thr Asp Asp Arg His Arg Ile	
530 535 540	
gag gag aaa cgt aaa agg aca tat gag acc ttc aag agc atc atg aag	1680
Glu Glu Lys Arg Lys Arg Thr Tyr Glu Thr Phe Lys Ser Ile Met Lys	
545 550 555 560	
aag agt cct ttc agc gga ccc acc gac ccc cgg cct cca cct cga cgc	1728
Lys Ser Pro Phe Ser Gly Pro Thr Asp Pro Arg Pro Pro Pro Arg Arg	
565 570 575	
att gct gtg cct tcc cgc agc tca gct tct gtc ccc aag cca gca ccc	1776
Ile Ala Val Pro Ser Arg Ser Ser Ala Ser Val Pro Lys Pro Ala Pro	
580 585 590	
cag ccc tat ccc ttt acg tca tcc ctg agc acc atc aac tat gat gag	1824
Gln Pro Tyr Pro Phe Thr Ser Ser Leu Ser Thr Ile Asn Tyr Asp Glu	
595 600 605	

ttt ccc acc atg gtg ttt cct tct ggg cag atc agc cag gcc tcg gcc	1872
Phe Pro Thr Met Val Phe Pro Ser Gly Gln Ile Ser Gln Ala Ser Ala	
610 615 620	
ttg gcc ccg gcc cct ccc caa gtc ctg ccc cag gct cca gcc cct gcc	1920
Leu Ala Pro Ala Pro Pro Gln Val Leu Pro Gln Ala Pro Ala Pro Ala	
625 630 635 640	
cct gct cca gcc atg gta tca gct ctg gcc cag gcc cca gcc cct gtc	1968
Pro Ala Pro Ala Met Val Ser Ala Leu Ala Gln Ala Pro Ala Pro Val	
645 650 655	
cca gtc cta gcc cca ggc cct cct cag gct gtg gcc cca cct gcc ccc	2016
Pro Val Leu Ala Pro Gly Pro Pro Gln Ala Val Ala Pro Pro Ala Pro	
660 665 670	
aag ccc acc cag gct ggg gaa gga acg ctg tca gag gcc ctg ctg cag	2064
Lys Pro Thr Gln Ala Gly Glu Gly Thr Leu Ser Glu Ala Leu Leu Gln	
675 680 685	
ctg cag ttt gat gat gaa gac ctg ggg gcc ttg ctt ggc aac agc aca	2112
Leu Gln Phe Asp Asp Glu Asp Leu Gly Ala Leu Leu Gly Asn Ser Thr	
690 695 700	
gac cca gct gtg ttc aca gac ctg gca tcc gtc gac aac tcc gag ttt	2160
Asp Pro Ala Val Phe Thr Asp Leu Ala Ser Val Asp Asn Ser Glu Phe	
705 710 715 720	
cag cag ctg ctg aac cag ggc ata cct gtg gcc ccc cac aca act gag	2208
Gln Gln Leu Leu Asn Gln Gly Ile Pro Val Ala Pro His Thr Thr Glu	
725 730 735	
ccc atg ctg atg gag tac cct gag gct ata act cgc cta gtg aca ggg	2256
Pro Met Leu Met Glu Tyr Pro Glu Ala Ile Thr Arg Leu Val Thr Gly	
740 745 750	
gcc cag agg ccc ccc gac cca gct cct gct cca ctg ggg gcc ccg ggg	2304
Ala Gln Arg Pro Pro Asp Pro Ala Pro Ala Pro Leu Gly Ala Pro Gly	
755 760 765	

ctc ccc aat ggc ctc ctt tca gga gat gaa gac ttc tcc tcc att gcg 2352  
 Leu Pro Asn Gly Leu Leu Ser Gly Asp Glu Asp Phe Ser Ser Ile Ala  
 770 775 780

gac atg gac ttc tca gcc ctg ctg agt cag atc agc tcc taa 2394  
 Asp Met Asp Phe Ser Ala Leu Leu Ser Gln Ile Ser Ser \*  
 785 790 795

<210> 14

<211> 797

<212> PRT

<213> Aequorea victoria and human

<400> 14

Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu  
 1 5 10 15  
 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly  
 20 25 30  
 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile  
 35 40 45  
 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr  
 50 55 60  
 Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys  
 65 70 75 80  
 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu  
 85 90 95  
 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu  
 100 105 110  
 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly  
 115 120 125  
 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr  
 130 135 140  
 Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn  
 145 150 155 160  
 Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser  
 165 170 175  
 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly  
 180 185 190

Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu  
 195 200 205  
 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe  
 210 215 220  
 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser  
 225 230 235 240  
 Gly Leu Arg Ser Arg Ala Met Asp Glu Leu Phe Pro Leu Ile Phe Pro  
 245 250 255  
 Ala Glu Pro Ala Gln Ala Ser Gly Pro Tyr Val Glu Ile Ile Glu Gln  
 260 265 270  
 Pro Lys Gln Arg Gly Met Arg Phe Arg Tyr Lys Cys Glu Gly Arg Ser  
 275 280 285  
 Ala Gly Ser Ile Pro Gly Glu Arg Ser Thr Asp Thr Thr Lys Thr His  
 290 295 300  
 Pro Thr Ile Lys Ile Asn Gly Tyr Thr Gly Pro Gly Thr Val Arg Ile  
 305 310 315 320  
 Ser Leu Val Thr Lys Asp Pro Pro His Arg Pro His Pro His Glu Leu  
 325 330 335  
 Val Gly Lys Asp Cys Arg Asp Gly Phe Tyr Glu Ala Glu Leu Cys Pro  
 340 345 350  
 Asp Arg Cys Ile His Ser Phe Gln Asn Leu Gly Ile Gln Cys Val Lys  
 355 360 365  
 Lys Arg Asp Leu Glu Gln Ala Ile Ser Gln Arg Ile Gln Thr Asn Asn  
 370 375 380  
 Asn Pro Phe Gln Val Pro Ile Glu Glu Gln Arg Gly Asp Tyr Asp Leu  
 385 390 395 400  
 Asn Ala Val Arg Leu Cys Phe Gln Val Thr Val Arg Asp Pro Ser Gly  
 405 410 415  
 Arg Pro Leu Arg Leu Pro Pro Val Leu Pro His Pro Ile Phe Asp Asn  
 420 425 430  
 Arg Ala Pro Asn Thr Ala Glu Leu Lys Ile Cys Arg Val Asn Arg Asn  
 435 440 445  
 Ser Gly Ser Cys Leu Gly Gly Asp Glu Ile Phe Leu Leu Cys Asp Lys  
 450 455 460  
 Val Gln Lys Glu Asp Ile Glu Val Tyr Phe Thr Gly Pro Gly Trp Glu  
 465 470 475 480  
 Ala Arg Gly Ser Phe Ser Gln Ala Asp Val His Arg Gln Val Ala Ile  
 485 490 495  
 Val Phe Arg Thr Pro Pro Tyr Ala Asp Pro Ser Leu Gln Ala Pro Val  
 500 505 510

Arg Val Ser Met Gln Leu Arg Arg Pro Ser Asp Arg Glu Leu Ser Glu  
 515 520 525  
 Pro Met Glu Phe Gln Tyr Leu Pro Asp Thr Asp Asp Arg His Arg Ile  
 530 535 540  
 Glu Glu Lys Arg Lys Arg Thr Tyr Glu Thr Phe Lys Ser Ile Met Lys  
 545 550 555 560  
 Lys Ser Pro Phe Ser Gly Pro Thr Asp Pro Arg Pro Pro Pro Arg Arg  
 565 570 575  
 Ile Ala Val Pro Ser Arg Ser Ser Ala Ser Val Pro Lys Pro Ala Pro  
 580 585 590  
 Gln Pro Tyr Pro Phe Thr Ser Ser Leu Ser Thr Ile Asn Tyr Asp Glu  
 595 600 605  
 Phe Pro Thr Met Val Phe Pro Ser Gly Gln Ile Ser Gln Ala Ser Ala  
 610 615 620  
 Leu Ala Pro Ala Pro Pro Gln Val Leu Pro Gln Ala Pro Ala Pro Ala  
 625 630 635 640  
 Pro Ala Pro Ala Met Val Ser Ala Leu Ala Gln Ala Pro Ala Pro Val  
 645 650 655  
 Pro Val Leu Ala Pro Gly Pro Pro Gln Ala Val Ala Pro Pro Ala Pro  
 660 665 670  
 Lys Pro Thr Gln Ala Gly Glu Gly Thr Leu Ser Glu Ala Leu Leu Gln  
 675 680 685  
 Leu Gln Phe Asp Asp Glu Asp Leu Gly Ala Leu Leu Gly Asn Ser Thr  
 690 695 700  
 Asp Pro Ala Val Phe Thr Asp Leu Ala Ser Val Asp Asn Ser Glu Phe  
 705 710 715 720  
 Gln Gln Leu Leu Asn Gln Gly Ile Pro Val Ala Pro His Thr Thr Glu  
 725 730 735  
 Pro Met Leu Met Glu Tyr Pro Glu Ala Ile Thr Arg Leu Val Thr Gly  
 740 745 750  
 Ala Gln Arg Pro Pro Asp Pro Ala Pro Ala Pro Leu Gly Ala Pro Gly  
 755 760 765  
 Leu Pro Asn Gly Leu Leu Ser Gly Asp Glu Asp Phe Ser Ser Ile Ala  
 770 775 780  
 Asp Met Asp Phe Ser Ala Leu Leu Ser Gln Ile Ser Ser  
 785 790 795

&lt;210&gt; 15

&lt;211&gt; 2394

&lt;212&gt; DNA

&lt;213&gt; Aequorea victoria and human

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(2394)

&lt;400&gt; 15

atg gac gaa ctg ttc ccc ctc atc ttc ccg gca gag cca gcc cag gcc	48
Met Asp Glu Leu Phe Pro Leu Ile Phe Pro Ala Glu Pro Ala Gln Ala	
1                      5                      10                      15	
tct ggc ccc tat gtg gag atc att gag cag ccc aag cag cgg ggc atg	96
Ser Gly Pro Tyr Val Glu Ile Ile Glu Gln Pro Lys Gln Arg Gly Met	
20                      25                      30	
cgc ttc cgc tac aag tgc gag ggg cgc tcc gcg ggc agc atc cca ggc	144
Arg Phe Arg Tyr Lys Cys Glu Gly Arg Ser Ala Gly Ser Ile Pro Gly	
35                      40                      45	
gag agg agc aca gat acc acc aag acc cac ccc acc atc aag atc aat	192
Glu Arg Ser Thr Asp Thr Thr Lys Thr His Pro Thr Ile Lys Ile Asn	
50                      55                      60	
ggc tac aca gga cca ggg aca gtg cgc atc tcc ctg gtc acc aag gac	240
Gly Tyr Thr Gly Pro Gly Thr Val Arg Ile Ser Leu Val Thr Lys Asp	
65                      70                      75                      80	
cct cct cac cgg cct cac ccc cac gag ctt gta gga aag gac tgc cgg	288
Pro Pro His Arg Pro His Pro His Glu Leu Val Gly Lys Asp Cys Arg	
85                      90                      95	
gat ggc ttc tat gag gct gag ctc tgc ccg gac cgc tgc atc cac agt	336
Asp Gly Phe Tyr Glu Ala Glu Leu Cys Pro Asp Arg Cys Ile His Ser	
100                      105                      110	
ttc cag aac ctg gga atc cag tgt gtg aag aag cgg gac ctg gag cag	384
Phe Gln Asn Leu Gly Ile Gln Cys Val Lys Lys Arg Asp Leu Glu Gln	
115                      120                      125	
gct atc agt cag cgc atc cag acc aac aac aac ccc ttc caa gtt cct	432

Ala Ile Ser Gln Arg Ile Gln Thr Asn Asn Asn Pro Phe Gln Val Pro	
130 135 140	
ata gaa gag cag cgt ggg gac tac gac ctg aat gct gtg cgg ctc tgc	480
Ile Glu Glu Gln Arg Gly Asp Tyr Asp Leu Asn Ala Val Arg Leu Cys	
145 150 155 160	
ttc cag gtg aca gtg cgg gac cca tca ggc agg ccc ctc cgc ctg ccg	528
Phe Gln Val Thr Val Arg Asp Pro Ser Gly Arg Pro Leu Arg Leu Pro	
165 170 175	
cct gtc ctt cct cat ccc atc ttt gac aat cgt gcc ccc aac act gcc	576
Pro Val Leu Pro His Pro Ile Phe Asp Asn Arg Ala Pro Asn Thr Ala	
180 185 190	
gag ctc aag atc tgc cga gtg aac cga aac tct ggc agc tgc ctc ggt	624
Glu Leu Lys Ile Cys Arg Val Asn Arg Asn Ser Gly Ser Cys Leu Gly	
195 200 205	
ggg gat gag atc ttc cta ctg tgt gac aag gtg cag aaa gag gac att	672
Gly Asp Glu Ile Phe Leu Leu Cys Asp Lys Val Gln Lys Glu Asp Ile	
210 215 220	
gag gtg tat ttc acg gga cca ggc tgg gag gcc cga ggc tcc ttt tcg	720
Glu Val Tyr Phe Thr Gly Pro Gly Trp Glu Ala Arg Gly Ser Phe Ser	
225 230 235 240	
caa gct gat gtg cac cga caa gtg gcc att gtg ttc cgg acc cct ccc	768
Gln Ala Asp Val His Arg Gln Val Ala Ile Val Phe Arg Thr Pro Pro	
245 250 255	
tac gca gac ccc agc ctg cag gct cct gtg cgt gtc tcc atg cag ctg	816
Tyr Ala Asp Pro Ser Leu Gln Ala Pro Val Arg Val Ser Met Gln Leu	
260 265 270	
cgg cgg cct tcc gac cgg gag ctc agt gag ccc atg gaa ttc cag tac	864
Arg Arg Pro Ser Asp Arg Glu Leu Ser Glu Pro Met Glu Phe Gln Tyr	
275 280 285	
ctg cca gat aca gac gat cgt cac cgg att gag gag aaa cgt aaa agg	912

Leu Pro Asp Thr Asp Asp Arg His Arg Ile Glu Glu Lys Arg Lys Arg	
290 295 300	
aca tat gag acc ttc aag agc atc atg aag aag agt cct ttc agc gga	960
Thr Tyr Glu Thr Phe Lys Ser Ile Met Lys Lys Ser Pro Phe Ser Gly	
305 310 315 320	
ccc acc gac ccc cgg cct cca cct cga cgc att gct gtg cct tcc cgc	1008
Pro Thr Asp Pro Arg Pro Pro Pro Arg Arg Ile Ala Val Pro Ser Arg	
325 330 335	
agc tca gct tct gtc ccc aag cca gca ccc cag ccc tat ccc ttt acg	1056
Ser Ser Ala Ser Val Pro Lys Pro Ala Pro Gln Pro Tyr Pro Phe Thr	
340 345 350	
tca tcc ctg agc acc atc aac tat gat gag ttt ccc acc atg gtg ttt	1104
Ser Ser Leu Ser Thr Ile Asn Tyr Asp Glu Phe Pro Thr Met Val Phe	
355 360 365	
cct tct ggg cag atc agc cag gcc tcg gcc ttg gcc ccg gcc cct ccc	1152
Pro Ser Gly Gln Ile Ser Gln Ala Ser Ala Leu Ala Pro Ala Pro Pro	
370 375 380	
caa gtc ctg ccc cag gct cca gcc cct gcc cct gct cca gcc atg gta	1200
Gln Val Leu Pro Gln Ala Pro Ala Pro Ala Pro Ala Pro Ala Met Val	
385 390 395 400	
tca gct ctg gcc cag gcc cca gcc cct gtc cca gtc cta gcc cca ggc	1248
Ser Ala Leu Ala Gln Ala Pro Ala Pro Val Pro Val Leu Ala Pro Gly	
405 410 415	
cct cct cag gct gtg gcc cca cct gcc ccc aag ccc acc cag gct ggg	1296
Pro Pro Gln Ala Val Ala Pro Pro Ala Pro Lys Pro Thr Gln Ala Gly	
420 425 430	
gaa gga acg ctg tca gag gcc ctg ctg cag ctg cag ttt gat gat gaa	1344
Glu Gly Thr Leu Ser Glu Ala Leu Leu Gln Leu Gln Phe Asp Asp Glu	
435 440 445	
gac ctg ggg gcc ttg ctt ggc aac agc aca gac cca gct gtg ttc aca	1392

Asp Leu Gly Ala Leu Leu Gly Asn Ser Thr Asp Pro Ala Val Phe Thr	
450 455 460	
gac ctg gca tcc gtc gac aac tcc gag ttt cag cag ctg ctg aac cag	1440
Asp Leu Ala Ser Val Asp Asn Ser Glu Phe Gln Gln Leu Leu Asn Gln	
465 470 475 480	
ggc ata cct gtg gcc ccc cac aca act gag ccc atg ctg atg gag tac	1488
Gly Ile Pro Val Ala Pro His Thr Thr Glu Pro Met Leu Met Glu Tyr	
485 490 495	
cct gag gct ata act cgc cta gtg aca ggg gcc cag agg ccc ccc gac	1536
Pro Glu Ala Ile Thr Arg Leu Val Thr Gly Ala Gln Arg Pro Pro Asp	
500 505 510	
cca gct cct gct cca ctg ggg gcc ccg ggg ctc ccc aat ggc ctc ctt	1584
Pro Ala Pro Ala Pro Leu Gly Ala Pro Gly Leu Pro Asn Gly Leu Leu	
515 520 525	
tca gga gat gaa gac ttc tcc tcc att gcg gac atg gac ttc tca gcc	1632
Ser Gly Asp Glu Asp Phe Ser Ser Ile Ala Asp Met Asp Phe Ser Ala	
530 535 540	
ctg ctg agt cag atc agc tcc ttg gat cca ccg gtc gcc acc atg gtg	1680
Leu Leu Ser Gln Ile Ser Ser Leu Asp Pro Pro Val Ala Thr Met Val	
545 550 555 560	
agc aag ggc gag gag ctg ttc acc ggg gtg gtg ccc atc ctg gtc gag	1728
Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu	
565 570 575	
ctg gac ggc gac gta aac ggc cac aag ttc agc gtg tcc ggc gag ggc	1776
Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu Gly	
580 585 590	
gag ggc gat gcc acc tac ggc aag ctg acc ctg aag ttc atc tgc acc	1824
Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr	
595 600 605	
acc ggc aag ctg ccc gtg ccc tgg ccc acc ctc gtg acc acc ctg acc	1872

Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu Thr	
610 615 620	
tac ggc gtg cag tgc ttc agc cgc tac ccc gac cac atg aag cag cac	1920
Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln His	
625 630 635 640	
gac ttc ttc aag tcc gcc atg ccc gaa ggc tac gtc cag gag cgc acc	1968
Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr	
645 650 655	
atc ttc ttc aag gac gac ggc aac tac aag acc cgc gcc gag gtg aag	2016
Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val Lys	
660 665 670	
ttc gag ggc gac acc ctg gtg aac cgc atc gag ctg aag ggc atc gac	2064
Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile Asp	
675 680 685	
ttc aag gag gac ggc aac atc ctg ggg cac aag ctg gag tac aac tac	2112
Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn Tyr	
690 695 700	
aac agc cac aac gtc tat atc atg gcc gac aag cag aag aac ggc atc	2160
Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile	
705 710 715 720	
aag gtg aac ttc aag atc cgc cac aac atc gag gac ggc agc gtg cag	2208
Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val Gln	
725 730 735	
ctc gcc gac cac tac cag cag aac acc ccc atc ggc gac ggc ccc gtg	2256
Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val	
740 745 750	
ctg ctg ccc gac aac cac tac ctg agc acc cag tcc gcc ctg agc aaa	2304
Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys	
755 760 765	
gac ccc aac gag aag cgc gat cac atg gtc ctg ctg gag ttc gtg acc	2352

Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val Thr  
 770 775 780

gcc gcc ggg atc act ctc ggc atg gac gag ctg tac aag taa 2394  
 Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys \*  
 785 790 795

<210> 16

<211> 797

<212> PRT

<213> Aequorea victoria and human

<400> 16

Met Asp Glu Leu Phe Pro Leu Ile Phe Pro Ala Glu Pro Ala Gln Ala  
 1 5 10 15  
 Ser Gly Pro Tyr Val Glu Ile Ile Glu Gln Pro Lys Gln Arg Gly Met  
 20 25 30  
 Arg Phe Arg Tyr Lys Cys Glu Gly Arg Ser Ala Gly Ser Ile Pro Gly  
 35 40 45  
 Glu Arg Ser Thr Asp Thr Thr Lys Thr His Pro Thr Ile Lys Ile Asn  
 50 55 60  
 Gly Tyr Thr Gly Pro Gly Thr Val Arg Ile Ser Leu Val Thr Lys Asp  
 65 70 75 80  
 Pro Pro His Arg Pro His Pro His Glu Leu Val Gly Lys Asp Cys Arg  
 85 90 95  
 Asp Gly Phe Tyr Glu Ala Glu Leu Cys Pro Asp Arg Cys Ile His Ser  
 100 105 110  
 Phe Gln Asn Leu Gly Ile Gln Cys Val Lys Lys Arg Asp Leu Glu Gln  
 115 120 125  
 Ala Ile Ser Gln Arg Ile Gln Thr Asn Asn Asn Pro Phe Gln Val Pro  
 130 135 140  
 Ile Glu Glu Gln Arg Gly Asp Tyr Asp Leu Asn Ala Val Arg Leu Cys  
 145 150 155 160  
 Phe Gln Val Thr Val Arg Asp Pro Ser Gly Arg Pro Leu Arg Leu Pro  
 165 170 175  
 Pro Val Leu Pro His Pro Ile Phe Asp Asn Arg Ala Pro Asn Thr Ala  
 180 185 190  
 Glu Leu Lys Ile Cys Arg Val Asn Arg Asn Ser Gly Ser Cys Leu Gly  
 195 200 205

Gly Asp Glu Ile Phe Leu Leu Cys Asp Lys Val Gln Lys Glu Asp Ile  
 210 215 220  
 Glu Val Tyr Phe Thr Gly Pro Gly Trp Glu Ala Arg Gly Ser Phe Ser  
 225 230 235 240  
 Gln Ala Asp Val His Arg Gln Val Ala Ile Val Phe Arg Thr Pro Pro  
 245 250 255  
 Tyr Ala Asp Pro Ser Leu Gln Ala Pro Val Arg Val Ser Met Gln Leu  
 260 265 270  
 Arg Arg Pro Ser Asp Arg Glu Leu Ser Glu Pro Met Glu Phe Gln Tyr  
 275 280 285  
 Leu Pro Asp Thr Asp Asp Arg His Arg Ile Glu Glu Lys Arg Lys Arg  
 290 295 300  
 Thr Tyr Glu Thr Phe Lys Ser Ile Met Lys Lys Ser Pro Phe Ser Gly  
 305 310 315 320  
 Pro Thr Asp Pro Arg Pro Pro Pro Arg Arg Ile Ala Val Pro Ser Arg  
 325 330 335  
 Ser Ser Ala Ser Val Pro Lys Pro Ala Pro Gln Pro Tyr Pro Phe Thr  
 340 345 350  
 Ser Ser Leu Ser Thr Ile Asn Tyr Asp Glu Phe Pro Thr Met Val Phe  
 355 360 365  
 Pro Ser Gly Gln Ile Ser Gln Ala Ser Ala Leu Ala Pro Ala Pro Pro  
 370 375 380  
 Gln Val Leu Pro Gln Ala Pro Ala Pro Ala Pro Ala Pro Ala Met Val  
 385 390 395 400  
 Ser Ala Leu Ala Gln Ala Pro Ala Pro Val Pro Val Leu Ala Pro Gly  
 405 410 415  
 Pro Pro Gln Ala Val Ala Pro Pro Ala Pro Lys Pro Thr Gln Ala Gly  
 420 425 430  
 Glu Gly Thr Leu Ser Glu Ala Leu Leu Gln Leu Gln Phe Asp Asp Glu  
 435 440 445  
 Asp Leu Gly Ala Leu Leu Gly Asn Ser Thr Asp Pro Ala Val Phe Thr  
 450 455 460  
 Asp Leu Ala Ser Val Asp Asn Ser Glu Phe Gln Gln Leu Leu Asn Gln  
 465 470 475 480  
 Gly Ile Pro Val Ala Pro His Thr Thr Glu Pro Met Leu Met Glu Tyr  
 485 490 495  
 Pro Glu Ala Ile Thr Arg Leu Val Thr Gly Ala Gln Arg Pro Pro Asp  
 500 505 510  
 Pro Ala Pro Ala Pro Leu Gly Ala Pro Gly Leu Pro Asn Gly Leu Leu  
 515 520 525

Ser Gly Asp Glu Asp Phe Ser Ser Ile Ala Asp Met Asp Phe Ser Ala  
 530 535 540  
 Leu Leu Ser Gln Ile Ser Ser Leu Asp Pro Pro Val Ala Thr Met Val  
 545 550 555 560  
 Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu  
 565 570 575  
 Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu Gly  
 580 585 590  
 Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr  
 595 600 605  
 Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu Thr  
 610 615 620  
 Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln His  
 625 630 635 640  
 Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr  
 645 650 655  
 Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val Lys  
 660 665 670  
 Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile Asp  
 675 680 685  
 Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn Tyr  
 690 695 700  
 Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile  
 705 710 715 720  
 Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val Gln  
 725 730 735  
 Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val  
 740 745 750  
 Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys  
 755 760 765  
 Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val Thr  
 770 775 780  
 Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys  
 785 790 795

&lt;210&gt; 17

&lt;211&gt; 2757

&lt;212&gt; DNA

<213> *Aequorea victoria* and human

<222> (1) . . . (2757)

atg gtg agc aag ggc gag gag ctg ttc acc ggg gtg gtg ccc atc ctg 48  
Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu  
1 5 10 15

gtc gag ctg gac ggc gac gta aac ggc cac aag ttc agc gtg tcc ggc 96  
Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly  
20 25 30

gag ggc gag ggc gat gcc acc tac ggc aag ctg acc ctg aag ttc atc 144  
Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile  
35 40 45

tgc acc acc ggc aag ctg ccc gtg ccc tgg ccc acc ctc gtg acc acc 192  
Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr  
50 55 60

ctg acc tac ggc gtg cag tgc ttc agc cgc tac ccc gac cac atg aag 240  
Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys  
65 70 75 80

cag cac gac ttc ttc aag tcc gcc atg ccc gaa ggc tac gtc cag gag 288  
Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu  
85 90 95

cgc acc atc ttc ttc aag gac gac ggc aac tac aag acc cgc gcc gag 336  
 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu  
 100 105 110

gtg aag ttc gag ggc gac acc ctg gtg aac cgc atc gag ctg aag ggc 384  
Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly  
115 120 125

atc gac ttc aag gag gac ggc aac atc ctg ggg cac aag ctg gag tac 432  
Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr  
130 135 140

aac tac aac agc cac aac gtc tat atc atg gcc gac aag cag aag aac 480  
Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn  
145 150 155 160

ggc atc aag gtg aac ttc aag atc cgc cac aac atc gag gac ggc agc 528  
Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser  
165 170 175

gtg cag ctc gcc gac cac tac cag cag aac acc ccc atc ggc gac ggc 576  
Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly  
180 185 190

ccc gtg ctg ctg ccc gac aac cac tac ctg agc acc cag tcc gcc ctg 624  
Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu  
195 200 205

agc aaa gac ccc aac gag aag cgc gat cac atg gtc ctg ctg gag ttc 672  
Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe  
210 215 220

gtg acc gcc gcc ggg atc act ctc ggc atg gac gag ctg tac aag tcc 720  
Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser  
225 230 235 240

gga ctc aga tct cga ggc aag atg gct gac ccg gct gcg ggg ccg ccg 768  
Gly Leu Arg Ser Arg Gly Lys Met Ala Asp Pro Ala Ala Gly Pro Pro  
245 250 255

ccg agc gag ggc gag gag agc acc gtg cgc ttc gcc cgc aaa ggc gcc 816  
Pro Ser Glu Gly Glu Glu Ser Thr Val Arg Phe Ala Arg Lys Gly Ala  
260 265 270

ctc cgg cag aag aac gtg cat gag gtc aag aac cac aaa ttc acc gcc 864  
Leu Arg Gln Lys Asn Val His Glu Val Lys Asn His Lys Phe Thr Ala  
275 280 285

cgc ttc ttc aag cag ccc acc ttc tgc agc cac tgc acc gac ttc atc 912  
 Arg Phe Phe Lys Gln Pro Thr Phe Cys Ser His Cys Thr Asp Phe Ile  
 290 295 300



tcc	ctc	aac	cct	gag	tgg	aat	gag	aca	ttt	aga	ttt	cag	ctg	aaa	gaa	1440
Ser	Leu	Asn	Pro	Glu	Trp	Asn	Glu	Thr	Phe	Arg	Phe	Gln	Leu	Lys	Glu	
465					470				475					480		
tcg	gac	aaa	gac	aga	aga	ctg	tca	gta	gag	att	tgg	gat	tgg	gat	ttg	1488
Ser	Asp	Lys	Asp	Arg	Arg	Leu	Ser	Val	Glu	Ile	Trp	Asp	Trp	Asp	Leu	
				485					490					495		
acc	agc	agg	aat	gac	ttc	atg	gga	tct	ttg	tcc	ttt	ggg	att	tct	gaa	1536
Thr	Ser	Arg	Asn	Asp	Phe	Met	Gly	Ser	Leu	Ser	Phe	Gly	Ile	Ser	Glu	
			500					505					510			
ctt	cag	aag	gcc	agt	gtt	gat	ggc	tgg	ttt	aag	tta	ctg	agc	cag	gag	1584
Leu	Gln	Lys	Ala	Ser	Val	Asp	Gly	Trp	Phe	Lys	Leu	Leu	Ser	Gln	Glu	
		515					520					525				
gaa	ggc	gag	tac	ttc	aat	gtg	cct	gtg	cca	cca	gaa	gga	agt	gag	gcc	1632
Glu	Gly	Glu	Tyr	Phe	Asn	Val	Pro	Val	Pro	Pro	Glu	Gly	Ser	Glu	Ala	
	530					535					540					
aat	gaa	gaa	ctg	cgg	cag	aaa	ttt	gag	agg	gcc	aag	atc	agt	cag	gga	1680
Asn	Glu	Glu	Leu	Arg	Gln	Lys	Phe	Glu	Arg	Ala	Lys	Ile	Ser	Gln	Gly	
545					550				555					560		
acc	aag	gtc	ccg	gaa	gaa	aag	acg	acc	aac	act	gtc	tcc	aaa	ttt	gac	1728
Thr	Lys	Val	Pro	Glu	Glu	Lys	Thr	Thr	Asn	Thr	Val	Ser	Lys	Phe	Asp	
				565					570					575		
aac	aat	ggc	aac	aga	gac	cgg	atg	aaa	ctg	acc	gat	ttt	aac	ttc	cta	1776
Asn	Asn	Gly	Asn	Arg	Asp	Arg	Met	Lys	Leu	Thr	Asp	Phe	Asn	Phe	Leu	
			580						585				590			
atg	gtg	ctg	ggg	aaa	ggc	agc	ttt	ggc	aag	gtc	atg	ctt	tca	gaa	cga	1824
Met	Val	Leu	Gly	Lys	Gly	Ser	Phe	Gly	Lys	Val	Met	Leu	Ser	Glu	Arg	
		595					600					605				
aaa	ggc	aca	gat	gag	ctc	tat	gct	gtg	aag	atc	ctg	aag	aag	gac	gtt	1872
Lys	Gly	Thr	Asp	Glu	Leu	Tyr	Ala	Val	Lys	Ile	Leu	Lys	Lys	Asp	Val	
	610					615				620						

gtg	atc	caa	gat	gat	gac	gtg	gag	tgc	act	atg	gtg	gag	aag	cgg	gtg	1920
Val	Ile	Gln	Asp	Asp	Asp	Val	Glu	Cys	Thr	Met	Val	Glu	Lys	Arg	Val	
625					630				635						640	
ttg	gcc	ctg	cct	ggg	aag	ccg	ccc	ttc	ctg	acc	cag	ctc	cac	tcc	tgc	1968
Leu	Ala	Leu	Pro	Gly	Lys	Pro	Pro	Phe	Leu	Thr	Gln	Leu	His	Ser	Cys	
				645					650					655		
ttc	cag	acc	atg	gac	cgc	ctg	tac	ttt	gtg	atg	gag	tac	gtg	aat	ggg	2016
Phe	Gln	Thr	Met	Asp	Arg	Leu	Tyr	Phe	Val	Met	Glu	Tyr	Val	Asn	Gly	
			660					665					670			
ggc	gac	ctc	atg	tat	cac	atc	cag	caa	gtc	ggc	cgg	ttc	aag	gag	ccc	2064
Gly	Asp	Leu	Met	Tyr	His	Ile	Gln	Gln	Val	Gly	Arg	Phe	Lys	Glu	Pro	
		675					680					685				
cat	gct	gta	ttt	tac	gct	gca	gaa	att	gcc	atc	ggc	ctg	ttc	ttc	tta	2112
His	Ala	Val	Phe	Tyr	Ala	Ala	Glu	Ile	Ala	Ile	Gly	Leu	Phe	Phe	Leu	
	690					695					700					
cag	agt	aag	ggc	atc	att	tac	cgt	gac	cta	aaa	ctt	gac	aac	gtg	atg	2160
Gln	Ser	Lys	Gly	Ile	Ile	Tyr	Arg	Asp	Leu	Lys	Leu	Asp	Asn	Val	Met	
705				710					715						720	
ctc	gat	tct	gag	gga	cac	atc	aag	att	gcc	gat	ttt	ggc	atg	tgt	aag	2208
Leu	Asp	Ser	Glu	Gly	His	Ile	Lys	Ile	Ala	Asp	Phe	Gly	Met	Cys	Lys	
			725						730				735			
gaa	aac	atc	tgg	gat	ggg	gtg	aca	acc	aag	aca	ttc	tgt	ggc	act	cca	2256
Glu	Asn	Ile	Trp	Asp	Gly	Val	Thr	Thr	Lys	Thr	Phe	Cys	Gly	Thr	Pro	
			740					745				750				
gac	tac	atc	gcc	ccc	gag	ata	att	gct	tat	cag	ccc	tat	ggg	aag	tcc	2304
Asp	Tyr	Ile	Ala	Pro	Glu	Ile	Ile	Ala	Tyr	Gln	Pro	Tyr	Gly	Lys	Ser	
	755						760					765				
gtg	gat	tgg	tgg	gca	ttt	gga	gtc	ctg	ctg	tat	gaa	atg	ttg	gct	ggg	2352
Val	Asp	Trp	Trp	Ala	Phe	Gly	Val	Leu	Leu	Tyr	Glu	Met	Leu	Ala	Gly	
	770					775				780						

cag gca ccc ttt gaa ggg gag gat gaa gat gaa ctc ttc caa tcc atc 2400  
Gln Ala Pro Phe Glu Gly Glu Asp Glu Asp Glu Leu Phe Gln Ser Ile  
785 790 795 800

atg gaa cac aac gta gcc tat ccc aag tct atg tcc aag gaa gct gtg 2448  
Met Glu His Asn Val Ala Tyr Pro Lys Ser Met Ser Lys Glu Ala Val  
805 810 815

gcc atc tgc aaa ggg ctg atg acc aaa cac cca ggc aaa cgt ctg ggt 2496  
Ala Ile Cys Lys Gly Leu Met Thr Lys His Pro Gly Lys Arg Leu Gly  
820 825 830

tgt gga cct gaa ggc gaa cgt gat atc aaa gag cat gca ttt ttc cgg 2544  
Cys Gly Pro Glu Gly Glu Arg Asp Ile Lys Glu His Ala Phe Phe Arg  
835 840 845

tat att gat tgg gag aaa ctt gaa cgc aaa gag atc cag ccc cct tat 2592  
Tyr Ile Asp Trp Glu Lys Leu Glu Arg Lys Glu Ile Gln Pro Pro Tyr  
850 855 860

aag cca aaa gct aga gac aag aga gac acc tcc aac ttc gac aaa gag 2640  
Lys Pro Lys Ala Arg Asp Lys Arg Asp Thr Ser Asn Phe Asp Lys Glu  
865 870 875 880

ttc acc aga cag cct gtg gaa ctg acc ccc act gat aaa ctc ttc atc 2688  
Phe Thr Arg Gln Pro Val Glu Leu Thr Pro Thr Asp Lys Leu Phe Ile  
885 890 895

atg aac ttg gac caa aat gaa ttt gct ggc ttc tct tat act aac cca 2736  
Met Asn Leu Asp Gln Asn Glu Phe Ala Gly Phe Ser Tyr Thr Asn Pro  
900 905 910

gag ttt gtc att aat gtg tag 2757  
Glu Phe Val Ile Asn Val \*  
915

<210> 18

<211> 918

&lt;212&gt; PRT

&lt;213&gt; Aequorea victoria and human

&lt;400&gt; 18

```

Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu
  1           5           10           15
Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly
      20           25           30
Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile
      35           40           45
Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr
      50           55           60
Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys
  65           70           75           80
Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu
      85           90           95
Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu
      100          105          110
Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly
      115          120          125
Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr
      130          135          140
Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn
  145          150          155          160
Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser
      165          170          175
Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly
      180          185          190
Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu
      195          200          205
Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe
      210          215          220
Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser
  225          230          235          240
Gly Leu Arg Ser Arg Gly Lys Met Ala Asp Pro Ala Ala Gly Pro Pro
      245          250          255
Pro Ser Glu Gly Glu Glu Ser Thr Val Arg Phe Ala Arg Lys Gly Ala
      260          265          270
Leu Arg Gln Lys Asn Val His Glu Val Lys Asn His Lys Phe Thr Ala
      275          280          285

```

Arg	Phe	Phe	Lys	Gln	Pro	Thr	Phe	Cys	Ser	His	Cys	Thr	Asp	Phe	Ile
290						295					300				
Trp	Gly	Phe	Gly	Lys	Gln	Gly	Phe	Gln	Cys	Gln	Val	Cys	Cys	Phe	Val
305					310					315					320
Val	His	Lys	Arg	Cys	His	Glu	Phe	Val	Thr	Phe	Ser	Cys	Pro	Gly	Ala
				325					330					335	
Asp	Lys	Gly	Pro	Ala	Ser	Asp	Asp	Pro	Arg	Ser	Lys	His	Lys	Phe	Lys
			340					345					350		
Ile	His	Thr	Tyr	Ser	Ser	Pro	Thr	Phe	Cys	Asp	His	Cys	Gly	Ser	Leu
		355					360						365		
Leu	Tyr	Gly	Leu	Ile	His	Gln	Gly	Met	Lys	Cys	Asp	Thr	Cys	Met	Met
	370					375					380				
Asn	Val	His	Lys	Arg	Cys	Val	Met	Asn	Val	Pro	Ser	Leu	Cys	Gly	Thr
385				390						395					400
Asp	His	Thr	Glu	Arg	Arg	Gly	Arg	Ile	Tyr	Ile	Gln	Ala	His	Ile	Asp
				405					410					415	
Arg	Asp	Val	Leu	Ile	Val	Leu	Val	Arg	Asp	Ala	Lys	Asn	Leu	Val	Pro
			420					425					430		
Met	Asp	Pro	Asn	Gly	Leu	Ser	Asp	Pro	Tyr	Val	Lys	Leu	Lys	Leu	Ile
	435						440					445			
Pro	Asp	Pro	Lys	Ser	Glu	Ser	Lys	Gln	Lys	Thr	Lys	Thr	Ile	Lys	Cys
	450					455					460				
Ser	Leu	Asn	Pro	Glu	Trp	Asn	Glu	Thr	Phe	Arg	Phe	Gln	Leu	Lys	Glu
465					470					475					480
Ser	Asp	Lys	Asp	Arg	Arg	Leu	Ser	Val	Glu	Ile	Trp	Asp	Trp	Asp	Leu
				485					490					495	
Thr	Ser	Arg	Asn	Asp	Phe	Met	Gly	Ser	Leu	Ser	Phe	Gly	Ile	Ser	Glu
			500					505					510		
Leu	Gln	Lys	Ala	Ser	Val	Asp	Gly	Trp	Phe	Lys	Leu	Leu	Ser	Gln	Glu
	515						520					525			
Glu	Gly	Glu	Tyr	Phe	Asn	Val	Pro	Val	Pro	Pro	Glu	Gly	Ser	Glu	Ala
	530					535					540				
Asn	Glu	Glu	Leu	Arg	Gln	Lys	Phe	Glu	Arg	Ala	Lys	Ile	Ser	Gln	Gly
545					550					555					560
Thr	Lys	Val	Pro	Glu	Glu	Lys	Thr	Thr	Asn	Thr	Val	Ser	Lys	Phe	Asp
				565					570					575	
Asn	Asn	Gly	Asn	Arg	Asp	Arg	Met	Lys	Leu	Thr	Asp	Phe	Asn	Phe	Leu
			580					585					590		
Met	Val	Leu	Gly	Lys	Gly	Ser	Phe	Gly	Lys	Val	Met	Leu	Ser	Glu	Arg
	595							600						605	

Lys Gly Thr Asp Glu Leu Tyr Ala Val Lys Ile Leu Lys Lys Asp Val  
 610 615 620  
 Val Ile Gln Asp Asp Asp Val Glu Cys Thr Met Val Glu Lys Arg Val  
 625 630 635 640  
 Leu Ala Leu Pro Gly Lys Pro Pro Phe Leu Thr Gln Leu His Ser Cys  
 645 650 655  
 Phe Gln Thr Met Asp Arg Leu Tyr Phe Val Met Glu Tyr Val Asn Gly  
 660 665 670  
 Gly Asp Leu Met Tyr His Ile Gln Gln Val Gly Arg Phe Lys Glu Pro  
 675 680 685  
 His Ala Val Phe Tyr Ala Ala Glu Ile Ala Ile Gly Leu Phe Phe Leu  
 690 695 700  
 Gln Ser Lys Gly Ile Ile Tyr Arg Asp Leu Lys Leu Asp Asn Val Met  
 705 710 715 720  
 Leu Asp Ser Glu Gly His Ile Lys Ile Ala Asp Phe Gly Met Cys Lys  
 725 730 735  
 Glu Asn Ile Trp Asp Gly Val Thr Thr Lys Thr Phe Cys Gly Thr Pro  
 740 745 750  
 Asp Tyr Ile Ala Pro Glu Ile Ile Ala Tyr Gln Pro Tyr Gly Lys Ser  
 755 760 765  
 Val Asp Trp Trp Ala Phe Gly Val Leu Leu Tyr Glu Met Leu Ala Gly  
 770 775 780  
 Gln Ala Pro Phe Glu Gly Glu Asp Glu Asp Glu Leu Phe Gln Ser Ile  
 785 790 795 800  
 Met Glu His Asn Val Ala Tyr Pro Lys Ser Met Ser Lys Glu Ala Val  
 805 810 815  
 Ala Ile Cys Lys Gly Leu Met Thr Lys His Pro Gly Lys Arg Leu Gly  
 820 825 830  
 Cys Gly Pro Glu Gly Glu Arg Asp Ile Lys Glu His Ala Phe Phe Arg  
 835 840 845  
 Tyr Ile Asp Trp Glu Lys Leu Glu Arg Lys Glu Ile Gln Pro Pro Tyr  
 850 855 860  
 Lys Pro Lys Ala Arg Asp Lys Arg Asp Thr Ser Asn Phe Asp Lys Glu  
 865 870 875 880  
 Phe Thr Arg Gln Pro Val Glu Leu Thr Pro Thr Asp Lys Leu Phe Ile  
 885 890 895  
 Met Asn Leu Asp Gln Asn Glu Phe Ala Gly Phe Ser Tyr Thr Asn Pro  
 900 905 910  
 Glu Phe Val Ile Asn Val  
 915

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 April 2000 (27.04.2000)

PCT

(10) International Publication Number  
**WO 00/23615 A3**

- (51) International Patent Classification<sup>7</sup>: **G01N 33/50**, 21/64
- (74) Agent: **PLOUGMANN, VINGTOFT & PARTNERS**  
A/S; Sankt Annæ Plads 11, P.O. Box 3007, DK-1021  
Copenhagen K (DK).
- (21) International Application Number: **PCT/DK99/00562**
- (22) International Filing Date: 15 October 1999 (15.10.1999)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
PA 1998 01320 15 October 1998 (15.10.1998) DK
- (71) Applicant (for all designated States except US): **BIOIM-AGE A/S [DK/DK]**; Mørkhøj Bygade 28, DK-2860 Søborg (DK).
- (81) Designated States (national): AE, AL, AM, AT, AU (utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ARKHAMMAR, Per, O., G. [SE/SE]**; Husensjövägen 97, S-25252 Helsingborg (SE). **TERRY, Bernard, Robert [GB/DK]**; Frederiksberg Allé 15,1., DK-1820 Frederiksberg C (DK). **SCUDDER, Kurt, Marshall [US/DK]**; Lavendelhaven 70, DK-2830 Virum (DK). **BJØRN, Sara, Petersen [DK/DK]**; Klampenborgvej 102, DK-2800 Lyngby (DK). **THASTRUP, Ole [DK/DK]**; Birkevej 37, DK-3460 Birkørød (DK). **HAGEL, Griith [DK/DK]**; Harevænget 109, DK-2791 Dragør (DK).
- Published:  
— With international search report.
- (88) Date of publication of the international search report:  
29 March 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **METHOD FOR EXTRACTING QUANTITATIVE INFORMATION RELATING TO AN INFLUENCE ON A CELLULAR RESPONSE**

(57) Abstract: An improved method and tools for quantifying the effect of an influence on cellular response is described. In particular, an improved method is described for detecting intracellular translocation or redistribution of biologically active polypeptides. The invention also describes several ways of contacting the cells with a substance influencing a cellular response and extracting quantitative information relating to the response in a highly parallel fashion. The method may be used as a very efficient procedure for testing or discovering the influence of a substance on a physiological process using commercially available parallel, high volume assay techniques, for example in connection with screening for new drugs, testing of substances for toxicity, and identifying drug targets for known or novel drugs.

WO 00/23615 A3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 99/00562

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 G01N33/50 G01N21/64

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 G01N C12Q C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 98 45704 A (TULLIN SOEREN ;KASPER ALMHOLT (DK); NOVONORDISK AS (DK); SCUDDER K) 15 October 1998 (1998-10-15) cited in the application See SEQ ID's SEQ ID's identical to SEQ ID 1,3,5,7,9,11,13 and 15 are present.	1-39
X	WO 96 23898 A (NOVONORDISK AS ;THASTRUP OLE (DK); TULLIN SOEREN (DK); POULSEN LAR) 8 August 1996 (1996-08-08) page 8 -page 17	29-38
X	WO 97 11094 A (NOVONORDISK AS ;THASTRUP OLE (DK); TULLIN SOEREN (DK); POULSEN LAR) 27 March 1997 (1997-03-27) the whole document	29-38
-/-		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

2 February 2000

Date of mailing of the international search report

23. 03. 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+31-70) 340-3016

Authorized officer

Hoekstra, S

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK 99/00562

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91 01305 A (UNIV WALES MEDICINE) 7 February 1991 (1991-02-07) page 5, line 15 - line 20	29-38
X	WO 95 07463 A (UNIV COLUMBIA ;WOODS HOLE OCEANOGRAPHIC INST (US); CHALFIE MARTIN) 16 March 1995 (1995-03-16) claim 26	29-38
X	WO 96 03649 A (UNIV NORTH CAROLINA) 8 February 1996 (1996-02-08) page 49; example 6.10	29-38
X	WO 97 20931 A (US HEALTH ;HTUN HAN (US); HAGER GORDON L (US)) 12 June 1997 (1997-06-12) claims 41-58	29-38
X	WO 97 30074 A (CYTOGEN CORP ;UNIV NORTH CAROLINA (US)) 21 August 1997 (1997-08-21) page 57	29-38
X	WO 98 02571 A (TSIEN ROGER Y ;CUBITT ANDREW B (US); UNIV CALIFORNIA (US)) 22 January 1998 (1998-01-22) claims	29-38
X	WO 98 30715 A (ISACOFF EHUD Y ;SIEGAL MICAH S (US); UNIV CALIFORNIA (US); CALIFOR) 16 July 1998 (1998-07-16) the whole document	29-38
X	SAKAI ET AL: "Translocation of protein kinase C-gamma and epsilon - Direct visualization in living cells using fusion protein with green fluorescent protein" THE JOURNAL OF CELL BIOLOGY,US,ROCKEFELLER UNIVERSITY PRESS, XP002078902 ISSN: 0021-9525 the whole document	29-38
X	SCHMIDT ET AL: "Dynamic analysis of alpha-PKC-GFP chimera translocation events in smooth muscle with ultra-high speed 3D fluorescence microscopy" FASEB JOURNAL,US,FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, vol. 3, no. 11, page A505 XP002077257 ISSN: 0892-6638 abstract	29-38
	-/-	

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/DK 99/00562

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SIDOROVA ET AL: "Cell cycle-regulated phosphorylation of Swi6 controls its nuclear localization" MOLECULAR BIOLOGY OF THE CELL,US,BETHESDA, MD, vol. 6, no. 12, page 1641-1658 XP002089512 ISSN: 1059-1524 the whole document	29-38
X	HAN HTUN ET AL: "VISUALIZATION OF GLUCOCORTICOID RECEPTOR TRANSLOCATION AND INTRANUCLEAR ORGANIZATION IN LIVING CELLS WITH A GREEN FLUORESCENT PROTEIN CHIMERA" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 93, no. 10, page 4845-4850 XP002029560 ISSN: 0027-8424 the whole document	29-38
X	CAREY K L ET AL: "EVIDENCE USING A GREEN FLUORESCENT PROTEIN-GLUCOCORTICOID RECEPTOR CHIMERA THAT THE RAN/TC4 GTPASE MEDIATES AN ESSENTIAL FUNCTION INDEPENDENT OF NUCLEAR PROTEIN IMPORT" THE JOURNAL OF CELL BIOLOGY,US,ROCKEFELLER UNIVERSITY PRESS, vol. 133, no. 5, page 985-996 XP000670316 ISSN: 0021-9525 the whole document	29-38
X	OGAWA H ET AL: "LOCALIZATION, TRAFFICKING, AND TEMPERATURE-DEPENDENCE OF THE AEQUOREA GREEN FLUORESCENT PROTEIN IN CULTURES VERTEBRATE CELLS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 92, no. 25, page 11899-11903 XP002029556 ISSN: 0027-8424 the whole document	29-38
X	WESTPHAL ET AL: "Microfilament dynamics during cell movement and chemotaxis monitored using a GFP - actin fusion protein" CURRENT BIOLOGY,GB,CURRENT SCIENCE,, vol. 7, no. 3, page 176-183 XP002090291 ISSN: 0960-9822 page 181, left-hand column, line 1	29-38

-/-

## INTERNATIONAL SEARCH REPORT

Int. . . . .ional Application No

PCT/DK 99/00562

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TODA ET AL: "The fission yeast <i>sts5+</i> gene is required for maintenance of growth polarity and functionally interacts with protein kinase C and an osmosensing MAP kinase pathway" JOURNAL OF CELL SCIENCE, GB, ESSEX, vol. 109, no. 9, page 2331-2342 XP002090292 abstract	29-38
X	WEBB ET AL: "Use of green fluorescent protein for visualization of cell-specific gene expression and subcellular protein localization during sporulation in <i>Bacillus subtilis</i> " JOURNAL OF BACTERIOLOGY, US, WASHINGTON, DC, vol. 177, no. 20, page 5906-5911 XP002089513 ISSN: 0021-9193 the whole document	29-38
X	WO 94 23039 A (CANCER RES INST ROYAL ;MARSHALL CHRISTOPHER JOHN (GB); ASHWORTH AL) 13 October 1994 (1994-10-13) the whole document	29-38
X	GERISCH ET AL: "Chemoattractant-controlled accumulation of coronin at the leading edge of Dictyostelium cells monitored using a green fluorescent protein-coronin fusion protein" CURRENT BIOLOGY, GB, CURRENT SCIENCE,, vol. 5, no. 11, page 1280-1285 XP002089510 ISSN: 0960-9822 page 1281, right-hand column	29-38

# INTERNATIONAL SEARCH REPORT

Inter. application No.  
PCT/DK 99/00562

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-28, 39  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(v) PCT - Presentation of information: The subject-matter of claim 39 is a "set of data". This is a mere representation of presentation for which the ISA is not required to establish a search report.
2. ☒ Claims Nos.: 1-28  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-28

Claim 1-28 are not supported by technical terms, as is required by Article 6 and Rule 6.3(a) PCT, which legitimately define the scope of the subject-matter for which protection is sought as no technical contribution to the state of the art commensurate to the scope of the present claims is derivable from the description in terms of a technical problem and a solution thereto as is required by Article 5 and Rule 5.1(iii) PCT. Insofar as claims 1-28 could be understood they would rely on the act of recording of signals from the underlying biological systems and the subsequent processing of the recorded signals. No technical features technically describing such act as a possible contribution to the state of the art is derivable other than the trivial use of state of the art photographic recording devices. No algorithms nor any unexpected combinations of hardware and software defines the subject-matter for which protection is sought. These flaws with respect to the requirements of Article 5 and 6 of the PCT are of such nature that a meaningful complete search could not be executed.

The only technical definition of subject-matter for which a meaningful search could be executed was found in claims limited to the involvement of the technically characterised luminophores as in claims 29-38 and in the parts of the description supporting these claims.

Moreover, the initial phase of the search for this limited subject-matter revealed a very large number of documents relevant to the issue of novelty of claim 1. So many documents were retrieved falling under the wide scope of claim 1-28 that it is impossible to determine which parts of these claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons also, a meaningful search over the whole breadth of the claim(s) is impossible.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 1.

2. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 3.

3. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 17

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 4. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 7.

## 5. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 9.

## 6. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 11.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 7. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 13.

## 8. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 15

## 9. Claims: 29-38 IN PART

A method for extracting quantitative information relating to an influence on a cellular response in mechanically intact or permeabilised living cells, the method comprising recording variation in spatially distributed light emitted from a GFP comprising luminophore, the luminophore being present in the cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a biochemically active component which is capable of being redistributed in a manner which is related to the degree of influence, as a change in light intensity measured by an instrument designed for the measurement of changes in fluorescence intensity. In which the GFP comprising luminophore is a polypeptide encoded by SEQ ID No. 17

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 99/00562

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9845704 A	15-10-1998	AU 6820998 A	30-10-1998
WO 9623898 A	08-08-1996	AU 4483096 A	21-08-1996
		CA 2217700 A	08-08-1996
		EP 0815257 A	07-01-1998
		US 5958713 A	28-09-1999
WO 9711094 A	27-03-1997	AT 184613 T	15-10-1999
		AU 4482996 A	09-04-1997
		CA 2232727 A	27-03-1997
		DE 69604298 D	21-10-1999
		EP 0851874 A	08-07-1998
		JP 11512441 T	26-10-1999
WO 9101305 A	07-02-1991	AU 6054590 A	22-02-1991
		CA 2064766 A	23-01-1991
		EP 0484369 A	13-05-1992
		JP 5501862 T	08-04-1993
		US 5683888 A	04-11-1997
WO 9507463 A	16-03-1995	US 5491084 A	13-02-1996
		AU 694745 B	30-07-1998
		AU 7795794 A	27-03-1995
		CA 2169298 A	16-03-1995
		EP 0759170 A	26-02-1997
		JP 9505981 T	17-06-1997
WO 9603649 A	08-02-1996	AU 3146095 A	22-02-1996
		CA 2195629 A	08-02-1996
		EP 0772773 A	14-05-1997
		JP 10503369 T	31-03-1998
WO 9720931 A	12-06-1997	AU 1283497 A	27-06-1997
		CA 2239951 A	12-06-1997
WO 9730074 A	21-08-1997	AU 2272397 A	02-09-1997
		CA 2246378 A	21-08-1997
		EP 0897392 A	24-02-1999
WO 9802571 A	22-01-1998	US 5912137 A	15-06-1999
		US 5925558 A	20-07-1999
		AU 3801997 A	09-02-1998
		EP 0915989 A	19-05-1999
WO 9830715 A	16-07-1998	AU 5090498 A	03-08-1998
WO 9423039 A	13-10-1994	AU 677834 B	08-05-1997
		AU 6382394 A	24-10-1994
		CA 2157774 A	13-10-1994
		EP 0703984 A	03-04-1996
		JP 9501302 T	10-02-1997
		US 5958721 A	28-09-1999
		AU 696939 B	24-09-1998
		AU 1586195 A	29-08-1995
		CA 2182967 A	17-08-1995
		EP 0742827 A	20-11-1996
		WO 9521923 A	17-08-1995
		JP 9508795 T	09-09-1997